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SUMMARY
Acute intermittent porphyria (AIP) is an inborn error of metabolism which is caused by 
deleterious mutations in the hydroxymethylbilane synthase (HMB-S) gene. The overall aims 
of the present study were to search for and characterise mutations in the HMB-S gene and 
to develop an in vitro expression system to confirm the pathogenic nature of these 
mutations.
Thirty individuals from fifteen families with AIP from South Africa, Scotland, England 
and the Republic of Ireland were studied. Initially, the entire coding sequence of the HMB- 
S  gene was screened using heteroduplex analysis (HA) and chemical cleavage mismatch 
(CCM) analysis. Any differences in the band patterns, when compared to the negative 
control in both techniques, were characterised by direct sequencing. The same region of the 
genomic DNA was also sequenced. This step was especially important in characterising 
splice site mutations responsible for exon skipping. Using the above strategies, six missense 
mutations, R22C, R26C, R26H, R116W, R173Q and L177R, one splice site mutation 
(345-1 G—»A) leading to the skipping of exon 8 and two frameshift mutations (771insT and 
delGioo2/ioo3/ioo4) were identified. Four of these mutations, R22C, 345- 1G—»A, 771insT and 
delGioo2/ioo3/ioo4, are novel. All the missense mutations resulted in the substitution of highly 
conserved residues, hence are considered to be potentially pathogenic. In addition, 
alternative splicing of exons 3 and 12, resulting in their exclusion from a proportion of 
mRNA transcripts, was identified in thirty AIP patients and forty-four healthy individuals.
The R22C mutation (R7 in the E. coli model) in exon 3 affects the highly conserved 
Arg22 residue and is caused by a C to T substitution at nucleotide 64. Arginine, a basic 
residue, is substituted by cysteine, a neutral polar amino acid and this is predicted to 
destabilise the protein. This mutation, initially detected in two Scottish siblings, was 
subsequently identified in three other family members by employing a simple restriction 
enzyme analysis using H inf I. R26C (Rll  in E. coli) is the result of a C to T transition in 
exon 3 at position 76. The highly conserved Arg26 residue in twelve species is substituted 
by the polar neutral cysteine residue. This mutation was present in two Irish siblings and 
was identified in three further relatives by performing a simple Aci I restriction enzyme
analysis. R26H is caused by a G to A transition of the adjacent base following that causing 
R26C and was confirmed by an Aci I digestion. R116W (R101 in E. coli) in exon 8 was 
identified in three unrelated South African patients and raised the possibility of these 
patients having a common Dutch ancestry, due to the high prevalence of this mutation in 
the Dutch population. R116W is a consequence of a C to T transition at nucleotide 346 
which was confirmed by an Aci I digestion. A destabilisation of the protein is expected with 
the substitution of the basic amino acid arginine with tryptophan, a neutral non-polar amino 
acid. The mutation in exon 10, R173Q (R155 in E. coli), is caused by a G to A transition at 
position 518 and a loss of an Nci I recognition site indicates a base change. In this case, the 
basic residue arginine is substituted with glutamine, a polar neutral residue. This 
replacement inhibits substrate binding and chain elongation. L177R (LI59 in E. coli), in 
exon 10, is the result of a T to G transversion at nucleotide 530, causing the non-polar 
neutral residue leucine to be replaced by the basic amino acid arginine. This introduces a 
destabilising effect in the mature protein and impairs its normal function. The Aci I 
restriction enzyme was employed to identify this mutation in five members of a Scottish 
family.
345-lG-»A is a 3' acceptor splice site mutation at position -1 of intron 7 which causes 
the skipping of exon 8 in three related individuals from England. 26 amino acids are 
predicted to be absent from the protein product but the translational reading frame is not 
altered. However, the codon at the junctions of exons 7 and 8 of the normal mRNA is now 
altered and encodes for asparagine instead of lysine. The application of Eco RII confirmed 
this mutation.
771insT was identified in exon 12 of a South African patient which results in a shift in 
the reading frame and the alteration of the thirty-two amino acids following this insertion 
before reaching a premature termination of translation at codon 290. This mutation 
affected a Sty I recognition site, which was used for confirmation. A protein product 
containing 289 amino acids is expected instead of the 361 amino acids normally found in a 
healthy individual, equivalent to the loss of approximately 20% of the protein. The 
mutation, delGioo2/ioo3/ioo4, also results in a termination codon, this time at codon 343, and
consequently a protein containing 342 amino acids is expected. This corresponds to a loss 
of approximately 5% of the mature protein.
Five of the missense mutations, R22C, R26C, R26H, R116W and R173Q, occur at the 
hypermutable CpG dinucleotide, a hotspot for mutations. The normal occurrence of 
alternative splicing of exons 3 and 12 had not been previously reported. Both exons are 
spliced out from the mRNA transcripts to various extents in thirty AIP patients and forty- 
four healthy individuals. A study of the frequency of occurrence of each base at each 
position of the 5' and 3' splice junctions of the HMB-S gene, and an analysis of the 
consensus values (CV) at both splice sites, according to the method of Shapiro and 
Senapathy (1987), did not reveal any irregularities.
The sensitivity and efficiency of the two screening techniques, HA and CCM, were 
compared. HA, although relatively simple and rapid, does not involve hazardous 
substances and was not able to detect one of the mutations identified in this study, thus 
giving an efficiency of about 90%. On the other hand, while CCM involves potentially 
hazardous materials and is time-consuming, it was able to detect all the mutations including 
the one missed by HA. Therefore, CCM was regarded as a better screening method for use 
in this project.
The second objective of this project was to develop an in vitro gene expression 
system. The pTrc 99A (Pharmacia) plasmid expression vector was used for expression 
studies and the accompanied protocol was followed. The appropriate fragments of interest 
were ligated to the vector and subcloned in the bacterial strain, JM109, of E. coli. The 
cloned inserts were then screened, by CCM, for extraneous misincorporations by Taq DNA 
polymerase and sequenced to confirm their integrity. Of the 126 clones screened, 44 
(34.9%) were found to have maintained their integrity and were suitable for expression 
studies. 5 of these, each harbouring a mutant allele, were subjected to in vitro expression 
studies. The clones with the mutations R26H, R116W and R173Q, were introduced into 
the expression system to determine their pathophysiology in AIP. The average specific 
activities of the three mutations, as determined by the in vitro expression system, were 0.83 
X 106 pmol/mg protein/hr for R173Q, 0.93 X 106 pmol/mg protein/hr for R116W and 1.07 
X 106 pmol/mg protein/hr for R26H.
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1.1 THE SPECTRUM OF MUTATIONS IN GENETIC DISEASE
The gene is the unit of heredity. It is composed of deoxyribonucleic acid (DNA), 
which contains genetic information that determines the order of amino acids in a peptide 
chain, and hence the three-dimensional structure of the protein which it encodes. Enzymes 
and other biologically important proteins consist of one or more peptide chains folded into 
a three-dimensional structure, the exact shape of which is crucial for their normal function.
There are various types of mutations in the human genome. The study of naturally 
occurring gene mutations is important in the understanding of the origins of genetic 
variation and the mechanisms of evolution. The various types of mutations (single base-pair 
substitutions, deletions, insertions, inversions and duplications) have been detected and 
characterised in many human genes, thus enabling the study of the underlying mutational 
mechanisms.
1.1.1 SINGLE BASE-PAIR SUBSTITUTIONS
Single base-pair substitutions may affect the transcription of the gene into messenger 
ribonucleic acid (mRNA), the translation of the mRNA into protein, the processing events 
following transcription or the accuracy of splicing. Point mutations can be divided into 
three groups, viz. missense mutations where the single nucleotide alteration results in the 
substitution of one amino acid for another, nonsense mutations where the substitution of a 
single nucleotide results in a premature termination codon and the formation of a truncated 
protein product, and sense mutations which change a termination codon to one that codes 
for amino acids and result in the translation of a protein beyond the normal termination 
signal until another termination codon is reached (Weatherall, 1991). Two variant forms of 
single base substitutions exist which have no apparent effect on the protein product: (i) the 
amino acid is not changed in the mature protein- they are known as silent mutations; and
(ii) the altered amino acid is from the same class as the normal amino acid (i.e.
l
neutral/basic/acidic, hydrophilic/hydrophobic) but the activity of the protein is not affected 
and the phenotypic effects are insignificant- these are known as neutral substitutions or 
conservative changes.
Missense mutations can be regarded as disease-causing from one or more of the 
following sources: (1) occurrence of the mutation in a region of known functional 
importance; (2) a conserved residue is affected; (3) an unrelated patient has the same 
mutation; (4) the absence of the mutation in a large number of healthy individuals; (5) the 
inheritance of the mutation and disease phenotype in a family; (6) demonstration that the 
mutant protein produced in vitro possesses similar biochemical properties and 
characteristics as its in vivo counterpart; and (7) reversal of the pathological phenotype in 
the patient/cultured cells by replacement of the mutant gene/protein with its wild-type 
counterpart.
CpG dinucleotides have long been recognised to be hotspots for mutations. In 
eukaryotic genomes, 5’-methylcytosine (5'-mC) occurs predominantly in CpG 
dinucleotides, the majority of which seem to be methylated (Cooper, 1983). Methylation of 
cytosine results in a high level of mutations due to the tendency of 5'-mC to undergo 
deamination to form thymine (Figure 1.1), which is not recognised by the DNA repair 
mechanisms and thus results in mutation (Cooper and Krawczak, 1991).
A survey of those single base-pair mutations responsible for human genetic disease, 
showed that 35% occurred within CpG dinucleotides (Cooper and Youssoufian, 1988), 
with C—>T or G—»A transitions occurring with a frequency of over 90%.
Single base-pair substitutions affecting mRNA splicing are non-randomly distributed, 
which can be related to the phenotypic consequences of mutation (Krawczak et al, 1992). 
Three types of point mutations exist that affect mRNA splicing: (i) mutations within the 5' 
or 3' consensus splice sites which usually reduce the amount of correctly spliced mature 
mRNA and/or lead to the utilisation of alternative splice sites in the vicinity. The resulting 
mRNAs either lack a portion of the coding sequence (exon skipping) or contain additional 
sequence of intronic origin (cryptic splice site utilisation); (ii) mutations within an intron or 
exon that may serve to activate cryptic splice sites and lead to the production of aberrant 
mRNA species; and (iii) mutations within a branch-point sequence (BPS).
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Figure 1.1: Schematic representation of the molecules for cytosine, 5-methyIcytosine 
and thymine and the chemical events for the transformation of cytosine 
to thymine.
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1.1.2 DELETIONS
Gene deletions have been reported to be responsible for at least 159 different human 
disorders (Cooper and Krawczak, 1993) and can be classified according to the length of 
DNA deleted, either one or a few base-pairs, or several hundred kilobases. Gross gene 
deletions may arise either by (i) homologous unequal recombination mediated by related 
gene sequences or repetitive sequence elements; or (ii) non-homologous recombination 
involving DNA with minimal sequence homology. The former involves cleavage and 
rejoining of non-sister chromatids at homologous but non-allelic DNA sequences, resulting 
in fusion genes if the recombination breakpoints are intragenic. The latter, however, 
involves non-homologous or illegitimate recombination between two sites which show little 
or minimal sequence homology. Short gene deletions (<20bp) have been studied by 
Krawczak and Cooper (1991) to understand the mechanisms involved. Direct repeats, 
palindromes and symmetric elements (e.g. CTGAAGTC, GGACAGG) could be potential 
mechanisms involved in gene deletions.
1.1.3 INSERTIONS
Insertions, like deletions, can involve either one or a few bases, or several hundred 
kilobases. The largest fragment inserted into a gene is 220kb in the Duchenne muscular 
dystrophy (DMD) gene (Bettecken and Muller, 1989). Studies by Cooper and Krawczak 
(1991) using short insertion-type mutations (<10bp) revealed that such a mutation is a non- 
random process which is dependent on the local DNA sequence environment. The majority 
of insertional mutations can be explained by (i) slipped mispairing; (ii) inverted repeats; or
(iii) symmetric elements.
1.1.4 INVERSIONS
Inversions are an extremely rare form of gene mutation. The P-globin gene cluster in 
Indian ^bp-thalassemia involves complex rearrangement (Jennings et al, 1985). Two 
fragments, 0.83kb and 7.46kb, were deleted and the intervening segment was 
simultaneously inverted and reintroduced between the \  and 5 gene loci. Jennings et al
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proposed that this event could be possible by the folding pattern of the chromatin in the 
cluster region bringing the ^  gene into close proximity with the 5- and p-globin genes. 
This rearrangement enhanced the expression of the upstream fetal Gy gene.
1.1.5 DUPLICATIONS
The duplication of either whole genes or their constituent exons have an important 
role in the evolution of the mammalian genome. However, they may also result in disease. 
Duplication of several amino acids may alter the protein conformation, resulting in an 
unstable protein, or may result in a frameshift in the mRNA producing a defective protein. 
The largest duplication reported to date is a 400kb internal duplication of the DMD gene 
involving exons 13 to 42 (Angelini et al, 1990), but the patient manifested the relatively 
mild Becker form of muscular dystrophy. Gene duplications may arise due to homologous 
or non-homologous recombination. For example, homologous recombination may occur 
between repetitive sequences such as the Alu elements. Non-homologous recombination 
between non-homologous sequences may result in duplication by random chromatid 
cleavage and rejoining events.
1.1.6 EXPANSION OF UNSTABLE REPEAT SEQUENCES
The expansion of unstable trinucleotide repeat sequences is one of the recently 
recognised mechanisms of mutagenesis. Examples of the disorders known to be due to the 
expansion of such repeats are Fragile X (Fu et al, 1991), spinobulbar muscular atrophy (La 
Spada et al, 1991), myotonic dystrophy (Fu et al, 1992), Huntington’s disease (The 
Huntington’s Disease Collaborative Research Group, 1993), spinocerebellar ataxia I (Orr 
et al, 1993), dentatorubral-pallidoluysian atrophy (DRPLA) (Koide et al, 1994), Machado- 
Joseph disease (Maciel et al, 1995) and Haw River syndrome (Burke et al, 1994), the latter 
of which has been shown to be caused by an expanded repeat in the same allele as that for 
DRPLA. Patients suffering from any one of these diseases manifest the condition when the 
size of the repeats expand beyond the normal size range.
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1.2 INBORN ERRORS OF METABOLISM- DISORDERS OF PORPHYRIN 
METABOLISM
Inborn errors of metabolism are metabolic diseases in which the characteristic classical 
pathological and biochemical abnormalities can be attributed to a deficient or defective 
gene product (protein) which, in turn, is due to the presence of a particular abnormal gene.
1.2.1 THE PORPHYRIAS
The porphyrias are a group of rare and complex metabolic disorders which affect the 
heme biosynthetic pathway. They may be inherited or acquired, and each results in a 
reduction in the activities of the respective enzymes in the pathway. Consequently, there is 
an excessive production of porphyrins or their precursors proximal to the block (Brodie et 
al, 1977), which can be detected in the urine, faeces or blood (Kappas et al, 1989) and 
results in the various forms of porphyria.
1.2.2 PORPHYRINS AND THE HEME BIOSYNTHETIC PATHWAY
Porphyrins are cyclic tetrapyrroles which are required for the formation of the essential 
heme-containing compounds such as cytochromes, catalase and peroxidase. Therefore, 
porphyrins are required as building blocks for heme biosynthesis. The porphyrins formed in 
the heme biosynthetic pathway are in the reduced forms of porphyrins (i.e. 
porphyrinogens), which are rapidly oxidised by air to form porphyrins. With the exception 
of the terminal step of the pathway involving the synthesis of heme from protoporphyrin 
and catalysed by ferrochelatase, all other enzymatic steps require porphyrinogens as 
substrates.
Heme is produced by a chemical pathway which consists of eight steps, each of which 
is enzymatically controlled (Figures 1.2a and 1.2b). Eight molecules of glycine and eight 
molecules of succinyl CoA are the initial substrates required to synthesise one molecule of 
heme. The first and last three enzymes of the pathway are localised in the mitochondria, 
while the intermediate enzymes are localised in the cytosol. The rate-limiting step is at the 
level of 5-aminolaevulinic acid (ALA) synthase. A negative feedback exists whereby heme
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Figure 1.2a: The heme biosynthetic pathway.
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acts as a negative regulator of the accumulation of ALA synthase. This means that the rate 
of accumulation of ALA synthase increases greatly in the absence of heme and is 
diminished in its presence. However, the rate-limiting feature of this enzyme occurs only in 
the liver and not in the erythroid cells. The erythron increases heme synthesis when there in 
an increase in cell number.
Two isoforms of ALA synthase and hydroxymethylbilane synthase (HMB-S) exist, one 
of which is expressed only in the erythrocytes and the other is expressed in all the other 
cells. Both isoforms are derived from a single gene. The transcripts of all other genes 
encoding the remaining enzymes in the heme biosynthetic pathway are identical both in the 
erythroid and non-erythroid cells.
1.2.3 CLASSIFICATION OF THE PORPHYRIAS
The porphyrias are classified as either hepatic or erythroid, depending on the site of 
expression of the enzymatic defect in each disorder (Table 1.1). The cardinal feature of the 
erythroid porphyrias is skin photosensitivity. With the exception of ALA dehydratase 
deficiency porphyria (ADP) and acute intermittent porphyria (AIP), where the main 
symptoms are neurovisceral attacks because they do not accumulate the photodynamically 
active porphyrins, and porphyria cutanea tarda (PCT) where patients suffer ffom skin 
photosensitivity, all the other hepatic porphyrias may involve neurovisceral attacks coupled 
with photosensitivity.
1.3 ACUTE INTERMITTENT PORPHYRIA (AIP)
1.3.1 INTRODUCTION
Acute intermittent porphyria (AIP) is the most common autosomal dominant form of 
the acute porphyrias. It has been estimated to have a prevalence of 1 in 10000-20000 in 
Europe (Goldberg et al, 1987), with the highest incidence of 1 in 1000 occurring in 
Swedish Lapland (Waldenstrom, 1957). Hence AIP is also known as Swedish porphyria. A
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Table 1.1: Classification of the Porphyrias.
Classification Defective enzyme Main presenting symptom(s)
Erythropoietic
Congenital Uroporphyrinogen III Photosensitivity
erythropoietic cosynthase
porphyria (CEP)
Erythropoietic Ferrochelatase Photosensitivity
protoporphyria (EPP)
Hepatic
ALA dehydratase 
deficiency porphyria 
(ADP)
ALA dehydratase Neurovisceral
Acute intermittent 
porphyria (AIP)
Hydroxymethylbilane
synthase
Neurovisceral
Hereditary Coproporphyrinogen Neurovisceral and/or
coproporphyria (HCP) oxidase photosensitivity
Variegate porphyria Protoporphyrinogen Neurovisceral and/or
(VP) oxidase photosensitivity
Porphyria cutanea tarda 
(PCT)
Uroporphyrinogen
decarboxylase
Photosensitivity
Hepatoerythropoietic Uroporphyrinogen Photosensitivity and/or
porphyria (HEP) decarboxylase neurovisceral
much higher prevalence of 2 to 5 per thousand psychiatric patients has also been reported 
(Tishler et al, 1985).
AIP is a consequence of a defect in the gene encoding the third enzyme of the heme 
biosynthetic pathway, hydroxymethylbilane synthase (HMB-S) (EC 4.3.1.8), resulting in a 
partial deficiency in its activity and an accumulation of the porphyrin precursors 5- 
aminolaevulinic acid (5-ALA) and porphobilinogen (PBG), leading to disease 
manifestations. Unlike most other porphyrias, which accumulate porphyrins, patients with 
AIP do not develop cutaneous photosensitivity, since they accumulate porphyrin 
precursors but not porphyrins, which are photodynamically inactive.
1.3.2 CLINICAL FEATURES OF AIP
AIP is a disorder of variable penetrance (Gates, 1946). Approximately 90% of carriers 
of the defective gene remain asymptomatic throughout their lives, while the remaining 10% 
manifest the disease to varying degrees of severity. The frequency of attacks may vary from 
one individual to another, and is more common in females than in males (Goldberg, 1959).
The clinical onset of AIP occurs during or after puberty and the main presenting 
symptoms are abdominal pain, tachycardia, hypertension, vomiting, neurological 
disturbances and psychiatric symptoms. Abdominal pain, which may be generalised or 
localised, is almost invariably present and is usually the initial symptom of an acute attack. 
Tachycardia and hypertension have been reported in more than half of all attacks (Moore et 
al, 1987). In up to 40% of patients, hypertension may become sustained between attacks. 
Severe vomiting results in dehydration and hyponatremia, accompanied by constipation 
(Moore and Brodie, 1990). Any type of neuropathy may occur, which may be symmetric, 
asymmetric or focal (Poser and Edwards, 1978). Muscle weakness can be severe due to a 
prolonged attack, and is due to the effects of porphyria on nerves that control muscles. It 
often begins proximally in the legs but may involve the arms or the distal extremities. The 
higher rate of occurrence of AIP in the psychiatric institutions could be attributed to the 
misdiagnosis of such patients as suffering from a genetic disorder.
10
1.3.3 PRECIPITANTS OF AIP
Approximately 90% of the defective gene carriers remain asymptomatic, although they 
may manifest the condition either by endogenous or exogenous environmental factors. The 
precipitants of AIP include certain therapeutic drugs, alcohol, infections, caloric 
deprivation and endocrine factors.
Barbiturates are the most potent of all drugs known to exacerbate acute porphyria. 
They are still widely used for the induction of anaesthesia during surgery and therefore it is 
vital that the patient’s condition is known well in advance of a surgical procedure. Alcohol 
and infections (both bacterial and viral) are known to contribute to the induction of an 
acute attack. Urinary 5-ALA and PBG excretion have been found to increase in AIP 
patients with reduced calorie intake. However, this situation is reversed if calories from a 
carbohydrate-rich diet are introduced into the diet. The clinical onset of AIP occurs during 
or after puberty, indicating that endocrine factors play a role in the genesis of an acute 
attack.
All the precipitating factors result in the induction of the rate-limiting enzyme of the 
pathway, ALA synthase (Kappas et al, 1995), which causes an overproduction of 5-ALA 
and PBG. A reduced activity of HMB-S is unable to prevent the accumulation of these 
compounds, thereby leading to the symptoms of AIP. It can be seen, therefore, that it is 
vital to identify carriers of this defective gene so that they can be appropriately advised to 
avoid these precipitating factors.
1.3.4 MOLECULAR GENETICS OF HYDROXYMETHYLBILANE SYNTHASE 
(HMB-S)
The human hydroxymethylbilane synthase (HMB-S) gene has been localised to 
11 q24.1 —>q24.2 (Namba et al, 1991) by in situ hybridisation and gene dosage studies. The 
gene is divided into 15 exons (Figure 1.3) and is spread over lOkb of genomic DNA 
(Chretien et al, 1988; Yoo et al, 1993). The length of individual exons ranges from 39 to 
438 base pairs (bp). The largest intron spans 2913bp and the smallest 87bp.
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Figure 1.3: The organisation of the human hydroxymethylbilane synthase (HMB-S) 
gene and its two transcripts. The vertical boxes in the genomic DNA 
represent the exons, drawn to scale. Ph and Pe indicate the promoters of 
the housekeeping gene and erythroid cell respectively.
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HMB-S is encoded by a single gene. Two distinct forms of the enzyme exist: a 
housekeeping isoenzyme of 44 kilodaltons (kD) which is present in all cells, and an 
erythroid-specific isoenzyme of 42kD. The two isoforms differ at the N-terminus where the 
housekeeping enzyme possesses 17 additional amino acids.
These two isoforms are a consequence of alternative splicing of two primary 
transcripts arising from two distinct promoters (Grandchamp et al, 1987; Chretien et al, 
1988). The housekeeping promoter is located in the 5' untranslated region, and its 
transcript comprises exons 1 and 3 to 15 while the erythroid promoter, located 3kb 
downstream, is in intron 1 and its transcript contains exons 2 to 15 (Figure 1.3). Two 
erythroid-specific transcription factors, GATA-1 and NF-E2, recognise the sequences in 
the HMB-S erythroid promoter. The translation initiation codon is not present in exon 2, 
therefore, the translated portion of the erythroid mRNA begins in exon 3.
The isolation and sequencing of the cDNAs encoding the two isoforms have been 
performed (Raich et al, 1986; Grandchamp et al, 1987) and revealed that the cDNA 
encoding the erythroid form has an open reading frame of 1032bp which codes for 344 
amino acids, while that for the housekeeping isoenzyme is 1083bp, coding for 361 amino 
acids. The complete coding sequence of the HMB-S gene is shown in Appendix 2.
1.3.5 THE THREE-DIMENSIONAL STRUCTURE OF HMB-S
The three-dimensional structure of wild-type HMB-S from E. coli has been elucidated 
by Louie et al (1996) at a resolution of 1.76A (Figure 1.4). The overall dimensions of the 
protein molecule are 57A X 43A X 32A. The polypeptide chain of HMB-S is folded into 
three a/p  domains of approximately equal size and the overall topology of domains 1 
(residues 3-99) and 2 (residues 105-193) were found to be similar based on the doubly- 
wound, five-stranded mixed P-sheet. At the interface of these two domains is an active site 
cleft with dimensions 15A X 13A X 12A. The major links between these two domains are 
two hinge regions. Domain 3 (residues 222-307), on the other hand, has an approximately 
equal interaction with the other two domains through hydrogen bonds and salt-bridges. 
The C-terminal of domain 3 is an open-faced, anti-parallel sheet consisting of three strands
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Figure 1.4: The three-dimensional structure o f the K  coli
hydroxymethylbilane synthase (HMB-S) protein.
The three domains of the enzyme are illustrated as different colours, with 
domain 1 being represented in gold, domain 2 in green and domain 3 
in blue. The dipyrromethane cofactor, which is situated in a deep active site 
cleft between domains 1 and 2, is shown in yellow. Examples of some of the 
mutations identified so far are shown according to the human numbering 
system and the sites of the mutations are depicted in red. The ft-strands are 
represented by wide arrows, a-helices as ribbons and loops as thin ropes. 
(Reproduced from Warren et al, 1996).
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Figure 1.4: The three-dimensional structure of the E. coli hydroxymethylbilane
synthase (HMB-S) protein.
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which forms a short segment with domain 1 through residues 218-221. The 
dipyrromethane cofactor is important in the assembly of the tetrapyrrole product. It is 
assembled by the apoenzyme from two molecules of PBG and is covalently attached, 
through a thioether bond, to the side chain of cysteine-242 located on a flexible loop of 
domain 3. The cofactor is important in the stabilisation of the protein structure since, once 
it is assembled, the protein undergoes a permanent and irreversible conformational change 
which maintains the cofactor at the active site. It forms hydrogen bonds and salt-bridges 
between its acetate and propionate side groups and the polypeptide chain. The second 
pyrrole ring (C2) of the cofactor is located internally in the active site cleft before 
oxidation. Upon oxidation, it was found to be externally located which may correspond to 
the site of substrate binding and polypyrrole chain elongation.
The majority of the invariant residues are clustered in the vicinity of the active site 
cleft. These residues are mainly involved in bond formation (Louie et al, 1996), particularly 
salt-bridges and hydrogen bonds, with the dipyrromethane cofactor and the PBG substrate, 
and also in the elongation of the product. Aspartic acid 84 (Asp84) has been identified as 
the key catalytic residue of HMB-S due to its strategic location in the vicinity of the active 
site cleft within the molecule. Replacement of this residue has been found to either reduce 
the specific activity of the protein (Glu84 has less than 1% of the wild-type specific 
activity) or completely abolish the catalytic activity (Ala84 and Asn84). The invariant 
residues located some distance away from the active site cleft are more important in 
stabilising the protein structure than interacting with the cofactor and product. Any 
disruption to these highly conserved residues will render the protein inactive or unstable 
and lead to the formation of a non-functional protein.
1.3.6 MOLECULAR PATHOLOGY OF AIP
To date, seventy-three different mutations have been reported to be responsible for 
AIP, indicating the immense molecular heterogeneity of this condition. Deletions, 
insertions, missense, nonsense and other point mutations causing splicing defects have been 
characterised (Table 4.1).
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Immunoassays have been developed to measure the antigenic concentration of 
erythrocyte HMB-S. AIP patients can be divided into two categories based on the 
measurements of the enzyme activity and immunoreactive concentration in erythrocytes. 
Patients who show the presence of a stable erythroid HMB-S but with 50% enzyme 
activity are classified as cross-reacting immunological material (CRIM)-positive, because 
antigenic material is present in excess of activity (Nordmann et al, 1990). CRIM-positive 
AIP is further subdivided into two types, Type 1 and Type 2, based on the ratio of the 
immunologic to enzymatic material (Table 1.2). Approximately 85% of AIP patients are 
classified as CRIM-negative, where the ratio of immunoreactive concentration to 
enzymatic activity in erythrocytes is 1.0. CRIM-negative AIP can be subdivided into Type 
1, where there is a reduction in the amounts of immunologic and enzyme material, and 
Type 2, where the activity and immunoreactive material are present at normal levels. The 
latter group of patients do not possess any mutations in their erythroid cells, therefore, 
their erythrocyte HMB-S activities are normal and the immunoreactive material is 
recognised by the antibodies raised against them. These patients can be differentiated from 
the healthy population as they have an increased urinary 5-ALA and PBG. The CRIM- 
status of the different mutations are stated in Table 4.1.
A large number of mutations occur at CpG dinucleotides, in line with the fact that they 
are known hotspots for mutations due to the spontaneous deamination of 5'-methylcytosine 
to thymine (Barker et al, 1984; Cooper and Youssoufian, 1988). This is true for the 
mutations responsible for AIP, with more than half of them involving mutations in CpG 
dinucleotides.
1.3.7 DIAGNOSIS OF AIP
All AIP patients, except those classified as CRIM-negative Type 2, and latent gene 
carriers, have approximately 50% HMB-S activity in their erythrocytes as compared to 
normal individuals. 5-ALA and PBG are excreted in large amounts in the urine between 
attacks in clinically expressed and some latent AIP patients. However, increased levels of 
5-ALA and PBG are also observed in hereditary coproporphyria (HCP) and variegate 
porphyria (VP). These porphyrias can produce the same symptoms as AIP and the pattern
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Table 1.2: Classification of AIP based on the ratio of immunoreactive concentration 
to enzyme activity in erythrocytes (adapted from Desnick et al, 1985).
Immunoreactive 
Concentration (%) (A)
Enzymatic Activity 
(%) (B)
Ratio (A/B)
Control 100 100 1.0
CRIM-negative
Type 1 50 50 1.0
Type 2 100 100 1.0
CRIM-positive
Type 1 85 50 1.7
Type 2 280 50 5.7
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of inheritance is also similar to AIP. The HMB-S activity is normal in HCP and VP, thus 
differentiating these two conditions from AIP.
The diagnosis of AIP, thus, depends on a reduced activity of HMB-S in erythrocytes. 
The diagnosis of asymptomatic heterozygotes, who possess normal levels of 5-ALA and 
PBG, has been difficult since there is a significant overlap of erythrocyte HMB-S activity 
between the affected and normal values (Lamon et al, 1979; McColl et al, 1982; Bonnaiti- 
Pellie et al, 1984; Pierach et al, 1987; Kappas et al, 1989). Therefore, a more definitive 
approach in the diagnosis of AIP is to use molecular techniques to identify specific 
mutations in AIP patients.
1.3.8 LINKAGE ANALYSIS
Ten diagnostically useful intragenic polymorphisms have been detected in the HMB-S 
gene (Astrin and Desnick, 1994). Since correct diagnosis is essential for the prevention of 
acute attacks, restriction fragment length polymorphism (RFLP) analysis provides a 
valuable diagnostic test for AIP at the DNA level. This test is especially valuable in AIP 
families with normal erythrocyte HMB-S activity.
Linkage analysis of AIP families using RFLPs has demonstrated close linkage of the 
disease with the HMB-S gene (Llewellyn et al, 1987; Lee et al, 1988; Grandchamp et al, 
1989c). Four intragenic RFLPs in intron 1, 1345G/A (Msp I), 1500T/C (Pst I), 2377C/A 
(Apa LI) and 2479A/G (Bst NI), have been shown to be in linkage disequilibrium with the 
HMB-S gene (Scobie et al, 1990a; Lee et al, 1991), which makes these RFLPs less useful 
in the diagnosis of AIP.
Linkage analysis may prove to be useful in the diagnosis of presymptomatic AIP 
heterozygotes in families whose molecular pathologies are not known. However, a key 
individual known to suffer from the condition has to be available to allow the RFLPs to be 
tracked through the generations. Another important point is that the individuals analysed 
should be informative for the markers. These limitations can be overcome by performing 
direct mutation detection using one of the methods described in section 1.4.
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1.4 METHODS AVAILABLE FOR MUTATION DETECTION
The detection of sequence changes in human DNA is of great importance in the 
understanding of the molecular pathologies involved in genetic disease. Many methods 
have been developed for the detection of base alterations but no single method is suitable 
for all situations. Each technique has its advantages and disadvantages for a given situation, 
therefore, the method of choice should be evaluated to suit the length of template available 
(e.g. length of cDNA to be analysed), number of samples to be screened, or the urgency of 
the results.
1.4.1 POLYMERASE CHAIN REACTION (PCR)
The polymerase chain reaction (PCR) is an in vitro nucleic acid amplification method 
which has revolutionised modem molecular genetics. Saiki et al (1985) were the first to 
describe the technique, which consequently, became more widely used as compared to 
cloning strategies.
PCR comprises repeated thermal cycling of the reaction mixture. The thermal cycling 
serves to dissociate the products of the previous thermal cycle, then allowing the 
association of these dissociated products with further reaction starting materials for another 
phase of synthesis. Specifically, the template DNA is denatured at a high temperature to 
give single-stranded molecules. This is followed by short oligonucleotide primers 
(amplimers) annealing to specific, nucleotide sequence-defined regions of the template at a 
lower temperature. The positions where the amplimers anneal to the template define the 
‘target’. The thermal cycle is concluded by the amplimers being enzymatically extended by 
the coupling of appropriately base-paired 2'-deoxynucleoside triphosphates (dNTPs) on the 
template at an intermediate temperature, thus producing another double-stranded DNA 
(dsDNA) copy of the original target.
Each PCR cycle comprises a set of time- and temperature-controlled incubations. The 
function of each incubation is to:
(i) denature the target nucleic acid at a high temperature, usually in the region of 94°C;
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(ii) anneal amplimers at a temperature dependent on their calculated annealing temperature 
(usually in the range 30 - 65°C);
(iii) extend the primers by using the thermostable enzyme DNA polymerase which catalyses 
the addition of nucleotides to the 3' end of each primer at a temperature of about 72°C.
Each cycle results in the exponential amplification of the number of copies of the target 
sequence.
All the mutation detection methods currently used are PCR-based. These include 
single strand conformation polymorphism (SSCP), heteroduplex analysis (HA), denaturing 
gradient gel electrophoresis (DGGE), temperature gradient gel electrophoresis (TGGE), 
chemical cleavage mismatch (CCM) analysis, RNase A cleavage analysis, protein 
truncation test (PTT) and direct sequencing.
1.4.2 SINGLE STRAND CONFORMATION POLYMORPHISM (SSCP) 
ANALYSIS
Single strand conformation polymorphism (SSCP) analysis allows the detection of 
single base changes in short DNA fragments due to the mobility differences of single­
stranded DNA molecules. It depends on the ability of the fragment to fold back on itself to 
give a unique conformation by intramolecular base pairing. It was first described by Orita 
et al (1989) and is based on the principle that single stranded DNA molecules assume a 
three-dimensional conformation which is highly dependent on the primary sequence. If 
there is a sequence difference between the wild-type and mutant DNA, each of the single 
strands will assume a different conformation from the wild-type strands after denaturation 
and migrate differently on a non-denaturing polyacrylamide gel (Figure 1.5). Under non­
denaturing gel conditions, the conformation of the single strands is stabilised by intrastrand 
interactions.
SSCP has a detection rate of about 70 - 95% for segments about 200bp in length, 
which is a drawback if a large region is to be analysed. Another disadvantage of SSCP 
analysis is that it does not allow the location of the mutation within the fragment.
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SSCP
Homozygote A Heterozygote Homozygote B
Denature with heat and Formamide
Native Gel Electrophoresis
►
Figure 1.5: Diagrammatic representation of the principle of SSCP. 
(Adapted from Flowgen FMC Bioproducts).
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1.4.3 HETERODUPLEX ANALYSIS (HA)
Heteroduplex analysis (HA) is a relatively simple and rapid method for detecting 
mismatches between double-stranded DNA containing one wild-type strand and a 
complementary strand with an altered nucleotide sequence (Figure 1.6). The 
heteroduplexes are formed during the later stages of PCR (Nagamine et al, 1989). 
Fragments between 200-600bp are optimal for resolution of the homo- and heteroduplexes. 
Its detection rate is 80 - 90% for fragments less than 300bp (Grompe, 1993). Therefore, 
larger fragments will have to be screened by another method.
1.4.4 DENATURING GRADIENT GEL ELECTROPHORESIS (DGGE)
Denaturing gradient gel electrophoresis (DGGE) is a rapid screening technique which 
allows the resolution of DNA fragments differing by as little as a single nucleotide change. 
The method is based on the differential electrophoretic mobilities of wild-type and mutant 
DNA through linearly increasing concentrations of a denaturing agent (formamide and urea 
are common denaturants) (Fischer and Lerman, 1983; Myers et al, 1985). Another method 
of generating a denaturing gradient is to use temperature, and the method is known as 
temperature gradient gel electrophoresis (TGGE) (Meyer et al, 1991). The melting 
properties of DNA molecules with a single base difference will cause them to migrate 
differently into discrete sequence-dependent domains of low melting temperature. When 
the concentration of the denaturing agent equals the melting temperature (Tm) of the lowest 
melting domain of the DNA fragment, its mobility will eventually be retarded. The Tm of a 
melting domain is highly dependent on its nucleotide sequence because the stacking 
interactions between adjacent bases have a considerable effect on the stability of the double 
helix. Therefore, when the wild-type and mutant DNA fragments differing by a single base 
are electrophoresed in a polyacrylamide gel that contains an increasing linear denaturing 
gradient from the top to the bottom, the molecules will melt accordingly. The wild-type 
and mutant DNA can be visualised as discrete bands and any differences between the wild- 
type and mutant DNA can be easily identified.
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Figure 1.6: Diagrammatic representation of the principle of HA. 
(Adapted from Flowgen FMC Bioproducts).
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DGGE has been reported to have a 95% accuracy in PCR products up to 600bp 
(Grompe, 1993). In order for DGGE to function efficiently, a “GC-clamp” of about 30- 
40 nucleotides long is required at the 5’ end of the primer to provide a high Tm domain to 
prevent complete denaturation (Myers et al, 1985a). Like SSCP, DGGE does not localise 
the base change within a fragment.
1.4.5 RNase A CLEAVAGE ANALYSIS
The principle of heteroduplex analysis is also applicable to RNase A cleavage analysis. 
In this technique, an RNA:DNA heteroduplex between a radioactive wild-type riboprobe 
and mutant DNA, generated by PCR, is subjected to RNase A cleavage (Myers et al, 
1985b). This enzyme will recognise and cleave single-stranded RNA at the points of 
mismatch. The reaction is analysed by electrophoresis and autoradiography. The mutation 
can be localised by this method but the use of radioactively labelled RNA is required and 
has a detection rate of only approximately 50%. Because of this, it has been replaced by 
chemical cleavage mismatch (CCM) analysis.
1.4.6 CHEMICAL CLEAVAGE MISMATCH (CCM) ANALYSIS
The chemical cleavage mismatch (CCM) technique was first described by Cotton et al 
(1988) and is based on the principle of generating a heteroduplex between a radiolabelled 
wild-type DNA and mutant DNA by boiling and reannealing. If a base alteration is present 
in the mutant DNA, a heteroduplex is formed between the control and test DNAs. The site 
of mismatch is chemically modified with hydroxylamine and osmium tetroxide, and the site 
of modification is cleaved by piperidine. This is followed by denaturing polyacrylamide gel 
electrophoresis and autoradiography. Osmium tetroxide modifies mispaired thymines and 
hydroxylamine modifies mispaired cytosines. Adenosine and guanosine mismatches of the 
wild-type sense strand are detected by labelling the antisense strand of wild-type DNA in 
the heteroduplex. CCM is a very sensitive technique with a detection rate of >95% when 
only the wild-type DNA is labelled and 100% when both the mutant and wild-type DNAs 
are labelled (Forrest et al, 1991). The advantages of this method are threefold: (i) up to 2kb 
segments can be screened for sequence alterations; (ii) the type of base change is known
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from the cleaving reagent; and (iii) the localisation of the change is indicated by the size of 
the cleavage products. However, the entire CCM procedure is lengthy and involves the use 
of hazardous chemicals and radioactivity. This technique has been improved with the use of 
silver staining instead of [a-32P]dCTP (Saleeba et al, 1992) as an alternative method of 
detection, thus eliminating the use of radioactivity.
1.4.7 PROTEIN TRUNCATION TEST (PTT)
One of the latest techniques developed for mutation detection is the protein truncation 
test (PTT), first described by Roest et al (1993). This technique is useful for detecting 
mutations leading to premature translation termination and is not applicable to other single 
base alterations. A relatively large segment of coding sequence (about 2.4kb) can be 
screened and the site of mutation is localised, hence only a small region needs to be 
sequenced.
1.4.8 DIRECT SEQUENCING
Direct sequencing is a technique used to analyse the sequence of PCR products, either 
using DNA or cDNA as templates for PCR without an additional prior subcloning step into 
sequencing vectors. For genes which are relatively small, such as the hydroxymethylbilane 
synthase (HMB-S), direct sequencing of the coding region is used as the main method of 
mutation detection (Mgone et al, 1992).
Two methods are available for sequencing- the Maxam and Gilbert method (1977), 
which is based on the chemical modification of a particular base, and the Sanger method 
(1977), also known as the dideoxy method, which is an enzyme-based method.
In the Maxam and Gilbert method, the template is cut with a restriction enzyme into 
fragments which are then sorted by size. Batches of identical fragments, which have been 
radioactively labelled at one end, are then divided into four separate reaction tubes and 
treated with specific reagents which modify one or two of the bases. Under the conditions 
used for cleavage, each template molecule is probably cut at a small number of sites but in 
the total mixture, every position should be cleaved. The fragments are separated by high
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resolution denaturing polyacrylamide gel electrophoresis and visualised by 
autoradiography.
The Sanger method, or dideoxy method, involves the synthesis of the complementary 
strand of a single-stranded template using DNA polymerase. The procedure consists 
essentially of three steps: (i) annealing; (ii) labelling; and (iii) termination. The primer is 
initially annealed to the template, followed by the incorporation of the four nucleotides into 
the growing strand catalysed by DNA polymerase. A radioactively labelled nucleotide is 
included in the mixture for visualisation by autoradiography after separation on denaturing 
polyacrylamide gels. The termination reaction involves the addition of dideoxynucleoside 
triphophates (ddNTPs) into the four separate reaction mixtures. ddNTPs lack a 3'-OH 
group which is necessary for chain elongation, resulting in fragments of various lengths. 
These can be visualised as a sequence of bands upon autoradiography after polyacrylamide 
gel electrophoresis.
Direct sequencing provides the exact information on the location and base change 
involved, therefore, has to be performed as a final confirmatory step in all mutation 
detection methods.
Therefore, the overall strategy adopted in the detection of mutations in the HMB-S 
gene was to screen the entire coding sequence using HA and CCM, followed by direct 
sequencing. This strategy was chosen because both screening technologies enable the rapid 
analysis of the cDNA, which is short, as well as allowing the detection of point mutations, 
which are predominant in AIP. Based on the features of AJP and the HMB-S gene, SSCP 
and PTT are not suitable for use in this study.
1.5 IN VITRO GENE EXPRESSION SYSTEMS
Five major expression systems are available to researchers for application in in vitro 
gene expression: (i) K. coli\ (ii) Bacillus subtilis; (iii) yeast; (iv) mammalian cells; and (v) 
baculovirus. Proteins can be grouped into four classes to simplify the selection of 
expression systems (Goeddel, 1990): (i) small peptides (<80 amino acids) are easily
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expressed as fusion proteins in E. coli; (ii) secreted proteins (e.g. enzymes, cytokines and 
hormones), 80 to 500 amino acids, can be subjected to direct expression in all five systems. 
Proteins 100 to 200 amino acids in size can be efficiently expressed directly in E. coli; (iii) 
large (>500 amino acids) secreted proteins and cell surface receptor proteins are best 
expressed in mammalian cell expression systems; and (iv) non-secreted proteins (>80 
amino acids) which have not yet been studied thoroughly.
One of the purposes for expressing a new gene or cDNA is to ensure that the isolation 
of the correct sequence has been successful. If this is the main purpose of the experiment, 
and the protein being expressed is derived from a higher eukaryote, transient expression in 
mammalian cells can be easily performed, giving results rapidly and usually a biologically 
active protein is produced.
A growing interest in in vitro gene expression is the production of a mutant protein, 
either for structure-function experiments, or the correlation of the activity of a mutant 
enzyme with the mutation present. Therefore, it is important to select an appropriate 
expression system which will allow the generation of mutants in an assayable form.
The E. coli expression system is the most widely used system for in vitro expression. 
A high level of gene expression is a key requirement for basic research and the production 
of useful biological materials. The amount of proteins produced in culture at the time of 
harvest is of utmost importance and this requirement is achieved by using E. coli which is 
able to attain very high cell densities. E. coli has been considered to be a good expression 
system for producing proteins to generate antibodies. The antigen can be expressed rapidly 
in large quantities in E  coli, making it an ideal choice for this purpose.
Although a large number of proteins can be produced in E. coli, a number of 
limitations exist for the protein produced. It should not be too small, too large, too 
hydrophobic or contain too many cysteines. These guidelines should generally be taken into 
account if a stable protein with the correct conformation is to be produced. Fusion protein 
expression strategies usually permit good translation initiation and allows one to generate 
stable protein products with small peptides.
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1.6 AIMS OF THE PRESENT STUDY
The main aims of this project were:
(I) To detect and fully characterise mutations in the hydroxymethylbilane synthase (HMB- 
S) gene in patients suffering from acute intermittent porphyria (AIP).
(II) To develop an in vitro gene expression system to correlate the activities of the enzyme 
with the severity of the mutations detected using the HMB-S gene as a model.
(I) Detection and characterisation of mutations in the HMB-S gene
(a) To amplify the HMB-S coding sequence for subsequent mutation screening by 
heteroduplex and CCM analyses.
(b) To characterise the alterations detected by direct sequencing.
(c) To predict the effects of the mutations identified on the structure and function of the
protein product.
(II) Development of an in vitro expression system using the HMB-S gene as a model
(a) To introduce the HMB-S coding sequence into a plasmid expression vector containing 
a strong trc promoter and a strong transcription termination signal (/rwB).
(b) To verify the sequence of the clones by CCM analysis and direct sequencing before 
proceeding to gene expression studies.
(c) To determine the specificity of the custom-made antibody for the human form of 
HMB-S in order to separate it from the E. coli form of the enzyme.
(d) To separate the human HMB-S from the E. coli form using a variety of protein
separation techniques.
(e) To measure the activity of the human enzyme in the in vitro expression system and to 
correlate with the mutation present.
(f) To compare, where possible, the activity levels of the enzyme in the erythrocyte with 
that obtained in an in vitro expression system.
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CHAPTER 2: 
MATERIALS AND METHODS
CHAPTER 2: MATERIALS AND METHODS
2.1 PATIENTS
Nine AIP samples from nine different families from the University of Cape Town, 
South Africa, were kindly provided by Dr. Richard Hift. In addition, three samples from 
one family from England where the index case was individual 111:2 of Pedigree 13519 
(Appendix 1), seven samples from two families from the Republic of Ireland where the 
index cases of Pedigree 13168 were individuals 111:1 and 111:3 (Appendix 1) (the pedigree 
of the other family was not available) and eleven samples from three families from Scotland 
where the index cases of Pedigree 9532 were individuals 111:8 and 111:9 (Appendix 1) and 
that of Pedigree 13543 was individual 111:6 (Appendix 1) (the individual from the third 
family was an isolated case), were sent to us for molecular analysis. All these patients were 
identified as AIP sufferers on the basis of at least one of the following criteria: (i) increased 
urinary excretion of PBG, decreased activity of erythrocyte HMB-S and at least one acute 
attack; (ii) a relative suffering from AIP; or (iii) equivocal biochemical values. The 
biochemical data of the patients from South Africa and members of Pedigree 13168 are 
shown in Tables 2.1 and 2.2 respectively. The other family members analysed in the four 
pedigrees available were: IV: 1 and IV:2 (Pedigree 13519) (11:2 and 111:5 were found to be 
affected based on their biochemical values which were not provided); 11:1 to 11:6 , 11:8 , 
111:2, 111:5 to 111:8, 1V: 1 and IV:2 (Pedigree 13168); 11:2, 111:3, 111:5, 111:7 and 111:11 
(Pedigree 9532) (11:7 was found to be affected based on his biochemical values which were 
not sent to us); and 11:3, 111:2, 111:3 and 111:5 (Pedigree 13543) (the biochemical data of 
11:1 was not available).
To confirm that any sequence alterations detected in any of the above patients was not 
a polymorphism, twenty healthy individuals from the normal population were analysed for 
the same base change.
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Table 2.2: Biochemical data of five members of Pedigree 13168.
Individual Erythrocyte HMB-S 
activity (nmol/ml RBC/hr)
11:6 2 0 . 6
111:1 18.4
111:2 28.7
111:3 19.8
111:5 29.5
Reference range 22-46
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2.2 EXTRACTION OF GENOMIC DNA FROM BLOOD
Genomic DNA was extracted from peripheral blood lymphocytes according to a 
variation of the method described by Kunkel et al (1977). 10ml of peripheral blood 
collected in tubes containing ethylenediamine tetraacetic acid (EDTA) as an anticoagulant 
was transferred to a labelled 50ml Falcon tube and 40ml of cold lysis buffer (0.32M 
sucrose, lOmM Tris-HCl pH 7.5, 5mM MgCh, 1% Triton X-1 0 0 ) was added. The 
contents of the tube were mixed gently by inversion and centrifuged at 2800rpm for 1 0  
minutes at 4°C. The supernatant was discarded and the resulting pellet was resuspended in 
3ml of nuclei lysis buffer (lOmM Tris-HCl pH 8.0, 0.44M NaCl, 2mM EDTA pH 8.2), 
followed by the addition of lOOpl of proteinase K (lOmg/ml) to catalyse the digestion of 
histones and other proteins, and 2 0 0 pl of 1 0 % SDS. The contents were thoroughly mixed 
by inversion (the mixture should become dark and viscous) and incubated overnight at 
37°C. 1ml of 6 M NaCl was added to the overnight mixture to remove proteins and other 
impurities and shaken vigorously for 15 seconds. The tube was spun at 2500rpm for 15 
minutes. The supernatant was transferred to a fresh Falcon tube and 3ml of 
phenol/chloroform was added. The tube was inverted gently for 2  to 3 minutes before 
spinning at lOOOrpm for 20 minutes. The upper aqueous layer was transferred to a fresh 
tube and the DNA was precipitated with 2 volumes of absolute ethanol. The DNA was 
spooled out using a sealed Pasteur pipette, washed in 70% ethanol, air-dried and 
resuspended in 500(.il of TE buffer (lOmM Tris-HCl pH 7.5, ImM EDTA). The DNA was 
stored at 4°C until required.
2.3 EXTRACTION OF TOTAL CELLULAR RNA FROM LYMPHOCYTES
All necessary precautions were taken to avoid contamination by RNases. Glassware 
and plasticware used for the storage and preparation of RNA were soaked overnight in 
0.1% diethyl pyrocarbonate (DEPC) in sterile distilled water (SDW), rinsed in SDW and 
autoclaved.
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The lymphocytes were separated from whole blood as follows:
10ml of whole blood was collected in tubes containing EDTA and gently layered over an 
equal volume of Histopaque^-1077 (SIGMA) in a Universal. The tube was centrifuged at 
1400rpm for 30 minutes at room temperature. The interphase layer, consisting of 
mononuclear cells including lymphocytes, was carefully removed with a pastette and 
transferred to a fresh Universal. The cells were washed with 20ml of cold phosphate 
buffered saline (PBS) (SIGMA; each tablet contains 0.01M phosphate buffer, 0.0027M 
KC1, 0.137M NaCl, pH 7.4 at 25°C) and pelleted by centrifugation at 1400rpm for 10 
minutes. The supernatant was discarded and the pellet was subjected to total cellular RNA 
extraction using one of the following methods.
2.3.1 THE ACID-GUANIDINIUM THIOCYANATE-PHENOL-CHLOROFORM  
METHOD
The cells were given another wash with PBS and RNA extraction was performed 
according to the method described by Chomczynski and Sacchi (1987). The resulting pellet 
was resuspended in 500pl of solution D (denaturing solution) (4M guanidinium 
thiocyanate, 25mM sodium citrate pH 7.0, 0.5% sarcosyl, O.lmM p-mercaptoethanol). At 
this stage, DEPC-treated tips and tubes are used. [To minimise the handling of the 
hazardous compound guanidinium thiocyanate, 250g of guanidinium thiocyanate (Fluka) 
was dissolved directly, without weighing, in 293ml of water in the manufacturer’s bottle, 
17.6ml of 0.75M sodium citrate, pH 7.0 and 26.4ml of 10% sarcosyl at 65°C]. The mixture 
was transferred to an autoclaved and DEPC-treated 1.5ml eppendorf tube and to it was 
added 50pl of 2M sodium acetate (pH 4.0), 500jil of water-saturated phenol and 100(^ 1 of 
chloroform-isoamyl alcohol (49:1 ratio). The mixture was vortexed and placed on ice for 
15 minutes, after which it was centrifuged at lOOOOrpm for 20 minutes at 4°C. The 
aqueous phase was transferred to a fresh 1.5ml DEPC-treated eppendorf tube and 1ml of 
isopropanol was added. The contents were mixed well and kept at -20°C for at least 1 
hour or at 4°C overnight. The tube was centrifuged and the supernatant discarded. The 
pellet was dissolved in 300pl of solution D and 300pl of isopropanol was added. The tube
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was left at -20°C for 1 hour and then spun for 10 minutes at 4°C. The pellet was washed in 
250pl of 75% ethanol, air-dried and dissolved in lOOpl of DEPC-treated water at 65°C for 
10 minutes. The RNA sample was stored at -20°C.
2.3.2 THE TRIZOL® METHOD
1 ml of TRIZOLR reagent (Gibco BRL) was added to the pellet to lyse the cells by 
passing the suspension several times through a DEPC-treated pipette tip. The lysate was 
transferred to a 1.5ml DEPC-treated eppendorf tube and incubated for 5 minutes at room 
temperature to permit the complete dissociation of nucleoprotein complexes. 2 0 0 (1 1  of 
chloroform per 1ml TRIZOL* reagent was added and shaken vigorously by hand for 15 
seconds. The mixture was incubated at room temperature for 2 to 3 minutes, after which it 
was centrifuged at no more than 12000g for 15 minutes at 4°C. The colourless upper 
aqueous phase, containing the RNA, was transferred to a fresh 1.5ml eppendorf tube. [The 
lower red, phenol-chloroform phase can be used for DNA extraction if required]. 500pl of 
isopropanol per 1 ml of TRIZOL* reagent used fo'r the initial homogenisation was added to 
precipitate the RNA from the aqueous phase and incubated at room temperature for 10 
minutes. The tube was centrifuged at 12000g for 10 minutes at 4°C, the supernatant was 
discarded and the RNA pellet was washed once with 1ml of 75% ethanol per 1ml of 
TRIZOL* reagent used for the initial homogenisation. The tube was vortexed and 
centrifuged at no more than 7500g for 5 minutes at 4°C to pellet the RNA. The 
supernatant was discarded, the RNA pellet was air-dried for 5 to 10 minutes and dissolved 
in an appropriate volume of RNase-free water. The tube was incubated at 55-60°C for 10 
minutes to ensure that the pellet had completely dissolved.
2.3.3 RNeasy" TOTAL RNA KIT
The RNeasy™ total RNA kit was obtained from QIAGEN Ltd. 350pl or 600(^ 1 
(depending on the number of cells available) of lysis buffer RLT (lOpl of |3- 
mercaptoethanol was added to 1 ml of lysis buffer RLT before use) was added to the pellet 
and transferred to a 1.5ml RNase-free eppendorf tube. The tube was centrifuged for 3
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minutes to pellet any insoluble material, 1 volume (350fil or 600jil) of 70% ethanol was 
added to the lysate, mixed by pipetting and applied onto an RNeasy spin column. The 
column was spun for 15 seconds at lOOOOrpm and the flow-through was discarded. The 
column was next washed with 700jil of wash buffer RW1, followed by 500|il of wash 
buffer RPE (the concentrated RPE solution was diluted with 4 volumes of ethanol). The 
flow-through was discarded and the column was washed with 500(j.l of wash buffer RPE 
and spun for 2 minutes to dry the membrane. The RNA was eluted with 30 to 50|nl of 
DEPC-treated water into a 1.5ml collection tube by spinning for 60 seconds at 8000g. The 
RNA was stored at -20°C.
2.4 VISUALISATION OF THE EXTRACTED RNA
To ascertain the quality of the extracted RNA, a 30ml 1% agarose checking gel was 
prepared by weighing out 0.45g of agarose into 22ml of dH20. After cooling the gel in a 
fume hood to 55°C, 5ml of (37%) formaldehyde and 3ml of 10X MOPS buffer [3-(N- 
morpholino) propanesulfonic acid] were added and the gel was immediately poured before 
setting, lpl of RNA was mixed with 5pl of formamide, 1.65|il of (37%) formaldehyde, l|il 
of 10X MOPS and 1.3pl of dH20. The preparation was heated to 55°C for 10 minutes, 
quenched on ice and 2pl of gel loading buffer (0.25% bromophenol blue, 0.25% xylene 
cyanol FF, 40% sucrose in water) was added. 1 fig of Escherichia coli (E. coli) ribosomal 
RNA (Boehringer Mannheim) was also loaded as size markers and electrophoresed at 75V 
for 1 hour with 1X MOPS as running buffer. After electrophoresis, the gel was soaked in 
SDW for 1 hour to remove the formaldehyde and stained in 5|ig/ml of ethidium bromide. 
The gel was destained overnight in water, after which it was viewed under UV light to 
check for the integrity of the ribosomal bands and to estimate the concentration of the 
RNA.
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2.5 DETERMINATION OF NUCLEIC ACID CONCENTRATION
The concentration of DNA and RNA was determined by spectrophotometry 
(Pharmacia GeneQuant II RNA/DNA calculator). The optical density (OD) was measured 
at 260nm and 280nm. Each sample was diluted by adding 5pl of sample to 995pl of dH20. 
An OD reading of 1 corresponds to approximately 40pg/ml of RNA and 50pg/ml of DNA. 
A value of 2 for the ratio of the absorbances at 260nm to 280nm indicates good quality 
nucleic acid.
2.6 DESIGN, SYNTHESIS AND PURIFICATION OF OLIGONUCLEOTIDES
The primers required for genomic DNA and RT-PCR amplifications were designed 
with the aid of the OLIGO™ Version 3 .4 (©Wojciech Rychlik; MEDPROBE). The primers 
were selected on the basis of the following criteria: (i) the average G+C content was 
around 50% and consisted of a random base distribution; (ii) the calculated Tm of both 
primers, where an addition of 2°C was used for A or T and 4°C for G or C was in the 
range of 50-75°C; and (iii) the length of the primers was about 20 to 30 bases, and 
palindromic sequences as well as a rich distribution of Cs or Gs at the 3' end were avoided. 
In addition, self-complementarity between the primers was avoided i.e. no internal duplex 
structures were allowed. The sequences of the primers used in this study are shown in 
Table 2.3.
All the primers were synthesised on the APPLIED BIOSYSTEMS 391 DNA 
SYNTHESISER. The primers required a deprotection stage to remove the oligonucleotide 
from the solid support and, hence, the column. This is done by using the double syringe 
method to flush the column several times (Sawadago and Van Dyke, 1991). This treatment 
removes the cyanoethyl phosphate protecting groups. 1ml of ammonia solution was 
pushed into the column over three 1 0 -minute intervals and collected at the other end by 
another 1ml syringe and placed in a Nunc tube. An additional 1ml of ammonia solution was 
added and the tube was incubated overnight at 55°C to remove the protecting groups on
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Table 2.3: Sequence of the primers used in this study showing their locations in the 
HMB-S gene.
Location Primer Sequence (5' —» 3')
5' UTR—»E 1 019H(F) tac ttt cca age gga gcc ATG
El 377H(F) CAT GTC TGG TAA CGG CAA TGC GG
E3 750D(F) GAT TCG CGT GGG TAC CCG CA
E4 Phe4-(R) GAG GCT TTC AAT GTT GCC AC
E5 F161(F) TTG CTA TGT CCA CCA CAG GGG
E6 Phe6 +(F) ATG CCC TGG AGA AGA ATG A
E7 R341(R) CAG ATG GCT CCG ATG GTG AAG
E8 F3 56(F) CTC ATG ATG CTG TTG TCT TTC
E8-»E9 F413(F) CAG AGA AGA GTG TGG TGG GAA
E9 R478(R) GCG GGA ACT TTC TCT GCA GCT
E9—»E10 F482(F) TGG AGT TCA GGA GTA TTC GGG
E10 PhelO+(F) GGA AGC TGG ACG AGC AGC AGG A
E ll Phel 1-(R) CAC AGC ATA CAT GCA TTC CTC A
E12 F6 6 6 (F) GGA AGT GCG AGC CAA GGA CCA
E12 F2CA(F) TGC TTC GCT GCA TCG CTG AA
E13 Phel3-(R) CTA CTG GCA CAC TGC AGC CTC
E13—»E14 F808(F) GCT ATG AAG GAT GGG CAA CTG
E14 749D(R) CAT GGA TGG TAG CCT GCA TGG TCT C
E15 F951(F) CAT CAC TGC TCG TAA CAT TCC
3' UTR 508D(R) cat ctg tgc ccc aca aac cag
3 'UTR 020H(R) atg tag gca ctg gac age age
17 17(F) aat acc agt gag ttg gca ate g
18 I8 (R) tcc ctg cat ctt ctg ggc aca t
UTR, E, I: untranslated region, exon, intron; (F), (R): forward, reverse; lower case: 
intronic sequence; upper case: exonic sequence.
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the exocyclic amines of the bases. The ammonia was evaporated off overnight until the 
solution was odourless. The OD was read at 260nm and an appropriate concentration of 
primers was used for PCR amplification.
2.7 PCR TECHNOLOGY
2.7.1 GENOMIC DNA-PCR
All PCR reactions were performed in lOOpl which contained IX PCR buffer [Perkin 
Elmer; lOmM Tris-HCl pH 8.3, 50mM KC1, 1.5mM MgCE, 0.001% (w/v) gelatin], 
200pM of each dNTP and 0.5pM of each primer. The mixture was UV-irradiated for 10 
minutes in the GRI-Amplirad to minimise contamination. 0.5-lng of DNA and 2 units of 
Taq DNA polymerase were added, overlaid with 50|il of light mineral oil and subjected to 
PCR, which was performed either on the TECHNE PHC1 automated thermocycler or the 
HYBAID OmniGENE. 35 cycles of PCR was carried out, each comprising a denaturing 
step at 95°C for 1 minute, annealed at 60°C for 1 minute and primer extension at 72°C for 
1.5 minutes. A final extension step of 10 minutes at 72°C was done after the completion of 
the 35 cycles. The PCR products were visualised on a 2% agarose gel containing ethidium 
bromide (lOpg/ml) run in IX TBE buffer (10X TBE: 108g Tris base, 55g boric acid, 9.3g 
EDTA and made up to 1 litre). The samples were prepared for loading by mixing 5(il of 
each sample with lpl of loading buffer (30% glycerol, 0.25% bromophenol blue).
2.7.2 REVERSE TRANSCRIPTASE PCR (RT-PCR)
PCR requires a double-stranded template to function. RNA is not recognised by Taq 
DNA polymerase to be a suitable template for extension, therefore, it has to be converted 
to complementary DNA (cDNA) for Taq DNA polymerase to function in PCR. This is 
achieved by RT-PCR, a sensitive and rapid method for screening mRNA molecules for size 
differences caused by deletions, insertions or splicing defects which lead to exon skipping.
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In this study, three different methods of priming were used to generate cDNA, as 
outlined below.
2.7.2.1 RT-PCR USING OLIGO(dT1218)
0.5-1 (ig of RNA diluted in DEPC-treated water was heated at 95°C for 5 minutes for 
denaturation and immediately quenched on ice. 0.2fig of oligo (dT^-is) (Pharmacia) was 
added to prime the reaction at 65°C for 1 0  minutes and immediately quenched on ice. 2jal 
of 0.1M DTT, 2j.il of 250jiM of each dNTP, 4|il of 5X reverse transcriptase buffer (Gibco 
BRL; 250mM Tris-HCl pH 8.3, 375mM KC1, 15mM MgCE) and 200 units of Moloney 
Murine Leukaemia Virus (MMLV) reverse transcriptase (Gibco BRL) were added. The 
volume was adjusted to 2 0 pl and the mixture was incubated at 37°C for 1 hour. After 
reverse transcription, the mixture was heated at 95°C for 5 minutes to inactivate the 
enzyme (Sellner et al, 1992) and to disrupt the mRNA:cDNA hybrid.
2.7.2.2 RT-PCR USING DOWNSTREAM PRIMERS
The methodology is exactly the same as in section 2.7.2.1 except that 0 .1  |xM of a 
gene-specific primer was used in place of oligo (dTms).
2.7.2.3 RT-PCR USING RANDOM HEXAMERS
0.2jig of random hexamers (Gibco BRL) was used to prime the RT reaction instead of 
oligo (dT,2.i8) or the downstream primer.
The cDNA synthesised by all three methods is ready for use as a template for PCR 
analysis. The entire reaction mixture was used for PCR which consisted of IX PCR buffer, 
0.5j.iM final concentration of each primer (except for the reverse primer used in section 
2.1.22 where 0.4pM should be added) and 2 units of Taq DNA polymerase. The volume 
was adjusted to 1 0 0 j.il, vortexed briefly and centrifuged quickly. The mixture was overlaid 
with light mineral oil (SIGMA) and PCR was performed as in section 2.7.1. If a good yield
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of PCR product was obtained as seen on an agarose gel (section 2.7.1), the remainder of 
the sample was electrophoresed, the appropriate band was excised from the gel and the 
cDNA was eluted by soaking for 24 hours in lOOpl of TE buffer at -20°C. The 
supernatant, containing the eluted cDNA, was transferred to a fresh tube for further 
analyses.
2.7.3 GENERATION OF RADIOACTIVELY LABELLED PCR PRODUCTS
2.7.3.1 5' END-LABELLED PCR PRODUCTS
This was necessary to generate the radioactive probe for CCM analysis. This was 
achieved by 5' end-labelling, in a total volume of 10pl, 50pmol of each primer with 5- 
lOpCi [y-32P]dATP (Amersham; 3000Ci/mmol; lOCi/ml) in IX T4 polynucleotide kinase 
buffer (Pharmacia; 10X buffer: lOOmM Tris-acetate, lOOmM magnesium acetate, 500mM 
potassium acetate) and 10 units of T4 polynucleotide kinase (Pharmacia). The mixture was 
incubated at 37°C for V2 -1 hour, after which it was ready for use in PCR.
2.7.3.2 INTERNALLY-LABELLED PCR PRODUCTS
To internally label PCR products for use in CCM analysis, PCR was carried out as 
before (section 2.7.1) except that the concentration of cold dCTP was reduced from 
200pM to 6 pM and 20pmol of [a-32P]dCTP (60pCi) (3000Ci/mmol; lOCi/ml) was added. 
The number of PCR cycles was reduced to prevent the generation of non-specific products 
by the misincorporation of alternate dNTPs as [dCTP] decreased.
2.7.4 ASYMMETRIC PCR
Asymmetric PCR was carried out to generate single-stranded templates for direct 
sequencing (Gyllensten and Erlich, 1988) as described by Mgone et al (1992). lOpl of the 
gel-eluted double-stranded PCR product was used as a template for asymmetric PCR, 
where one primer was 50 to 100 times less concentrated than the other (0.5 to 1 .OpM) in a 
total volume of 10 0 f.il. The other components were the same as for symmetric PCR but the 
number of cycles was increased to 40 to 45 cycles as there is a linear increase in the
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amount of PCR products due to the limiting concentration of one primer. The asymmetric 
PCR product yield was monitored by agarose gel electrophoresis as previously described 
(section 2.7.1), with a double-stranded control and a suitable marker [Gibco BRL; lkb 
ladder (l.Olpg/pl) or lOObp ladder (lpg/pl)] run at the same time to determine the 
position and amount of the single strands. If sufficient single strands are available, they can 
be used for direct sequencing.
2.7.5 PCR SCREENING FOR RECOMBINANT CLONES
To screen bacterial colonies for the presence of the successful ligation of the insert to 
the plasmid after transformation, primers were designed where one spanned across the 
plasmid-insert junction (pTrc 99A, Table 2.4) and the other was a primer corresponding to 
the sequence of the insert (R341, Table 2.3). This was to ensure that the colonies which 
gave positive PCR results are due to the successfully ligated fragments.
The PCR reaction mixture contained the same concentrations of PCR buffer, dNTPs 
and primers as before (section 2.7.1). The template used here was that of the 
bacterial colony, scraped (one-sixth of the colony) from the agar plate with a toothpick, 
and dipped into the PCR mixture to release the cells. The mixture was vortexed and heated 
at 99°C for 10 minutes. The tube was immediately placed on ice and Taq DNA polymerase 
was added. PCR was carried out as in section 2.7.1, except that the annealing temperature 
was 57°C. At the same time, the colonies were grown in a 5ml culture containing 1 0 0 |ig/ml 
of ampicillin. Colonies which yielded a positive PCR result had the plasmid DNA extracted 
from the corresponding cultures (section 2.9.6). Confirmatory steps of restriction mapping, 
CCM and direct sequencing were performed before proceeding to large scale preparation 
of plasmid DNA (section 2.9.7).
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Table 2.4: Primers used for in vitro expression studies.
Primer Orientation Sequence (5'—>3')
pTrc 99A Forward TTG ACA ATT AAT CAT CCG GC
p214 Forward CGT ATA ATG TGT GGA ATT GTG
p383 Reverse GCG TTC TGA TTT AAT CTG TAT C
PheN Forward GAG CCA TGG CTG GTA ACG GCA ATG C
PheH Reverse CCC AAG CTT CTG TGC CCC ACA AAC CA
pTrc 99A was used in conjunction with R341 (Table 2.3) to amplify across the plasmid- 
insert junction. p214 and p383 were used to amplify part of the region of the plasmid 
flanking the insert to enable sequencing across the plasmid-insert junctions at both the 5' 
and 3' ends. PheN and PheH incorporate the Nco I and Hind III restriction sites 
respectively to enable ligation of the insert into the expression vector for further analysis.
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2.7.6 RESTRICTION ENDONUCLEASE ANALYSIS OF RESTRICTION SITES
2.7.6.1 DETERMINATION OF RESTRICTION SITES
The flanking region of any sequence alteration was analysed on the GCG Package for 
any creation or destruction of restriction sites. Table 3.3 lists the various restriction 
enzymes employed in this study for the confirmation of a nucleotide change or to determine 
the carrier status of a relative of an affected individual where possible.
2.7.6.2 ETHANOL PRECIPITATION OF PCR PRODUCTS
To prepare the PCR products for restriction enzyme digestion, ethanol precipitation 
was carried out to purify the products. 40pl of PCR product was mixed with one-tenth its 
volume of 3M sodium acetate (pH 5.2) and 2 volumes of absolute ethanol. The tube was 
kept at -20°C for 1 0  minutes, spun for 1 0  minutes and washed in 70% ethanol for 5 
minutes. The resulting pellet was air-dried and resuspended in IOjj.1 of dH20. 2pl of the 
appropriate enzyme buffer and 1 unit of the restriction enzyme was added in a total volume 
of 20pl. The tube was incubated at 37°C for at least 1 hour. The digests were checked on 
an agarose gel to ensure that the digestion was successful and that it had gone to 
completion.
2.8 MUTATION DETECTION TECHNIQUES
In this project, three different mutation detection methods were employed for the 
initial screening and characterisation of mutations. These were: (i) heteroduplex analysis 
(HA); (ii) chemical cleavage mismatch (CCM) analysis; and (iii) direct sequencing. All 
three techniques are PCR-based.
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2.8.1 HETERODUPLEX ANALYSIS (HA)
Heteroduplex analysis (HA) was performed using the MDE Heteroduplex Kit from 
FLOWGEN. The kit consists of 500ml of 2X MDE gel solution, 60|il of a 350bp 
heteroduplex control in triple dye loading buffer and 1.1 ml of 6 X triple dye loading buffer. 
The PCR conditions for the products generated for subsequent HA must be fully optimised 
to ensure that no non-specific products are present which may interfere with the 
heteroduplex bands.
At the end of the final PCR cycle, EDTA was added to a final concentration of 5mM 
(lpl of 0.5M EDTA per 100^1 reaction) to inactivate the DNA polymerase. 5pl of each 
sample was heated at 95°C for 3 minutes, and cooled slowly to 37°C over a period of 30 
minutes for the formation of heteroduplexes. 1 |il of the triple dye loading buffer was added 
to each sample tube and mixed well.
The gel was made using the Bio-Rad Sequencing Cell apparatus with 1mm spacers and 
comb. The gel was composed of 50ml of 2X MDE Gel Solution, 6 ml of 10X TBE buffer, 
15g of urea and made up to 100ml with dH20. 400(j.l of freshly prepared 10% ammonium 
persulphate (APS) and 40pl of N,N,N,N-tetramethylethylenediamine (TEMED) were 
added to facilitate the polymerisation of the gel. 0.6X TBE buffer was used as the running 
buffer. The samples, together with the appropriate DNA size markers and the 350bp 
control heteroduplex, were loaded onto the gel and electrophoresed overnight for 16-20 
hours at a constant voltage of 20V/cm of the gel. For a 50cm gel, a constant voltage of 
1 0 0 0 V was used.
2.8.1.1 SILVER STAINING OF POLYACRYLAMIDE GELS
After the gel run, silver staining was carried out. For all the steps, the gel should be 
kept totally submerged in solution with gentle shaking. The gel was fixed in a solution of 
10% ethanol/0.5% acetic acid for 10 minutes. The solution was discarded and the gel was 
stained in 0 .1% silver nitrate for 15 minutes, after which it was briefly rinsed twice in 
ddH20. The bands were developed in a solution of 1.5% sodium hydroxide/0.1% 
formaldehyde for 2 0  minutes, or until the bands were of the desired intensity. The gel was
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fixed in 0.75% sodium carbonate for 10 minutes, sealed in a plastic bag and photographed 
immediately.
2.8.2 CHEMICAL CLEAVAGE MISMATCH (CCM) ANALYSIS
This technique is able to detect point mutations, small deletions and insertions. It is 
based on the cleavage of mismatched bases which are modified chemically (Cotton et al, 
1988).
There are five major steps in this method: (i) preparation of the labelled DNA probe 
and unlabelled test DNA; (ii) formation of heteroduplexes; (iii) chemical modification; (iv) 
chemical cleavage of mismatched base pairs; and (v) electrophoresis and autoradiography.
(i) PREPARATION OF LABELLED DNA PROBE AND UNLABELLED TEST DNA
The probe and test samples required in this step were generated by PCR amplification 
as described in sections 2.7.3 and 2.7.1 respectively. The PCR products were purified to 
remove ethidium bromide, primers and unincorporated dNTPs, either directly or after 
electrophoresis in a low melting point agarose gel (Nusieve from FMC Bioproducts), 
depending on whether non-specific bands were present. For this, the GENECLEAN II® 
KIT (Bio 101) was used. To the PCR product or gel slice (excised from the low melting 
point agarose gel) was added 3 volumes of 6 M Nal solution, the latter was incubated at 
45-55°C until the gel slice was dissolved. 1 0 pl of the glassmilk suspension was added to 
allow the DNA to adsorb onto the glassmilk matrix. The tubes were vortexed and kept on 
ice for 15 minutes, after which they were centrifuged for 5 seconds. The glassmilk-DNA 
complex was washed three times with the NEW WASH buffer (diluted as instructed by the 
manufacturer). The pellet was resuspended in 15-20pl of TE buffer (section 2.2) and 
incubated at 65°C for 10 minutes to elute the DNA. The mixture was centrifuged for 10 
minutes and the supernatant was transferred to a fresh tube. Approximately 100ng/|il of 
DNA was typically recovered. The procedure was repeated for the radiolabelled probe.
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(ii) FORMATION OF HETERODUPLEXES
Two sets of labelled 1.5ml siliconised eppendorf tubes were prepared for each sample, 
one for the hydroxylamine reaction and the other for the osmium tetroxide reaction. 1 0 - 
15ng of labelled probe (105 cpm) was mixed with a 10-fold excess of unlabelled test DNA 
(100-150ng), 18f.il of 10X hybridisation buffer (1M Tris-HCl pH 8.0, 3M NaCl) and the 
total reaction volume adjusted to 180|nl with TE buffer. lOOfil of light mineral oil was 
overlaid onto the mixture which was boiled for 5 minutes and immediately transferred to a 
water-bath set at 65°C for a 5- to 16-hour incubation for the formation of heteroduplexes. 
750f.il of precipitation mix (63mM sodium acetate, 20(iM EDTA, 80% ethanol) and 3jj,1 of 
mussel glycogen (Boehringer Mannheim; 20mg/ml) were added and the mixture was kept 
on dry ice for 15 minutes, after which it was spun at 12000rpm for 10 minutes. The pellet 
was washed with 70% ethanol, air-dried and resuspended in 7fil of TE buffer.
(iii) CHEMICAL MODIFICATION
HYDROXYLAMINE REACTION
20f.il of hydroxylamine solution [1.39g of hydroxylamine hydrochloride (BDH), 1.6ml 
of pre-warmed (37°C) ddH20 , adjusted to pH 6.0 with approximately 1.6ml of 
diethylamine] was added to the designated tubes containing 7fxl of the heteroduplex and 
incubated at 37°C for 2 hours.
OSMIUM TETROXIDE REACTION
18fil of osmium tetroxide solution [1.5^1 of 4% osmium tetroxide solution (Aldrich) 
which is stable at 4°C for up to 3 months, 6.75(il of pyridine (BDH), 154fj.l of TE buffer] 
was added to the other set of tubes designated for the osmium tetroxide reaction. The 
tubes were incubated at 37°C for 2 hours.
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Both the hydroxylamine and osmium tetroxide reactions were stopped by adding 
750pl of precipitation mix and kept on dry ice for 10 minutes. The tubes were centrifuged 
for 10 minutes at 12000rpm and the pellet was washed with 70% ethanol and air-dried.
(iv) PIPERIDINE CLEAVAGE OF MISMATCHED BASE PAIRS
50pl of a 10% piperidine solution (Fluka) was added to each pellet, vortexed for 30 
seconds and incubated at 90°C for 30 minutes. The reaction was stopped with the addition 
of 750|il of precipitation mix and incubated on dry ice for 10 minutes. The tube was spun 
as before and the pellet was resuspended in lOpl of formamide loading buffer (95% 
formamide, 1 OmM EDTA, 1 Omg/ml bromophenol blue, 1 Omg/ml xylene cyanol FF).
(v) GEL ELECTROPHORESIS AND AUTORADIOGRAPHY
The samples were heated at 95°C for 5 minutes, snap-chilled on ice and subjected to 
electrophoresis on a 0.4mm-thick 8 % denaturing polyacrylamide gel containing 7M urea as 
denaturant, prepared by using the sequencing gel apparatus (Bio-Rad; Sequigen) at 35W 
until the xylene cyanol is at the bottom of the gel. The gel solution was made up of 12ml of 
a 40% acrylamide.bisacrylamide (19:1) (NBL Ltd.), 25.3g urea, 6 ml of 10X TBE buffer 
and dH20  to adjust the volume to 60ml. 100pl of a freshly prepared 25% APS and 
TEMED were added. IX TBE buffer was used as the running buffer. A labelled DNA 
marker (Gibco BRL; lkb or lOObp) was run together with the samples to allow the 
determination of the size of the cleavage products. The gel was transferred onto a piece of 
3 mm Whatman paper, cut to the size of the gel, overlaid with SARAN WRAP™ and 
autoradiographed using KODAK X-Omat AR film for 12 to 16 hours.
The labelled DNA marker was prepared as follows: 
lpl of the appropriate DNA marker was mixed with lpl of 10X T4 polynucleotide kinase 
buffer (Pharmacia), 7pl of dH20 , 5 units of T4 polynucleotide kinase (Pharmacia) and 5pCi 
[y-32P]dATP. The mixture was incubated at 37°C for Vi - 1 hour and the reaction was
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stopped with 50jj.l of formamide loading buffer [section 2.8.2(iv)]. It was denatured 
together with the samples for CCM analysis prior to loading.
2.8.3 DIRECT SEQUENCING
Direct sequencing of the HMB-S DNA or cDNA was carried out using the dideoxy 
chain terminating method (Sanger et al, 1977) using the Sequenase™ Version 2.0 
sequencing kit (Amersham). Single-stranded templates required for sequencing were 
generated by asymmetric PCR (section 2.7.4). The asymmetric PCR products were purified 
by adding an equal volume of 4M ammonium acetate and 2 volumes of isopropanol. The 
mixture was incubated at room temperature for 1 0  minutes, centrifuged for 1 0  minutes, 
washed in 70% ethanol and resuspended in 14pl of dH20. 7pl was used for each 
sequencing reaction.
Sequencing was performed according to the manufacturer’s instructions. 7pl of the 
single-stranded template was mixed with 2pl of 5X Sequenase™ reaction buffer (to give a 
final concentration of 40mM Tris-HCl pH 7.5, 20mM MgCl2, 50mM NaCl) and lpmol of 
the appropriate sequencing primer. The mixture was annealed by incubating at 65°C for 2 
minutes and then allowed to cool slowly to less than 35°C over a period of 30 minutes. 
[While cooling, four tubes (for each of the termination mixtures) for each sample were 
labelled, 2.5pl of each termination mixture (containing 80pM of each dNTP and 8 pM of 
each ddNTP) was transferred to the appropriate tube and pre-warmed at 42°C]. The 
mixture was immediately placed on ice and to it was added 1 pi of 0.1 M DTT, 2pl of a 1:5 
dilution of labelling mix (7.5pM of each dNTP except dATP), 0.5pl of [a-35S]dATP 
(lOOOCi/mmol; lOpCi/pl), Ipl of Mn buffer (0.15M sodium isocitrate, 0.1M MnCl2) if 
sequences close to the primer are to be read, and 2pl (1.5 units) of a 1:8 dilution of T7 
DNA polymerase [25j.il of Sequenase™ Version 2.0, 13 units/pl; diluted with 25pl of 
inorganic pyrophosphatase (5 units/ml in lOmM Tris-HCl pH 7.5, 0.1 mM EDTA, 50% 
glycerol) and 150j.il of glycerol enzyme dilution buffer (20mM Tris-HCl pH 7.5, 2mM 
DTT, 0.1 mM EDTA, 50% glycerol)]. The mixture was incubated at room temperature for 
2 to 5 minutes. 3.5j.il of the labelling reaction was then added to each termination mix at
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42°C and incubated at 42°C for a further 5 minutes, after which 4fil of formamide-dye stop 
solution (95% formamide, 20mM EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol 
FF) was added to terminate the reaction. The samples can be stored at -20°C until 
required.
Because the Sequenase™ enzyme was diluted in glycerol-containing buffer, the buffer 
used in the polyacrylamide gel should be a glycerol tolerant gel buffer (20X TTE: 216g 
Tris base, 72g taurine, 4g Na2EDTA.2 H20  and made up to 1 litre). The gel used to run the 
sequencing reactions was an 8 % polyacrylamide gel containing 7M urea with IX TTE 
buffer as the gel and running buffers. The gel was pre-warmed to 50°C before sample 
loading. Once the gel had reached the desired temperature (as determined by a temperature 
indicator), the samples were heated at 75°C for 2 minutes, snap-chilled on ice and loaded 
onto the gel. The gel was electrophoresed at 50°C for 2 to 4 hours, after which it was fixed 
in 10% methanol/10% acetic acid for 10 minutes, dried in a vacuum gel drier (Bio-Rad) at 
80°C for at least 30 minutes and exposed for 16 to 18 hours to KODAK X-Omat AR film 
in a cassette using intensifying screens.
2.9 TECHNIQUES IN RECOMBINANT DNA
2.9.1 RESTRICTION DIGESTS OF DOUBLE-STRANDED DNA AND VECTOR
The primers used for the amplification of the fragments to be cloned have each been 
modified to contain a restriction site, Nco I for the 5' primer, and Hind III for the 3' primer 
(primers PheN and PheH respectively, Table 2.4) for ligation with the expression vector, 
pTrc 99A (Pharmacia). The amplified products were visualised on a 1% agarose gel and 
ethanol precipitated as in section 2.7.6.2. Both restriction enzymes were obtained from 
Pharmacia and the digestion was carried out on both the DNA fragments and vector for 2 
hours at 37°C using 5 units of each enzyme.
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2.9.2 LIGATION
The digested fragments and vector were added in a molar ratio of 3:1 of insert to 
vector. In a 0.5ml sterile eppendorf tube, 100-200ng of the linearised vector was added to 
approximately one-tenth of the purified digested insert, 1 pi of 1 OX ligase buffer (Promega; 
300mM Tris-HCl pH 7.8, lOOmM MgCl2, lOOmM DTT, 5mM ATP) and 0.1 to 1 Weiss 
unit of T4 DNA ligase. The volume was brought to lOpl with dH20. The reaction mixture 
was incubated at 15°C for 16 hours as recommended by the manufacturer.
2.9.3 TRANSFORMATION OF COMPETENT CELLS
The strain of K co/i competent cells used was JM109 (Promega). 5pl of the ligation 
mixture was added to 1 OOpl of ice-cold JM109 competent cells and incubated for a further 
30 minutes on ice. The mixture was given a heat-shock treatment at 42°C for 1 minute and 
then chilled on ice for 2 minutes. 500pl of L-broth medium (lOg bactotryptone, 5g yeast 
extract, lOg NaCl, pH 7.5) was added followed by an incubation at 37°C for 1 hour in an 
orbital shaker, after which lOOpl of the mixture was spread onto agar plates (L-broth 
medium + 1.5% agar) containing lOOpg/ml of ampicillin. The plates were incubated at 
room temperature for 5 minutes before incubation overnight in a 37°C incubator.
2.9.4 SCREENING FOR PUTATIVE RECOMBINANT CLONES
The colonies formed on the agar plates were screened for the presence of the insert as 
described in section 2.7.5.
2.9.5 PREPARATION OF GLYCEROL STOCKS
Colonies which did not contain any extraneous misincorporations were immortalised 
as glycerol stocks. This was done by growing the colony in 10ml of L-broth medium 
containing lOOpg/ml of ampicillin overnight at 37°C with shaking, after which a 15% 
glycerol stock was made and stored at -70°C.
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2.9.6 MINIPREPARATION OF PLASMID DNA
Three different methods were used in the mini preparation of plasmid DNA: (i) alkali- 
lysis method; (ii) QIAprep™ Plasmid Kit; and (iii) INSTA-MINI-PREP™ kit.
(i) ALKALI-LYSIS METHOD
Minipreparation of plasmid DNA was carried out by the alkali-lysis method according 
to Sambrook et al (1989). A single bacterial colony was inoculated in 5ml of L-broth 
medium containing lOOpg/ml of ampicillin overnight at 37°C with shaking. 1.5ml of this 
culture was spun for 15 seconds to pellet the cells which were resuspended in 1 OOjj.1 of 
solution A (25mM Tris-HCl pH 8.0, lOmM EDTA, 50mM glucose). 2mg/ml of lysozyme 
was freshly added. 200pl of solution B (0.2M NaOH, 1% SDS) was next added and the 
tube was mixed by rocking. The tube was left on ice for 5 minutes. 150pl of cold solution 
C (5M potassium acetate, 11.5% acetic acid, pH 4.8) was added and the contents were 
mixed by inversion, vortexed quickly and held on ice for 5 minutes to precipitate the DNA 
and proteins. The tube was centrifuged at maximum speed for 1 minute and the supernatant 
was transferred to a fresh 1.5ml eppendorf tube where one-tenth its volume of 3M sodium 
acetate (pH 5.0) and an equal volume of isopropanol were added and the tube was 
incubated at -40°C for 1 'A to 2 hours. The tube was centrifuged for 10 to 15 minutes to 
precipitate the RNA and plasmid DNA and the pellet was washed with 70% ethanol. The 
pellet was resuspended in 50pl of TE buffer (lOmM Tris, 0.25mM EDTA, pH 7.4) and 
treated with RNase at a final concentration of lOpg/ml for 30 minutes at 37°C.
(ii) QIAprep™ PLASMID KIT
The kit used was obtained from QIAGEN Ltd. and the protocol was carried out 
according to the manufacturer’s instructions. A single bacterial colony was inoculated in 1- 
5ml of L-broth medium containing 100|ig/ml of ampicillin overnight at 37°C with shaking. 
The culture was centrifuged for 15 minutes to pellet the cells and resuspended in 250^1 of 
buffer PI (containing RNase A and stored at 4°C). Following this, 250pl of buffer P2 was
51
added and the tube was gently inverted 4 to 6  times to mix. 350pl of buffer N3 was next 
added and the tube was immediately inverted gently 4 to 6  times and centrifuged for 10 
minutes. During centrifugation, a QIAprep spin column placed in a 2ml collection tube was 
prepared. The supernatant was applied to the column, which was then centrifuged for 30 to 
60 seconds and the flow-through was discarded. The QIAprep spin column was washed 
with 0.5ml of buffer PB, centrifuged for 30 to 60 seconds, and the flow-through was 
discarded. The column was next washed with 0.75ml of buffer PE and spun for 30 to 60 
seconds. The flow-through was discarded and the column was spun for a further 1 minute 
to remove residual wash buffer. The column was placed in a clean 1.5ml eppendorf tube 
and the DNA was eluted with 50pl of lOmM Tris-HCl (pH 8.5) or H2O. The column was 
kept at room temperature for 1 minute, centrifuged for 1 minute and l|tl was used for 
checking on a 1% agarose gel.
(iii) INSTA-MINI-PREP™ KIT
This kit was purchased from 5 Prime-»3 Prime, Inc. and minipreparation of plasmid 
DNA was performed as outlined by the manufacturer. A single bacterial colony was 
inoculated in l-3ml of L-broth medium containing 100|ag/ml of ampicillin overnight at 
37°C with shaking. The unopened INSTA-MINI-PREP™ tube was centrifuged at 12000g 
for 10 to 30 seconds to pellet the INSTA-MINI-PREP™ gel. 1.5ml of the overnight 
bacterial culture was transferred to a 1.5ml eppendorf tube and centrifuged at 12000 to 
16000g for 30 seconds. This step can be repeated if necessary. 50-1 00jj.1 of either 
molecular biology grade water, TE (lOmM Tris-HCl, ImM EDTA, pH 8.0) or STE 
(lOOmM NaCl, lOmM Tris-HCl, ImM EDTA, pH 8.0) was added to the pellet and 
vortexed to fully resuspend the bacterial cells. The entire suspension was transferred to the 
pre-spun INSTA-MINI-PREP™ tube by pipetting, followed by the addition of 300|al of 
shaken PCI solution (50 Phenol: 49 Chloroform: 1 Isoamyl alcohol) and mixed thoroughly 
by repeated vigorous inversion. The INSTA-MINI-PREP™ tube was centrifuged at 12000g 
for 30 seconds, after which 300pl of Cl solution (49 Chloroform: 1 Isoamyl alcohol) was 
added and the two liquid upper phases were mixed by repeated vigorous inversion (do not
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vortex or allow the lower organic phase to mix with the upper aqueous phase). The 
contents were centrifuged at 12000g for 30 seconds and the topmost aqueous phase was 
transferred to a fresh eppendorf tube.
2.9.7 LARGE SCALE PREPARATION OF PLASMID DNA
Large scale plasmid DNA preparation was achieved with the QIAGEN PLASMID 
MAXI KIT. A single bacterial colony was inoculated in 10ml of L-broth medium 
containing lOOpg/ml of ampicillin. The culture volume was increased to 500ml and 
inoculated with 1ml of the overnight culture. Another overnight incubation at 37°C with 
shaking was carried out and the cells were harvested by centrifugation at 6000rpm for 15 
minutes at 4°C in a Sorvall rotor. All traces of supernatant were removed by inverting the 
tube before proceeding to the next step.
The bacterial pellet was resuspended in 10ml of buffer PI (lOOpg/ml RNase A, 50mM 
Tris-HCl, lOmM EDTA, pH 8.0). 10ml of buffer P2 (200mM NaOH, 1% SDS) was next 
added, mixed gently by inverting 4 to 6  times and incubated at room temperature for 5 
minutes. 10ml of chilled buffer P3 (3.0M potassium acetate, pH 5.5) was next added and 
the contents were mixed immediately but gently before incubating on ice for 2 0  minutes. 
The mixture was centrifuged at 15000rpm for 30 minutes at 4°C and the supernatant was 
discarded. During the centrifugation, a QIAGEN-tip 500 was equilibrated with 10ml of 
buffer QBT (750mM NaCl, 50mM MOPS, 15% ethanol, pH 7.0, 0.015% Triton X-100) 
and the column was allowed to empty by gravity flow. The supernatant was applied to the 
column which was allowed to empty as before. The column was washed twice, each with 
30ml of buffer QC (1.0M NaCl, 50mM MOPS, 15% ethanol, pH 7.0). The plasmid DNA 
was eluted with 15ml of buffer QF (1.25M NaCl, 50mM Tris-HCl, 15% ethanol, pH 8.5) 
and precipitated with 0.7 volumes of isopropanol. The mixture was immediately 
centrifuged at 6000rpm for 30 minutes at 4°C, and the pellet was washed in 15ml of cold 
70% ethanol. The pellet was dissolved in 500pl of TE buffer.
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2.9.8 RELEASING THE DNA FRAGMENT FROM THE VECTOR
The isolated plasmid DNA from sections 2.9.6 and 2.9.7 was digested with Nco I and 
Hind III to release the insert from the plasmid. Further manipulations can be performed on 
the released insert.
2.9.9 CHECKING THE INTEGRITY OF THE INSERT
In order to rule out a base change as being due to misincorporation by Taq DNA 
polymerase, several independent clones were screened by CCM (section 2.8.2) and direct 
sequencing (section 2.8.3).
2.10 IN VITRO GENE EXPRESSION STUDIES: PROTEIN ANALYSIS
2.10.1 IN  VITRO GENE EXPRESSION
Colonies which have maintained their integrity, as determined by CCM and direct 
sequencing, were suitable for in vitro gene expression. The protocol followed was exactly 
as described for the pTrc 99A expression kit (Pharmacia). A loopful of bacterial cells 
(stored as a glycerol stock) was inoculated in 5ml of L-broth medium containing lOOpg/ml 
of ampicillin overnight at 37°C with shaking. 500pl of the overnight culture was inoculated 
in 50ml of L-broth medium containing 1 OOpg/ml of ampicillin and the cells were grown at 
37°C to mid-log phase i.e. A6oo = 0.6-»1.0. Expression was induced with the addition of 
isopropylthio-p-D-galactopyranoside (IPTG; Gibco BRL) to a final concentration of 
l.OmM. The culture was spun at 1500g for 1 0  minutes at 4°C and the pelleted cells were 
washed with cold 10mmol/l Tris-HCl (pH 8.0). This was repeated twice. The cells were 
resuspended in 10mmol/l Tris-HCl (pH 8.0) and sonicated using the MSE Soniprep, after 
which the tube was centrifuged at 12000g for 30 minutes and the supernatant was filtered 
through a 0 .2 2 pm filter unit.
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2.10.2 QUANTIFYING PROTEINS
This was performed according to the method of Lowry et al (1951). A fresh solution 
of 98% of solution A (2% Na2C0 3  in 0.1M NaOH), 1% of solution B1 (1% Q 1SO4 in 
ddH20 ) and 1% of solution B2 (2% Na K tartrate in ddH20 ) was prepared, and a 1:1 
dilution of Folins Reagent (BDH) in ddH20  was made. At the same time, a 500|xg/ml 
standard solution of bovine serum albumin (BSA; SIGMA) was diluted down in distilled 
water to give a 500j.ig to 50|ig standard curve. To 800|il of the A+B1+B2 solution was 
added 80jj.l of sample, which was then left at room temperature for 1 0  minutes. 80|il of the 
diluted Folins Reagent was next added, while mixing, and the tube was left in the dark for 
45 minutes, after which the absorbance at 750nm was read and compared with the standard 
curve.
2.10.3 PRODUCTION OF POLYCLONAL ANTIBODIES
The antibody used in this study was custom-made by GENOSYS BIOTECH, Inc. 
using rabbits as hosts and following a 90-day standard immunisation schedule. The choice 
of the peptide sequence to raise the antisera was based on the following criteria set out by 
GENOSYS BIOTECH, Inc.: (i) N- or C-terminal sequences were preferred, although 
internal sequences which represent regions that are surface-exposed in the intact protein 
are acceptable; (ii) 1 0  to 15 amino acids with less than 6  hydrophobic residues and no more 
than 4 adjacent hydrophobic residues should be selected. If conditions (i) and (ii) are 
adhered to, the peptides are likely to be soluble in aqueous solvents, easier to couple to 
carriers and more likely to be immunogenic.
The choice of peptide sequence used in this project was made by comparing the 
sequences of the human and E. coli, and the sequence of the peptide used to raise the 
antibody was HTAMKDGQLYLTGG, corresponding to the amino acids His-Thr-Ala- 
Met-Lys-Asp-GIy-Gln-Leu-Tyr-Leu-Thr-Gly-Gly. This sequence (i) fulfilled the criteria set 
out by GENOSYS BIOTECH, Inc.; and (ii) was found to contain the least sequence 
homology between the two species.
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Y2.10.4 PURIFICATION OF ANTISERA
The antisera supplied by GENOSYS BIOTECH, Inc. were unpurified and contained 
the different isotypes of immunoglobulins (Ig) i.e. IgA, IgG, IgM. The fraction of interest 
is the IgG isotype, therefore, IgG has to be separated from the total Ig content and this has 
been achieved using the Protein A Sepharose* 4 Fast Flow (Pharmacia).
The 20% ethanol solution in which the gel was packed was removed by transferring 
the gel to a column and allowing the ethanol to flow through until just above the level of 
the beads. Ten column volumes (i.e. 10 X 1ml) of O.lmol/1 sodium phosphate (pH 7.0) was 
passed through the column, after which the unpurified antiserum was applied gently to the 
column. 1ml fractions were immediately collected and their absorbances at 280nm were 
read and graphically represented. The absorbance should gradually increase and reach a 
maximum level for approximately 5 X 1ml fractions before decreasing to baseline level. 
This indicates that all proteins, apart from IgG which has bound to the Protein A beads, 
have been eluted from the column. Once this has been achieved, the elution buffer (0.1M 
glycine-HCl, pH 3.0) was applied to the column. Again, 1ml fractions were immediately 
collected into tubes containing 2mol/l Tris-HCl (pH 8.0) to neutralise the pH and their 
absorbances were read at 280nm. A similar profile should be observed as before since the 
IgG is now eluted from the column. Fractions showing a high protein content, as 
determined by the absorbances at 280nm, were combined and dialysed overnight at 4°C in 
phosphate buffered saline (0.05mol/l potassium phosphate, O.lmol/1 NaCl, pH 7.4). After 
dialysis, the amount of IgG present was quantified as in section 2.10.2.
2.10.5 ANALYSIS OF IN  VITRO GENE EXPRESSION
In order to determine if in vitro gene expression was successful, the total proteins 
present in the lysate were separated by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) according to the method described by Laemmli U.K. (1970) 
followed by Western blotting with a specific antibody.
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2.10.5.1 SDS-PAGE
The Protean* II xi Cell (Bio-Rad) was assembled according to the manufacturer’s 
instructions. A 10-12% separating gel [10-12ml of 30% acrylamide/bisacrylamide (29:1), 
7.8ml of solution A (1.5M Tris, 0.4% SDS, pH 8.8) and made up to 30ml with dH20] was 
first prepared, and 300j.il of freshly prepared 10% APS and 30jil of TEMED were added 
just before pouring the gel. The gel was poured to a level such that the space above the 
separating gel corresponded to the length of the teeth of the comb and an additional 1cm. 
The spacers and comb used were 0.75mm thick. The gel was overlaid with dH20  to 
exclude air which slows down the polymerisation process. After polymerisation (about 1 
hour), the overlay was poured off and a 5% stacking gel [1.6ml of 30% 
acrylamide/bisacrylamide (29:1), 2.6ml of solution B (0.5M Tris, 0.4% SDS, pH 6.8) and 
made up to 10ml] was poured over the separating gel and the comb was immediately 
inserted. After polymerisation, the comb was removed and the wells were cleaned with the 
running buffer (10X TGS: 250mM Tris, 2.5M glycine, 1% SDS). lOOpg of each sample 
and the Rainbow™ coloured protein molecular weight markers (Amersham) were diluted in 
the ratio 5 parts 2X gel loading buffer: 4 parts sample/marker: 1 part 1M DTT (2X gel 
loading buffer: 1.2ml of 1M Tris-HCl pH 6.8, 2ml of glycerol, 4ml of 10% SDS, 0.01% 
bromophenol). The samples and marker were heated at 90°C for 5 minutes prior to 
loading. The gel was electrophoresed for 4 to 6 hours at a constant voltage of 250V. The 
apparatus was disassembled and Western blotting was performed.
2.10.5.2 WESTERN BLOTTING
The gel was pre-equilibrated in cold transfer buffer (0.025M Tris, 0.192M glycine, 
20% methanol) for 15 minutes. A sheet of HYBOND ECL™ membrane (Amersham) was 
initially soaked in dH20  and then equilibrated in transfer buffer for 15 minutes. The 
electroblotting cassette (Bio-Rad) was assembled according to the manufacturer’s 
instructions. Two pieces of filter paper and the fibre pads were soaked in transfer buffer 
and a gel-membrane sandwich was set up in the following order:
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cathode side ->fibre ->filter ->gel -»HYBOND —>filter ->fibre->anode side of 
of holder pad paper ECL™ paper pad holder
The Trans Blot™ apparatus (Bio-Rad) was assembled and transfer was carried out 
overnight at 4°C at a constant voltage of 30V. After transfer, the filter was subjected to 
immunodetection while the gel was stained with Coomassie Brilliant Blue [50% methanol, 
10% acetic acid, 0.05% Coomassie Brilliant Blue (R250)] to assess the transfer efficiency.
2.10.5.3 IMMUNODETECTION
The filter was rinsed briefly in Tris buffered saline (TBS: 20mM Tris, 137mM NaCl, 
pH 7.6), after which it was blocked in blocking buffer [TBS, 0.2% (v/v) Tween 20, 5% 
(w/v) BSA, pH 7.6] for 2 hours. The blocking buffer was discarded and the filter was 
incubated overnight with shaking in the wash buffer [TBS-T: TBS, 0.1% (v/v) Tween 20] 
containing the primary antibody (obtained from section 2.10.4) diluted 1:10000 to 1:5000 
and 0.2% (w/v) BSA. The solution was then discarded and the filter was washed 8 X 1 5  
minutes with TBS-T. The secondary antibody [horseradish peroxidase conjugated goat 
anti-rabbit IgG (whole molecule); SIGMA] was added at a dilution of 1:40000 and the 
filter was incubated at room temperature for 2 hours with shaking, after which it was 
washed 8 X1 5  minutes as before.
The detection system employed was based on chemiluminescence using the ECL™ 
Western Blotting Detection Reagents (Amersham) and performed according to the 
manufacturer’s instructions. Equal volumes of solutions 1 and 2 were placed in two 
separate Universals (the final volume required is 0.125ml/cm2 filter). Excess wash buffer 
was drained off from the filter and placed on a piece of SARAN WRAP™ with the protein 
side up. The two detection solutions were mixed and applied to the protein side of the 
filter, ensuring that the filter does not become uncovered. The filter was incubated for 1 
minute at room temperature without agitation. The excess detection solutions were drained 
off from the filter which was wrapped in SARAN WRAP™ with the protein side down to 
form an envelope, avoiding pressure on the filter. The membrane was placed in a film
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cassette with the protein side up and exposed to a sheet of HYPERFILM ECL 
(Amersham), initially for 15 seconds, then exposed to another sheet of film accordingly.
2.10.6 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)
High performance liquid chromatography (HPLC) is an analytical technique used in 
the separation of macromolecules and small molecules by passing them through a column 
containing a separation matrix under high pressure. The desired fractions collected can then 
be subjected to further investigations.
HPLC has several advantages over other forms of liquid chromatography (LC): (i) the 
HPLC column can be used repeatedly without regeneration (Hamilton and Sewell, 1982); 
(ii) less hands-on time required, hence less dependence on the operator’s skill; (iii) a higher 
resolution is achieved with greater reproducibility; (iv) automation and quantitation take 
control over operating conditions such as column temperature, inlet pressure, flow rate and 
separation time; and (v) shorter analysis times are possible.
The HPLC system used in this project consisted of: (i) LKB 2152 HPLC controller;
(ii) 2158 Uvicord SD; (iii) LKB 2150 HPLC pump; (iv) LKB 2210 Recorder (2-channel); 
and (v) Mono Q* anion exchange column (HR 5/5, 0.5 X 5cm, Pharmacia). The column 
was equilibrated with buffer A (10mmol/l Tris-HCl, pH 8.0). 1 0 0 jj.1 of sample was injected 
into the system and the run was started. The elution buffer B was 1M NaCl in buffer A. 
The gradient elution programme (Table 2.5) was initiated from the controller with the 
profile being monitored at a wavelength of 280nm and visualised on the chart recorder at a 
speed of 5mm/minute. The flow rate of the sample was set at 1 ml/minute and the sensitivity 
was set at 0.2 absorbance units full scale (AUFS).
2.10.7 ISOELECTRIC FOCUSING (IEF)
Isoelectric focusing (IEF) is an electrophoretic technique used in the separation of a 
mixture of proteins based on the differences in their net charge. Proteins, being amphoteric 
(zwitterionic) compounds, are either positively or negatively charged as they contain both 
acidic and basic residues. The charge of a protein is derived from the pH-dependent
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Table 2.5: Gradient elution programme for the separation of the human and E. coli 
HMB-S proteins.
Time (min) Flow rate (ml/min) % Buffer A % Buffer B
0.0 1.0 100 0
6.0 1.0 99 1
26.0 1.0 85 15
28.0 1.0 0 100
30.0 1.0 100 0
ionisation of the amino acid side-chain carboxyl and amino groups (-COOH COO' + H+;
-NH2 + H f <-> NH3 ).
Each protein has a pH at which its net charge is zero. This pH is known as its 
isoelectric point (pi) and is the point where the number of positive charges is equal to the 
number of negative charges. Factors which affect the pi of a protein are ionic strength, 
temperature and native or denaturing conditions. In IEF, the proteins migrate through a pH 
gradient until they reach their pi where migration ceases. If the local environment is below 
the pi of the protein, the protein will migrate towards the negative electrode (cathode). If 
the protein is in a solution which has a pH higher than its pi, it will migrate towards the 
positive electrode (anode).
(i) POLYACRYLAMIDE GEL PREPARATION
The gel was prepared by adding 10ml of 29.1% acrylamide, 10ml of 0.9% N,N- 
methylenebisacrylamide, 7ml of 87% (v/v) glycerol and 1.5ml of ampholine (Pharmacia; pH 
3.5-9 5) to 31.5ml of ddH20. The solution was degassed for 10 minutes and 1.5ml of 
freshly prepared 1% APS and 50pl of TEMED were added.
(ii) CONSTRUCTION OF GEL MOULD
A 3mm thick glass plate (125mm X 260mm) was bordered by a 2mm thick rubber 
gasket and a second glass plate was placed on top to form the gel mould, which was held 
together by twelve clamps. A portion of the gel mould gasket was eased out at one comer 
and the freshly prepared gel solution was carefully introduced into the mould with a 60ml 
syringe attached to a short length of rubber tubing. The gasket was reclosed and clamped. 
After polymerisation (about 1 Vi hours), the clamps and gasket were removed and the plates 
gently prised apart with a spatula. The plate carrying the gel was placed on top of the LKB 
Multiphor apparatus which has cold water (4°C) circulating. The electrode paper wicks 
were soaked in 1M NaOH (cathode) and 1M H 3PO 4 (anode) and placed along the 
appropriate edges of the gel. Either sample pads (1.5cm X 0.5cm of filter paper) or the 
applicator strip (Pharmacia), applied close to the cathodic side of the gel, could be used for
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sample loading. 15j.il of sample was loaded onto the sample pad or applicator strip, 
together with the pi markers (Pharmacia, pi 3.5-9.5), and the electrode lid was placed 
over the gel ensuring that the platinum electrode wires were in contact with the electrode 
strips. The gel was focussed at 30W for 1 Vi to 2 hours, after which it was subjected to one 
of the following staining methods.
(iii) IEF POLYACRYLAMIDE GEL STAINING
(iiia) COOMASSIE BRILLIANT BLUE STAINING
Before staining, the gel was fixed in fixing solution (115g trichloroacetic acid, 34.6g 
sulphosalicylic acid and made up to 1 litre) for 15 to 30 minutes, in a stainless steel tray 
and covered, to precipitate the proteins and wash out the ampholines. The gel was then 
immersed in staining solution (500ml ethanol, 160ml acetic acid, 0.115% Coomassie 
Brilliant Blue R250 and made up to 2 litres) overnight, and destained with several changes 
of destaining solution (staining solution without Coomassie Brilliant Blue R250).
(iiib) SILVER STAINING
This was achieved using the Silver Stain Plus (Bio-Rad) for detecting proteins. The gel 
was initially fixed in fixing solution as previously described [section 2.10.7(iiia)], and then 
fixed in the Fixative Enhancer Solution [50% (v/v) methanol, 10% (v/v) acetic acid, 10% 
(v/v) fixative enhancer concentrate, 30% deionised distilled water] for 30 minutes with 
gentle agitation. The gel was stained in the staining solution (prepared 5 minutes before 
use) [175ml deionised distilled water, 25ml silver complex solution, 25ml reduction 
moderator solution, 25ml image development reagent, and 50ml of room temperature 
Development Accelerator Solution added immediately before use (50g Development 
Accelerator Reagent, 950ml deionised distilled water and made up to 1 litre, stored at 
4°C)] for approximately 20 minutes or until the desired staining intensity was achieved. 
The reaction was stopped with 5% acetic acid for 15 minutes and rinsed in deionised
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distilled water for 5 minutes. The gel was sealed in a plastic bag and photographed 
immediately.
2.10.8 HMB-S ASSAY
The assay was adopted according to the method described by de Rooij et al (1987). 
Tris-HCl buffer (50mmol/l, pH 8.0) containing BSA (lg/1) and PBG (100|amol/l, SIGMA) 
was added to samples of 50 to 200pl to a final volume of 600pl. The mixture was 
incubated for 60 minutes at 37°C and 600pl of trichloroacetic acid (1.5mol/l) was added to 
stop the reaction. The mixture was exposed to UV light at 350nm for 30 minutes to 
convert the uroporphyrinogen to uroporphyrin, after which it was centrifuged at room 
temperature for 10 minutes at 1500g. The fluorescence was measured on the Perkin Elmer 
fluorescence spectrophotometer MPF-44B at an excitation wavelength of 399nm and an 
emission wavelength of 640nm. Coproporphyrin I (SIGMA) was used as a standard and 
the activity was expressed as pmol/ml/hr at 37°C.
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CHAPTER 3: 
RESULTS
CHAPTER 3: RESULTS
3.1 STRATEGY FOR DETECTING MUTATIONS WITHIN THE HMB-S GENE
Due to the small size of the coding sequence of the HMB-S gene (1.1 kb), total cellular 
RNA was extracted from peripheral blood lymphocytes of the thirty patients with AIP and 
analysis was performed directly on the coding sequence as shown in Figure 3.1. If the 
patient was found to carry a mutation leading to exon skipping, then the strategy depicted 
in Figure 3.2 was followed to characterise the mutation present. All the mutations detected 
at the RNA level were also analysed at the DNA level by amplifying the corresponding 
exon and sequencing was performed.
3.1.1 RT-PCR OF THE HMB-S mRNA
The entire coding sequence of the HMB-S gene was amplified by RT-PCR as a single 
segment. Primers located in the 5' and 3' untranslated regions (019H and 020H 
respectively, Table 2.3) were used in the initial amplification process to yield a fragment 
size of 1.3 kb and nested primers were employed on the amplified product for screening by 
HA and CCM, characterisation by direct sequencing of both strands was done and 
restriction endonuclease digestion was carried out as a final confirmatory step. CCM with 
osmium tetroxide consistently failed to reveal any cleavage products, therefore, further 
screening by CCM was carried out using hydroxylamine for modification.
The mRNA was also subjected to exon-by-exon amplification to locate the region of 
exon skipping or deletion in products showing a shorter transcript.
3.1.2 AMPLIFICATION OF SELECTED EXONS OF GENOMIC DNA
DNA was used as a template for PCR when size differences were detected at the 
mRNA level after RT-PCR. Primers were designed using OLIGO™ Version 3.4 according 
to the criteria stated in section 2.6 to amplify across the 5' and 3' exon-intron junctions for
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Total cellular RNA
v
RT-PCR
V
HA/CCM
V
Asymmetric PCR
V
Direct cDNA sequencing
Figure 3.1: Strategy adopted when using RNA as a template.
This is the principal strategy followed in this study in the identification of the 
molecular pathology of AIP. Any mutation detected was then analysed at the 
DNA level as shown in Fig. 3.2.
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Genomic DNA
V
DNA-PCR
V
Asymmetric PCR
V
Direct sequencing
Figure 3.2: Strategy adopted when using genomic DNA as a template.
This strategy was followed to analyse the sequences at the exon-intron 
boundaries if exon skipping was detected at the RNA level, as well as to detect 
the presence of the same mutation found after amplification using RNA as the 
initial template.
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subsequent characterisation of any base change by direct sequencing of both strands.
3.2 SUMMARY OF MUTATIONS DETECTED IN THE HMB-S GENE
By employing the strategies outlined in section 3.1, nine different mutations, of which 
four were novel, and two polymorphisms, were identified. In addition, the phenomenon of 
exons 3 and 12 undergoing alternative splicing was also encountered. The list of mutations 
detected in this study are tabulated in Table 3.1 and sub-divided according to the origins of 
the families as shown in Table 3.2.
The base changes detected were confirmed by using the appropriate restriction enzyme 
to see if the recognition site of the enzyme was created or abolished. The GCG Package 
“MAP” programme was used to search for the relevant restriction enzymes. The use of 
restriction enzyme digestion is simple and rapid in determining the carrier status of family 
members of an affected individual, as well as to screen a large number of healthy 
individuals to find out if the sequence alteration was polymorphic. The list of restriction 
enzymes employed in this study as a further confirmatory step is shown in Table 3.3.
A total of nine different and potentially pathogenic mutations identified in this study 
have been fully characterised. These include six missense mutations, one insertion, one 
deletion and one splice site mutation leading to exon skipping. The missense mutations 
include R22C, R26C, R26H, R116W, R173Q and L177R, the insertional mutation 
771insT, the deletion mutation delG 1002/1003/1004 and the splice acceptor site mutation was in 
intron 7 (345-lG->A). Five of the missense mutations occurred at the hypermutable CpG 
dinucleotide. In two of the South African patients, no sequence alterations were identified 
in their coding sequence. An analysis of the promoter region of the DNA would have been 
done, however, the DNA samples of these patients were not sent to us for further analysis.
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Table 3.1: Summary of HM B-S  mutations and polymorphisms detected in this study.
The table summarises the mutations and polymorphisms identified in this study, showing the 
method of screening used in the identification of each base change, the location of each 
sequence alteration, the base change involved and the effects of these alterations.
*denotes novel mutations
^denotes mutations involving the hypermutable CpG dinucleotide
lower case nucleotide: intronic sequence
upper case nucleotide: exonic sequence
The underlined bases are the bases which have been altered.
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Table 3.1: Summary of HM B-S  mutations and polymorphisms detected in this study.
Mutation Method of 
Screening
Exon/
Intron
Nucleotide
position
Base change Effect of 
mutation
R22C*“ CCM,
sequencing
E3 64 CGC—»TGC Arg—»Cys
R26C* CCM, HA, 
sequencing
E3 76 CGC-»!GC Arg->Cys
R26H* CCM, HA, 
sequencing
E3 77 CGC—»CAC Arg-»His
S45S* sequencing E4 135 TCG—»TCA Ser->Ser
345-1G—>A* RT-PCR,
HA,
sequencing
17 345-1 cag—>caa E8 skipping
R116W* CCM, HA, 
sequencing
E8 346 CGG—»TGG Arg->Trp
R173Q* CCM, HA, 
sequencing
E10 518 CGG->CAG Arg-»Gln
L177R CCM, HA, 
sequencing
E10 530 CTG—»CGG Leu->Arg
V202V sequencing E10 606 GTG-»GTT Val->Val
771insT* HA,
sequencing
E12 771 T insertion Stop codon 
33aa away
delG 1002/1003/1004 CCM, HA, 
sequencing
E15 1002, 1003 
or 1004
G deletion Stop codon 
8aa away
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Table 3.2: Mutations identified according to the origins o f the families.
Origin Mutation Number of families
South Africa R26H 1
R116W* 3
R173Q 1
771insT 1
delG 1002/1003/1004 1
Scotland L177R 2
R22C 1
England E8 skipping 1
Ireland R26C 1
R116W* 1
*denotes a recurrence of mutation in two different populations.
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3.3 ANALYSIS OF MUTATIONS IN THE HMB-S CODING SEQUENCE
3.3.1 SMALL ALTERATIONS
3.3.1.1 MISSENSE MUTATIONS
In 27 of the 30 patients studied, RT-PCR products of the expected size (1.3kb) were 
observed upon electrophoresis in a 2% agarose gel, thus ruling out the possibility of large 
deletions or exon skipping. Abnormal band patterns were observed on heteroduplex 
(Figure 3.3) and CCM analyses (using hydroxylamine for chemical modification), which 
were subsequently characterised by direct sequencing and reconfirmed by restriction 
enzyme digestion, where applicable.
(\) R22C f EXON 31
This novel mutation was initially detected in two Scottish siblings (Appendix 1, 
Pedigree 9532, individuals 111:8 and 111:9) by CCM analysis with hydroxylamine (Figure 
3 .4a). Upon sequencing in the region of the cleavage site, a C to T transition at nucleotide 
position 64 (Figure 3.4b) was observed in both siblings, which was confirmed after 
sequencing the opposite strand and by Hitif I digestion (Figures 3.4c and 3.4d). Subsequent 
analysis of five family members (11:2, 111:3, 111:5, 111:7 and 111:11) by H inf I digestion 
revealed that three of them carry the mutation. This mutation causes arginine to be 
substituted by cysteine. Arg22 (equivalent to Arg7 in E. coli), which is highly conserved in 
ten species (Louie et al, 1996), is the residue affected. Its high degree of conservation is an 
indication that it has an important role in the proper functioning of the enzyme. Arginine, a 
basic residue, is substituted by cysteine, a neutral, polar amino acid which is predicted to 
destabilise the protein. However, the precise role of this residue is not known at the present 
time.
There is a family history of this condition. 11:9 had succumbed to the disease and 11:7 
is a known carrier of the defective gene. The R22C mutation was transmitted from 
individual 11:7 to three of his daughters. 111:8 and 111:9 have reduced HMB-S activity (21.0 
and 22.0 units respectively) (normal range 30 - 54 units). His fourth daughter, 111:10, had
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Figure 3.3: Heteroduplex analysis of 10 patients with different mutations.
Heteroduplex analysis was performed on 10 patients with different mutations. 
Each of the mutations revealed a different heteroduplex pattern on the MDE Gel 
solution (Flowgen).
The primers used for amplifying the products in lanes 1 to 9 and 12 to 13 were 
019H and R478 (Table 2.3) to yield a fragment of 496bp and the primers Phe6+ 
and Phel 1- were used to amplify the products in lanes 10 and 11 to give a product 
of398bp.
L: 1 kb ladder (Gibco BRL)
HC: heteroduplex control (350bp) supplied by Flowgen
Lanes 1 to 3: negative controls
Lanes 4 and 5: R26C
Lanes 6 to 8: R116W
Lane 9. R26H
Lane 10: 771insT
Lane 11: delG 1002 1003 1004
Lane 12: R173Q
Lane 13: L177R
A non-specific band was observed in lanes 2 to 5 and 9 as indicated by the arrow.
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Figure 3.4a: Chemical cleavage mismatch analysis showing the cleavage 
product due to the R22C mutation.
The fragment amplified for CCM analysis with the primers 019H and 020H (Table
2.3) in the 2 siblings (111:8 and 111:9 of Pedigree 9532 in Appendix 1) and 20 
healthy individuals gave a product of 1.3kb. A cleavage product of 82bp was 
observed in both siblings as shown by the arrow, indicating a sequence alteration 
of C to T at nucleotide position 64 of the sense strand from the translation 
initiation codon since the primer 019H is located 18bp upstream from the 
translation initiation site. P = patient, C = normal control.
Figure 3.4b: Sequence analysis of exon 3 (R22C).
Partial sequence of the HMB-S cDNA in the region of the cleavage product in 
Figure 3.4a confirmed a C64->T transition as indicated in both individuals 111:8 and 
111:9 of Pedigree 9532 (Appendix 1) but not in 20 healthy individuals. P = patient, 
C = normal control.
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Figure 3.4c: Restriction map o f H in f l  to detect the R22C mutation.
Restriction map of the amplified cDNA fragment using primers 019H and R341 
(Table 2.3) showing the restriction fragment sizes expected for the normal (132bp, 
126bp, 78bp and 23bp) and mutant (132bp, 204bp and 23bp) alleles upon 
digestion with H infl. The C64~>T transition abolishes the Hinfl*  recognition site 
to yield a fragment of204bp from the mutant allele.
Figure 3.4d: Restriction analysis of R22C with H infl.
Restriction enzyme digestion with H in fl on a 3% SeaKem (GTG) agarose gel. In 
Pedigree 9532, a 204bp fragment, which indicates the loss of the Hinf I* 
restriction site due to the mutation, was seen in individuals 11:2, 111:5, 111:8 and 
ni:9 and 111:11 but not in individuals 111:3 and 111:7 and 20 normal controls. L = 
lOObp ladder (Gibco BRL), P = digested PCR products from the patient, C = 
normal control.
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not been analysed by molecular techniques but her HMB-S activity was below the normal 
range (22.9 units).
(n) R26C (EXON 3)
This mutation was initially identified in two of three Irish siblings (Appendix 1, 
Pedigree 13168, individuals 111:1 and 111:3 but not 111:2). The cleavage products and 
heteroduplexes observed on hydroxylamine modification in CCM analysis (Figure 3.5a) and 
HA (Figure 3.3) respectively were due to a missense mutation as revealed by direct 
sequencing. A C to T transition at position 76 was present (Figure 3.5b) which caused 
arginine to be substituted by cysteine. This mutation abolishes an A d  I restriction site 
(Figures 3.5c and 3.5d) which was employed to rapidly determine the carrier status of a 
further thirteen members of this family (11:1 to 11:6, 11:8, 111:5 to 111:8, IV: 1 and IV:2), 
three of whom (individuals 11:8, IV: 1 and IV:2) were found to be carriers and one (11:7), 
who is deceased, was inferred to be a carrier of the defective gene from the results obtained 
for the other family members.
Arg26 (Argl 1 in E. coh), which is a conserved residue in twelve species, serves to 
form a salt-bridge with the acidic side chain of the second pyrrole ring of the cofactor. This 
mutation affects the P-sheet conformation and results in a defective enzyme being 
produced. Since the basic arginine residue is replaced by the polar uncharged cysteine, this 
is predicted to destabilise the protein.
Family studies indicated that 11:7 had most probably succumbed to the disease, 
therefore, all her offspring were analysed for the presence of a mutation in the HMB-S 
gene. 111:1 and 111:3 have lower than normal HMB-S activity levels (Table 2.2), which 
indicate that they could be carriers of the defective gene. This was confirmed by 
molecular analysis and restriction enzyme digestion (Figure 3.5). Both 111:2 and 111:5 have 
activity levels within the normal range, thus ruling out the possibility that they could be 
harbouring the defective gene. 11:6 has a low HMB-S activity but no sequence alterations 
were detected in his coding sequence. One possibility could be that he has a much higher 
proportion of alternatively spliced exons 3 and 12 in his coding sequence, which is a 
normal occurrence in the general population (as seen in section 3.4), thus resulting in a
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Figure 3.5a: Chemical cleavage mismatch analysis showing the cleavage 
product due to the R26C mutation.
The fragment amplified for CCM analysis with the primers 019H and 020H (Table
2.3) in three Irish siblings (111:1 to 111:3 of Pedigree 13168 in Appendix 1) and 20 
healthy individuals gave a product of 1.3kb. A cleavage product of 94bp was 
observed in 111:1 and 111:3 but not in 111:2 as indicated by the arrow, thus 
indicating a C to T transition at nucleotide position 76 of the sense strand from the 
translation initiation codon since the primer 019H is located 18bp upstream from 
the translation initiation site. P = patient, C = normal control.
Figure 3.5b: Sequence analysis of exon 3 (R26C).
Partial sequence of the HMB-S cDNA in the region of the cleavage product in 
Figure 3.5a confirmed a C76—>T transition as indicated in both individuals 111:1 and 
111:3 of Pedigree 13168 but not in 111:1 and 20 healthy individuals. P = patient, C = 
normal control.
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Figure 3.5c: Restriction map of A d  I to detect the R26C mutation.
Restriction map of the amplified cDNA fragment using primers 377H and R341 
(Table 2.3) showing the restriction fragment sizes expected for the normal (266bp, 
44bp and 28bp) and mutant (310bp and 28bp) alleles upon digestion with Aci I. 
The Aci I* restriction site is removed as a result of the mutation, yielding a 310bp 
fragment.
Figure 3.5d: Restriction analysis of R26C with Aci L
Restriction enzyme digestion with Aci I on a 3% SeaKem (GTG) agarose gel. In 
Pedigree 13168, a 310bp fragment, which indicates the loss of the Aci I* 
restriction site due to the mutation, was seen in individuals 11:8, IV: 1 and IV: 2 but 
not in II: 1 to II: 6  and 111:5 to III: 8  and 20 healthy individuals. L = lOObp ladder 
(Gibco BRL), C = normal control, P = digested PCR products from the patient.
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lower HMB-S activity. It would be extremely useful and important to compare his 
measurement with those of his siblings to aid in the clarification of his carrier status.
From Pedigree 13168, individual 11:7 is deduced to be a carrier for the mutant allele 
because (i) her husband does not have the mutation; (ii) two of her children are carriers of 
the mutant allele; and (iii) she has an affected sister (individual 11:8). Another interesting 
observation was that 11:7 also had the V202V polymorphism because two of her unaffected 
children had the V202V allele, while the other two affected children had the mutant allele 
but not the polymorphic allele. It is fortunate that 11:6 is homozygous for the G allele, thus 
allowing the deduction of the genotype of the deceased individual 11:7.
Presymptomatic testing was carried out for IV: 1 and IV:2, who are 6 and 3 years old 
respectively. This is extremely vital since both individuals were found to be carrying the 
defective gene. Consequently, they can be appropriately advised to avoid the precipitants 
of AIP and subsequently lead normal lives without manifesting the condition.
(iii) R26H (EXON 3)
This mutation is in the same codon as R26C but the mutated nucleotide is the second 
nucleotide of codon 26 whereas the mutated nucleotide for R26C is the first nucleotide. 
Positive CCM and HA results (Figures 3.6a and 3.3 respectively) were obtained for this 
missense mutation which, upon sequencing, was found to be due to a G to A transition at 
nucleotide 77 (Figure 3.6b), resulting in the substitution of arginine with histidine. Aci I 
was used again to confirm the base change (Figures 3.6c and 3.6d). Arg26 is situated with 
its side chain pointing into the interior of the active site cleft and is close to the negatively 
charged carboxylate groups on ring C2 of the dipyrromethane cofactor (Jordan and 
Woodcock, 1991). The replacement of arginine with histidine severely inhibits substrate 
binding and chain elongation. Both arginine and histidine are basic amino acids but, 
because they affect key residues which are highly conserved in the protein, they are 
predicted to be the primary cause of this condition. The South African patient with this 
mutation had suffered two previous attacks but has remained well since then.
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Figure 3.6a: Chemical cleavage mismatch analysis showing the cleavage 
product due to the R26H mutation.
The fragment amplified for CCM analysis with hydroxylamine using the primers 
019H and 020H (Table 2.3) in the South African patient 644 and 20 normal 
controls gave a product of 1 3kb. A cleavage product of 95bp was observed in the 
patient as shown by the arrow, indicating a C to T transition had occurred at 
nucleotide position 77 from the translation initiation codon since the primer 019H 
is located 18bp upstream from the translation initiation site. C = normal control, P 
= patient.
Figure 3.6b: Sequence analysis of exon 3 (R26H).
Partial sequence of the HMB-S cDNA in the region of the cleavage product in 
Figure 3.6a confirmed a G77->A transition on the antisense strand as indicated by 
the arrow but was not detected in 20 healthy individuals. P = patient, C = normal 
control.
The quality of the sequence around this region was the same despite repeated 
attempts.
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Figure 3.6c: Restriction map o f A ci I to detect the R26H mutation.
Restriction map of the amplified cDNA fragment using primers 377H and R341 
(Table 2.3) showing the restriction fragment sizes expected for the normal (266bp, 
44bp and 28bp) and mutant (310bp and 28bp) alleles upon digestion with Aci I. 
The Aci I* restriction site is removed as a result of R26H, yielding a 310bp 
fragment.
Figure 3.6d: Restriction analysis of R26H with Aci L
Restriction enzyme digestion with Aci I on a 3% SeaKem (GTG) agarose gel. The 
South African patient 644 revealed a 310bp fragment which indicates the loss of 
the Aci I* restriction site due to the mutation. The 310bp fragment was not present 
in any of the 20 healthy individuals analysed. L = lOObp ladder (Gibco BRL), P = 
digested PCR products from the patient, C = normal control.
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(iv) R116W fEXON 8)
This missense mutation was detected in three unrelated South African patients and two 
members of a family from the Republic of Ireland (pedigree not available). Its presence was 
initially seen on CCM and heteroduplex analyses (Figures 3.7a and 3.3 respectively). The 
substitution of the highly conserved arginine with tryptophan was the result of a C to T 
transition at nucleotide 346 (Figure 3.7b). It abolishes the restriction site for Aci I (Figures 
3.7c and 3.7d) to yield the restriction fragments shown in Table 3.3. A further three 
members of the Irish family were found to be negative for this mutation after employing the 
Aci I restriction enzyme.
This mutation was first reported by Lee et al (1990) in a Swedish family with AIP. The 
residue involved, A rgll6 (ArglOl in E. coli) is substituted by tryptophan. The 
consequence of the substitution of the basic amino acid arginine with tryptophan, a neutral, 
non-polar amino acid, is the destabilisation of the protein. Argl 16, which is conserved in 
twelve species, interacts with the interdomain hinge region by forming a salt-bridge with 
Glu231 and a hydrogen bond with the backbone carbonyl group of residue 198. Its 
replacement with tryptophan results in the destabilisation of the protein, possibly due to the 
loss of these stabilising interactions.
In the three unrelated South African patients (635, 638 and 639) who carry this 
mutation, they did not suffer any serious attacks. Their erythrocyte HMB-S activity varied 
very widely (patients 635 and 638, Table 2.1) but they have remained well. This mutation 
was also identified in two members of an Irish family (pedigree not available). R116W was 
previously reported in patients of French and Dutch origins (Gu et al, 1993). 
Approximately 30% of the Dutch patients analysed had the R116W mutation as compared 
with 3% of the French patients, indicating the high frequency of this mutation in the Dutch 
population.
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Figure 3.7a: Chemical cleavage mismatch analysis showing the cleavage 
product due to the R116W mutation.
The fragment amplified for CCM analysis with the primers 019H and 020H (Table
2.3) in the South African patients 635, 638 and 639 and 20 healthy individuals 
gave a product of 1.3kb. A cleavage product of 364bp was observed in all three 
patients as indicated by the arrow, indicating a C to T transition at nucleotide 
position 346bp from the translation initiation codon since the primer 019H is 
located 18bp upstream from the translation initiation site. L = radiolabelled lkb 
ladder (Gibco BRL), P = patient, C = normal control.
Figure 3.7b: Sequence analysis of exon 8 (R116W).
Partial sequence of the HMB-S cDNA showed the C?46-»T transition in the region 
of the cleavage product in Figure 3.7a as indicated by the arrow. This sequence 
alteration was not observed in 20 healthy individuals. M = mutant sample, N -  
normal control.
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Figure 3.7c: Restriction map o f A ci I to detect the R116W mutation.
Restriction map of the amplified cDNA fragment using primers Phe6+ and Phel 1- 
(Table 2.3) showing the restriction fragment sizes expected for the normal (98bp, 
130bp and 170bp) and mutant (228bp and 170bp) alleles upon digestion with Aci 
I. The Aci I* restriction site is removed as a result of R116W, yielding a 228bp 
fragment.
Figure 3.7d: Restriction analysis of R116W with Aci L
Restriction enzyme digestion with Aci I on a 3% SeaKem (GTG) agarose gel. The 
three South African patients, 635, 638 and 639, and a further two members of an 
Irish family revealed an extra 228bp fragment upon Aci I digestion which was not 
seen in 20 healthy individuals. A 228bp fragment indicates the loss of the Aci I* 
restriction site due to the mutation. L = lOObp ladder (Gibco BRL), P = digested 
PCR products from the patient, C = normal control.
Aci I* Aci I
98 130 170 Normal
Aci I
228 170 M utant
Figure 3.7c
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M  R173Q (EXON 101
This mutation was detected by CCM and heteroduplex analyses (Figures 3.8a and 3.3 
respectively) and was found to be due to a G to A transition at position 518 on sequence 
analysis (Figure 3.8b). It destroys the recognition site for Nci I (Figures 3.8c and 3.8d), 
resulting in the presence of a larger restriction fragment in the mutant sample and not in the 
negative control. Argl73 (Argl55 in E. coli) is a very highly conserved residue, being 
maintained in thirteen different species. It forms salt-bridges with the propionate group of 
the first pyrrole ring of the cofactor and the carboxylate side group of the substrate 
molecule. The substitution of the basic residue, arginine, with the polar, neutral residue, 
glutamine prevents binding interactions with the substrate, leading to the inhibition of 
substrate elongation. The affected patient, of South African origin, suffered severe attacks 
of the condition which required two to three monthly hospital admissions.
(vh L177R (EXON 10)
Another highly conserved residue to be substituted is Leu 177. It was detected in five 
members of a Scottish family (Appendix 1, Pedigree 13543, individuals 11:3, 111:2, 111:3, 
111:5 and 111:6) and another unrelated Scottish patient. Its replacement with arginine was 
due to a T to G transversion at nucleotide 530, initially detected by CCM and heteroduplex 
analyses (Figures 3.9a and 3.3 respectively) and characterised by sequencing (Figure 3.9b). 
This mutation results in the creation of an Aci I restriction site (Figures 3.9c and 3.9d), 
which was employed to screen IV: 1, IV:3 and IV:4, all of whom have affected parents, but 
were fortunately found to be negative for this mutation. Leu 177 (Leu 159 in E. coli) is a 
highly conserved residue in eleven species. It forms part of the hydrophobic core of the 
molecule and its replacement with arginine would be structurally deleterious. This is 
because leucine, which is a non-polar, neutral amino acid, is being replaced with a basic 
amino acid, arginine. This is predicted to have an adverse effect on the hydrophobic part of 
the molecule by destabilising the protein structure due to the loss of stabilising interactions 
with the introduction of a charged group within the apolar core.
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Figure 3.8a: Chemical cleavage mismatch analysis showing the cleavage 
product due to the R173Q mutation.
The fragment amplified for CCM analysis using hydroxylamine with the primers 
019H and 020H (Table 2.3) in the South African patient 637 and 20 normal 
controls gave a product of 1.3kb. A cleavage product of 536bp was observed in 
the South African patient as shown by the arrow, thus indicating a C to T 
transition at nucleotide position 518 from the translation initiation codon since the 
primer 019H is located 18bp upstream from the translation initiation site. P = 
patient, C = normal control.
Figure 3.8b: Sequence analysis of exon 10 (R173Q).
Partial sequence of the HMB-S cDNA in the region of the cleavage product in 
Figure 3.8a confirmed a Gsis-^A transition as indicated in the South African 
patient but not in 20 healthy controls. N = normal control, M = mutant sample.
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Figure 3.8c: Restriction map o f N ci I to detect the R173Q mutation.
Restriction map of the amplified cDNA fragment using primers F413 and Phell- 
(Table 2.3) showing the restriction fragment sizes expected for the normal (104bp, 
85bp and 44bp) and mutant (189bp and 44bp) alleles upon digestion with Nci I. 
The Nci I* restriction site is removed as a result of R173Q to produce a 189bp 
fragment.
Figure 3.8d: Restriction analysis of R173Q with Nci L
Restriction enzyme digestion with Nci I on a 3% SeaKem (GTG) agarose gel. The 
South African patient 637 revealed a 189bp fragment upon digestion with Nci I, 
which was not present in a further 20 normal controls. A 189bp fragment indicates 
the loss of the Nci I* restriction site due to R173Q. L = lOObp ladder (Gibco 
BRL), P = digested PCR products from the patient, C = normal control.
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Figure 3.9a: Chemical cleavage mismatch analysis showing the cleavage 
product due to the L177R mutation.
The fragment amplified for CCM analysis using hydroxylamine with the primers 
019H and 020H (Table 2.3) is 1.3kb. The L177R mutation was identified in an 
isolated case from a Scottish family and five members of Pedigree 13543 
(individuals 11:3, 111:2, 111:3, 111:5 and 111:6 in Appendix 1) but not in 20 normal 
controls. A cleavage product of 548bp was observed in these patients, indicating a 
cytosine mismatch at position 530bp on the sense strand from the translation 
initiation codon since the primer 019H is located 18bp upstream from the 
translation initiation site. C = normal control, P = patient.
Figure 3.9b: Sequence analysis of exon 10 (L177R).
Partial sequence of the HMB-S cDNA in the region of the cleavage product in 
Figure 3.9a revealed a T530—>G transversion as indicated in all the patients 
mentioned in Figure 3.9a but not in 20 normal controls. M = mutant sample, N = 
normal control.
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Figure 3.9c: Restriction map of A d  I to detect the L177R mutation.
Restriction map of the amplified cDNA fragment using primers F413 and Phell- 
(Table 2.3) showing the restriction fragment sizes expected for the normal (170bp 
and 63bp) and mutant (117bp, 53bp and 63bp) alleles upon digestion with Aci I. 
The Aci I* restriction site is created as a result of L177R, producing two 
additional fragments, 117bp and 53bp.
Figure 3.9d: Restriction analysis of L177R with A d  L
Restriction enzyme digestion with Aci I on a 10% non-denaturing polyacrylamide 
gel. All the patients with the L177R mutation, i.e. individuals 11:3,111:2,111:3, ID:5 
and 111:6 from Pedigree 13543 (Appendix 1), and the isolated case from a Scottish 
family, revealed the additional 117bp fragment, indicating a sequence alteration. 
This fragment was not present in IV: 1, IV: 3 and IV:4 (Pedigree 13543) and 20 
healthy individuals. Li = lkb ladder (Gibco BRL), L2 = lOObp ladder, C = normal 
control, P = digested PCR products from the patient.
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This mutation was identified in a Scottish patient who manifested the main presenting 
symptoms of this condition which included abdominal pain and vomiting. It is suspected 
that these symptoms had arisen due to calorie restriction. Her erythrocyte HMB-S activity 
was found to be 18 nmol/hr/ml (normal range 30 - 67 nmol/hr/ml) upon biochemical 
analysis, which is very much reduced from the normal range.
Several members of a Scottish family were also found to carry the L177R mutation. 
As seen from Pedigree 13543 (Appendix 1), all the offspring of 11:3 have the defective 
gene. Initially, 111:6 was thought to be a sporadic case of AIP. Subsequent screening of 
family members revealed that this was not the case. Her siblings, mother and mother’s half- 
sister (who was not analysed in this study but was diagnosed as suffering from AIP based 
on her biochemical values) were identified as carriers of the defective gene. IV: 3 and IV:4, 
12 and 9 years old respectively, had a presymptomatic testing performed and were found 
not to have inherited the defective gene.
3.3.1.2 FRAMESHIFT MUTATIONS
(h 771insT (EXON 121
This novel frameshift mutation was detected in one South African patient with a very 
severe phenotype. This mutation showed a positive result on heteroduplex analysis (Figure
3.3), and direct sequencing revealed a one base-pair insertion at position 771 (Figure 
3.10a) which resulted in the formation of a premature stop codon 33 amino acids 
downstream from the insertion. Sty I digestion was done as a confirmatory step (Figures 
3.10b and 3.10c). This frameshift mutation (Ong et al, 1996) resulted in the alteration of 
the thirty-two amino acids following the insertion, prior to the formation of a premature 
stop codon. The resulting truncated protein, if stable, is anticipated to contain 289 amino 
acids instead of the normal 361 i.e. a loss of approximately 20% of the translated protein is 
predicted and this causes impaired protein function.
Gu et al (1994) have reported the largest insertion in the HMB-S gene: 8bp were 
inserted in exon 12, resulting in the formation of a stop codon 10 amino acids away. Large 
insertions are not a common feature in the molecular pathology of AIP.
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Figure 3.10a: Sequence analysis o f exon 12 (771insT).
Sequencing the entire HMB-S cDNA revealed a 771insT mutation in the South 
African patient 632 as indicated but not in 20 normal controls. N = normal control, 
M = mutant sample.
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Figure 3.10b: Restriction map o f Sty  I to detect the 771insT mutation.
Restriction map of the amplified cDNA fragment using primers F666 and 508D 
(Table 2.3) showing the restriction fragment sizes expected for the normal (431bp 
and 12bp) and mutant (340bp, 91 bp and 12bp) alleles upon digestion with Sty I. 
The Sty I* restriction site is created as a result of 771insT, producing a 340bp 
fragment, in addition to the 431bp fragment derived from the normal allele.
Figure 3.10c: Restriction analysis of 771insT with Sty L
Restriction enzyme digestion with Sty I on a 3% SeaKem (GTG) agarose gel. L = 
lOObp ladder (Gibco BRL), C = normal control, P = digested PCR products from 
the patient. The presence of a 340bp restriction fragment from South African 
patient 632, in addition to the 431bp fragment derived from the normal allele, is 
indicative of the mutation. This mutation was not detected in 20 healthy 
individuals.
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(ii) dclG1002/1003/1004 (EXON 15)
The patient with this mutation suffered a severe course of the disease and finally 
succumbed to the disease. CCM and heteroduplex analyses both revealed abnormal bands 
(Figures 3 .11a and 3 .3 respectively) and was identified as being due to a deletion of either 
one of three G nucleotides at positions 1002 to 1004 of the coding sequence (Figure 
3.11b). This mutation in exon 15 results in seven altered amino acids following the 
deletion, resulting in a premature stop codon 8 codons downstream from the point of 
deletion and is anticipated to result in the loss of approximately 5% of the mature protein. 
A truncated protein containing 342 amino acids instead of the normal 361 is produced.
This mutation provided some difficulty in assigning exactly which nucleotide was 
deleted. This is because three consecutive Gs are present in this region. As seen from 
Figure 3.1 lb, the sequence read in the sense direction shows that Gkhm is deleted, whereas 
Gioo2 is deleted when the sequence is read in the antisense direction. At this stage, the 
conclusion which can be drawn about this mutation is that one of the three Gs at positions 
1002, 1003 or 1004, has been deleted which, consequently, results in the formation of a 
truncated protein.
From Table 4.1, it is observed that the deletions reported so far involve only one or 
two bases. Large deletions, like insertions, are not a common feature in the molecular 
pathology of AIP.
This patient had suffered four acute attacks, two of which were mild and another two 
were severe. One of the severe attacks was associated with some neuropathy and the other 
was marked by severe hyponatraemia and convulsions, which required the administration 
of hypertonic saline. This patient’s father and sister are known to carry the defective gene 
but have remained well. This patient finally succumbed to the disease. This case is proof 
that AIP is a disease of variable expression even among individuals with the same 
genotype, thus making the correlation of genotype with phenotype almost impossible.
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Figure 3.11a: Chemical cleavage mismatch analysis showing the cleavage 
product due to the delGioo2/ioo3/ioo4 mutation.
The fragment amplified for CCM analysis using hydroxylamine with the primers 
019H and 020H (Table 2.3) in one South African patient and 20 healthy 
individuals gave a product of 1.3kb. A cleavage product in the region of 1020- 
1022bp was present in the South African patient but not in 20 healthy individuals 
analysed. This indicates that a mismatched cytosine or guanine is present in this 
region of the cDNA. C = control, P = patient.
Figure 3.11b: Sequence analysis of exon 15 (delGioo2/ioo3/ioo4).
Partial sequence of the HMB-S cDNA of the South African patient in the region of 
the cleavage product in Figure 3.11a, both of the antisense (AS) and sense (S) 
strands, showing the deletion of G1002 in the former and G 1004 in the latter. This 
sequencing pattern was not observed in 20 normal controls.
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3.3.1.3 SILENT MUTATIONS AND POLYMORPHISMS
(i) S45S (EXON 41
Direct sequencing revealed a G to A transition at position 135 (Figure 3.12) which 
maintains the serine residue at position 45. This sequence alteration was not detected in the 
other 29 patients and therefore, is considered to be a silent mutation. This sequence 
variation was detected in one patient with the L177R mutation and this phenomenon was 
also reported by Mgone et al (1992). However, this base change was not detected in the 
other five patients with the L177R mutation, thus excluding the possibility of this silent 
mutation being in linkage disequilibrium with L177R.
(ih V202V (EXON 10)
This is a previously reported intragenic polymorphism (Figure 3.13) reported by Mgone et 
al (1992) which maintains the valine residue at position 202.
3.3.2 LARGE ALTERATIONS
(i) Exon 8 skipping
The only mutation which showed the presence of a shorter transcript after RT-PCR 
was that of exon 8  skipping in a father and two of his daughters (Appendix 1, Pedigree 
13519, individuals 111:2, IV: 1 and IV:2). The region surrounding exon 8  was amplified and 
a shorter product was seen (Figure 3.14a). This shorter product could be due to the 
absence of either exon 7 or exon 8 , both of which are equal in size. Therefore, direct 
sequencing of the entire segment was carried out and exon 8  was found to be missing. 
Intronic primers I7F and I8 R (Table 2.3), flanking exon 8 , were designed and used initially 
for screening the region flanking exon 8  in the genomic DNA by HA (Figure 3.14b), and 
then for sequencing across the exon-intron boundaries of genomic DNA. A G to A 
transition at position -1 of the invariant AG dinucleotide at the 3' acceptor splice site of 
intron 7 (Figure 3 .14c) was responsible for the skipping of exon 8 . This mutation was
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Figure 3.12: Sequence analysis of the exon 4 silent mutation (S45S).
Partial sequence analysis of the HMB-S cDNA showing the G135—>A transition, 
resulting in the silent mutation S45S. This silent mutation was identified in a 
patient with the L177R mutation, and was previously identified independently in 
another Scottish patient by Mgone et al (1992). Therefore, all the other patients 
with the L177R mutation, as well as the other AIP patients and 20 normal 
controls, were also analysed for this silent mutation but was not found in any of the 
individuals analysed. From the results obtained, this sequence alteration was found 
to be a silent mutation which was not in linkage disequilibrium with the L177R 
mutation.
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Figure 3.13: Sequence analysis of the exon 10 polymorphism (V202V).
Partial sequence analysis of the HMB-S coding sequence showing the G/T 
polymorphism at position 606 as indicated.
Panels 1 and 3 show homozygosity for the G and T alleles respectively and panel 2 
shows G/T heterozygosity.
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Figure 3.14a: RT-PCR products showing the absence o f exon 8.
RT-PCR products using the primers Phe6 + and R478 (Table 2.3) to yield a 
product of 231 bp. A shorter transcript (154bp) in 3 patients from England (111:2, 
IV: 1 and IV:2 of Pedigree 13519 in Appendix 1) was present but not in 20 
negative controls (231 bp). L = lOObp ladder (Gibco BRL), C = negative control, P 
= patient.
Figure 3.14b: Heteroduplex analysis showing positive results in three 
patients.
Heteroduplex analysis of genomic DNA in the region of the exon skipping using 
primers I7F and I8 R revealed a slower moving heteroduplex in the three patients 
but not in 20 normal controls. The commercial heteroduplex control (350bp) was 
run alongside the samples. L = lkb ladder (Gibco BRL), HC = commercial 
heteroduplex control (350bp) from Flowgen, C = normal control, P = patient.
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Figure 3.14c: Sequence analysis o f intron 7 (345-1G—>A).
Partial sequence analysis of intron 7 acceptor splice site of the genomic DNA from 
the three patients, 111:2, IV: 1 and IV:2 of Pedigree 13519 (Appendix 1), revealed a 
G to A transition at the last position of this splice site as indicated. This sequence 
alteration was not present in 20 healthy individuals. P = patient, C = normal 
control.
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Figure 3.14d: Restriction map o f Eco  RTT to detect the 345-lG ->A  mutation.
Restriction map of the amplified genomic DNA fragment flanking exon 8  using 
primers Phe6 + and I8 R (Table 2.3) showing the restriction fragment sizes expected 
for the normal (220bp, 208bp, 254bp, 92bp, 39bp, 22bp, 21bp, 9bp and 3bp) and 
mutant (220bp, 208bp, 346bp, 39bp, 22bp, 21 bp, 9bp and 3bp) alleles upon 
digestion with Eco RLE. The Eco RII* restriction site is removed as a result of the 
mutation, yielding an additional 346bp fragment.
Figure 3.14e: Restriction analysis of 345-1G—>A with Eco RII.
Restriction enzyme digestion with Eco RII on a 3% SeaKem (GTG) agarose gel. 
In Pedigree 13519, individuals ni:2, IV: 1 and IV:2 revealed an additional 346bp 
fragment upon digestion with Eco RII. This fragment was not present in 20 healthy 
individuals. A 346bp fragment (*) indicates the loss of the Eco RII* restriction site 
due to the mutation. L = lOObp ladder (Gibco BRL), C = normal control, P = 
digested PCR products from the patient.
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confirmed by an Kco RII digestion (Figures 3.14d and 3.14e). This mutation does not 
disrupt the translational reading frame but is predicted to result in the exclusion of 26 
amino acids from the mature protein product. The codon at the junction of exons 7 and 8  
of the normal mRNA is now altered i.e. AAG (lysine) to AAT (asparagine). The basic 
amino acid, lysine, is substituted with asparagine, a neutral amino acid and this is predicted 
to cause the mature protein to be unstable.
This family was identified as there was a family history of the condition. 111:2 had an 
increased urinary excretion of PBG (97mg/l), compared with the reference samples (0 - 
0.3mg/l). He has also suffered recurrent crises of abdominal pain, the cardinal feature of 
AIP. Presymptomatic testing for IV: 1 and IV:2, who are 11 and 8  years old respectively, 
revealed that they have inherited the mutant allele from 111:2. They can, therefore, be 
appropriately advised to avoid the precipitants of AIP.
From Table 2.1, there is a wide range of erythrocyte HMB-S activities among the 
South African patients, ranging from 5.05 nmol PBG/g Hb/hr to 12.1 nmol PBG/g Hb/hr. 
However, a lower erythrocyte HMB-S activity is not associated with a more severe 
phenotype. Patient 632 has an erythrocyte activity of 9.41 nmol PBG/g Hb/hr, which is 
higher than that for patients 638 (5.41 nmol PBG/g Hb/hr) and 637 (8.11 nmol PBG/g 
Hb/hr). The former has the most severe phenotype among all the South African patients. 
637 also has a higher erythrocyte activity than two other patients (644 and 638) but 
presents with a much more severe phenotype. The urinary PBG excretion is not a good 
indication of the severity of the condition. 632 has the highest level of urinary PBG 
excretion and this can be a preliminary indication of the degree of severity. However, if the 
values for the other patients are compared, this correlation is invalid. Patient 639 has a 
relatively low, although elevated, level of urinary PBG excretion (88.6|amol/10mmol 
creatinine) but, had nevertheless, previously suffered a very mild attack. Patient 635, on the 
other hand, has a markedly elevated urinary PBG excretion (233.0|imol/10mmol 
creatinine) but remains asymptomatic.
The type of mutation the patients have are all very destructive to the mature protein. 
Despite this, the patients present with a range of phenotypes. A possible reason for this
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difficulty in correlating the genotype with the phenotype is that AIP is a disease of variable 
expression, with environmental factors influencing the degree of manifestation of the 
condition. This, to some extent, makes this correlation impossible. Another reason could be 
that insufficient clinical and biochemical data for some of the patients may hinder such a 
correlation to be made.
A G/T polymorphism in exon 10 at nucleotide 606, previously reported by Mgone et 
al (1992), was detected in three unrelated South African patients with the R116W mutation 
and two Irish patients with the R26C mutation. Initially, it was thought that this intragenic 
polymorphism was in linkage disequilibrium with the R116W mutation. However, this was 
discounted since it also exists with two other mutations, Gsoo->A and Cioo—»A (Mgone et 
al, 1992), and in this study, C?g->T, all of which are likely to be responsible for AIP.
An interesting application of this polymorphism was observed for Pedigree 13168. 
Ill: 1 and 111:3 carry the R26C mutation but do not have the V202V polymorphism. On the 
other hand, 111:2 and 111:5 are free from the defective gene but possess the V202V 
polymorphism. On screening the coding sequence of the HMB-S gene of 11:6, he was found 
not to have the polymorphism. Therefore, the genotype of the deceased individual, 11:7, 
can be deduced to be positive for the R26C mutation and the V202V polymorphism, both 
of which are present on different chromosomes.
The S45S silent mutation was found in a Scottish patient with the L177R mutation. 
This association was previously reported by Mgone et al (1992) but does not provide 
sufficient evidence that S45S is in linkage disequilibrium with L177R because it is not 
detected in the other five patients with the same mutation, thus excluding the possibility of 
linkage disequilibrium.
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3.4 ALTERNATIVE SPLICING OF HM B-S  mRNA REMOVES EXONS 3 AND 12
In addition to the occurrence of alternative splicing of HMB-S mRNA which excludes 
exon 1 from the erythroid cells and exon 2 from the housekeeping cells, exons 3 and 12 
were found, in this study, to have undergone varying degrees of alternative splicing, both in 
thirty AIP patients and forty-four healthy individuals (Figures 3.15a and 3.16a). 
Sequencing the cDNA in the region of exon skipping revealed that exon 1 was directly 
spliced to exon 4 and that exon 11 was precisely spliced to exon 13 (Figures 3.15b and 
3.16b respectively). The transcript missing exon 3 is 54bp shorter than the normal 
transcript and that missing exon 12 is 120bp shorter. The ratio of PCR products generated 
during the log-phase of amplification for the regions flanking exon 12 (19 cycles of 
amplification) shown in Figure 3.16c was the same as that generated after 35 cycles (Figure 
3.16d), indicating that these ratios reflect the true concentrations of the differentially 
spliced mRNA molecules in vivo. No PCR products were visible on the agarose gel after 
12 cycles of amplification. In addition, exon 3 alone was found to be missing in a 
proportion of the transcripts, as well as in a proportion of those transcripts with exon 12 
also missing (Figure 3 .17). Approximately 10 to 50% of the transcripts were observed to 
be alternatively spliced. Sequencing the DNA in the vicinity of the exon-intron boundaries 
did not reveal any abnormal sequences. Analysis of the other exons of the HMB-S mRNA 
by RT-PCR revealed that none of them had undergone alternative splicing (Figures 3.17a, 
3.17b, 3.17c and 3.17d). All the individuals who showed alternative splicing of exons 3 and 
12 were analysed on three further occasions and the pattern of alternative splicing was 
reproducible.
A schematic representation of alternative splicing of exons 3 and 12 is depicted in 
Figure 3.18. The primers used to detect exon 3 skipping were 377H and Phe4-, while 
Phel0+ and 749D were used to detect exon 12 skipping.
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Figure 3.15: RT-PCR and sequence analysis of the region showing exon 3
skipping.
(a): RT-PCR results of a representative group of individuals showed two bands, 
13 lbp and 77bp, whose size difference corresponds to the absence of exon 3. 
The upper panel shows the RT-PCR products of 19 AIP patients and the 
lower panel represents RT-PCR products of 19 normal individuals. In both 
groups of patients, it was observed that exon 3 was spliced out to varying 
degrees.
(b): Sequence analysis of the excised upper and lower bands from (a) showed that 
exon 3 is missing from the lower band, resulting in exon 1 being directly 
spliced to exon 4.
124
131 bp
77bp
131 bp
£
K
77bp
Figure 3.15a
UPPER
BAND
T C G A
LOWER
BAND
T C G A
EXON 3 EXON 4
EXON 1 EXON 1
Figure 3.15b
125
Figure 3.16: RT-PCR and sequence analysis of the region showing exon 12
skipping.
(a): RT-PCR results of a representative group of individuals showed two bands, 
378bp and 258bp, whose size difference corresponds to the absence of exon 
12. The upper panel shows the RT-PCR products of 19 AIP patients and the 
lower panel represents RT-PCR products of 19 normal individuals. In both 
groups of patients, it was observed that exon 12 was spliced out to varying 
degrees.
(b): Sequence analysis of the excised upper and lower bands from (a) showed that 
exon 12 is missing from the lower band, resulting in exon 11 being directly 
spliced to exon 13.
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Figure 3.16c: RT-PCR products of four individuals after 19 cycles of 
amplification.
The four individuals show varying degrees of splicing out of exon 12 after 19 cycles of 
amplification (log-phase PCR).
Figure 3.16d: RT-PCR products of the four individuals from Figure 3.16c after 
35 cycles of amplification.
The RT-PCR products of the individuals in Figure 3.16c reveal a similar ratio of 
amplification products as in Figure 3.16c after 35 cycles of PCR.
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Figure 3.17: Evidence for 4 different mRNA transcripts in the lymphocyte 
population.
The full length HMB-S cDNA was amplified using the primers 019H and 020H 
(Table 2.3), giving a fragment of 1 3kb. The amplified products were analysed on a 
2% Metaphor gel (Flowgen), where 4 different mRNA transcripts were present as 
described below:
Lane 1:
L: 1 kb ladder (Gibco BRL)
intact transcript (i.e. exons 3 and 12 present)
Lanes 2 to 7, 9, 10: exons 3 and 12 missing from the smallest allele
Lanes 8, 11, 12: exon 12 missing from the smaller allele
Lane 12. exon 3 missing from the larger allele
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Figure 3.17a: RT-PCR products of the region spanning exons 1 to 8 of a 
number of individuals.
The region spanning exons 1 to 8 of the HMB-S mRNA did not show any 
extraneous bands due to exon skipping, except that due to exon 3 skipping as seen 
by the presence of a shorter transcript. L = lOObp ladder.
Figure 3.17b: RT-PCR products of the region spanning exons 7 to 11 of a 
number of individuals.
The region spanning exons 7 to 11 of the HMB-S mRNA showed the presence of 
only one population of mRNA transcript (398bp), thus eliminating the possibility 
of exon skipping in this region. L = lOObp ladder.
Figure 3.17c: RT-PCR products of the region spanning exons 9 to 11 of a 
number of individuals.
The RT-PCR products encompassing exons 9 to 11 of the HMB-S mRNA showed 
only the expected amplification products (290bp). L = lOObp ladder.
Figure 3.17d: RT-PCR products of the region spanning exons 13 to 15 of a 
number of individuals.
The RT-PCR products covering exons 13 to 15 of the HMB-S mRNA revealed 
only amplification products of the expected size (442bp). L = lOObp ladder.
Exon 12 was not analysed here as it had already been shown to undergo varying 
degrees of alternative splicing (Figure 3.16a).
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Figure 3.18: Schematic representation of the location of primers used to 
detect exons 3 and 12 skipping.
A schematic representation showing the location of the primers used in this study 
(arrowed) to detect the regions of alternative splicing. The upper diagram shows 
the mRNA transcript of one allele before splicing while the lower diagram shows 
the transcript after splicing. The exons in bold type are removed as a result of 
alternative splicing.
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3.5 IN  VITRO GENE EXPRESSION
3.5.1 HMIi-S RECOMBINANT CLONES
The clones constructed for subsequent in vitro expression studies consisted of the 
plasmid expression vector, pTrc 99A (Pharmacia) and the segment of interest which was 
amplified by PCR. The expression vector consists of a strong Ire promoter which directs a 
controlled, high-levelled expression of foreign inserts. It also possesses a strong 
transcription termination signal (rrnB) downstream.
In this study, three missense mutations, R26H, R116W and R173Q, were successfully 
expressed in the in vitro expression system. An attempt was made to express the other 
mutations, R22C, R26C, 345-lG-»A, L177R, 771insT and delGioo2/ioo3/ioo4, in the system 
but was unsuccessful.
3.5.2 VERIFICATION OF THE INTEGRITY OF THE CLONES
Since the segment of interest was generated by PCR, its sequence has to be verified 
before proceeding to expression studies. CCM analysis was the screening method of choice 
since it enabled the verification of the entire insert in a single analysis. The sequence of the 
clone was then compared with that of the wild-type. The sequences of the primers used in 
cloning are shown in Table 2.4.
Of the 126 cloned inserts screened by CCM analysis, 44 (34.9%) did not show any 
misincorporations by Taq DNA polymerase. 39 of these intact fragments were those of the 
normal allele while the remaining 5 had incorporated the mutated allele, which were 
suitable for expression studies. A typical result obtained after CCM analysis consists of a 
mixture of clones with misincorporated nucleotides (seen as cleavage products of various 
sizes), clones with the normal allele (no cleavage products) and clones with the mutated 
allele (various cleavage products corresponding to the location of the mutations present in 
each clone) (Figure 3.19).
To prove that there were no misincorporations present, the clones not showing any 
cleavage products, as well as those clones which showed cleavage products of the correct
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Figure 3.19: CCM analysis of clones to check for misincorporations by Taq 
DNA polymerase.
A variety of cleavage products are observed after subcloning the human HMB-S 
coding sequence into the expression vector pTrc 99A, with hydroxylamine being 
the chemical used for modification.
Lanes 1 to 3, 6: clones showing random misincorporations
Lanes 4, 5, 7 to 10: clones not revealing any cleavage products
Lane 11: positive control showing the cleavage product due to the
mutation R116W
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sizes, were sequenced to ensure that, in the former case, there were no base changes and in 
the latter case, the cleavage products were due to the mutation present.
3.5.3 ANALYSIS OF PROTEIN EXPRESSION
After subjecting the HMB-S clones to in vitro expression, Western blotting was 
performed to accomplish a threefold purpose: (i) to verify the specificity of the custom- 
made antibody; (ii) to determine if expression was successful; and (iii) to quantify the 
amount of proteins generated.
Varying concentrations of primary and secondary antibodies were used and the 
washing conditions were modified from standard protocols to obtain the highest signal to 
background ratio (Figures 3.20a and 3.20b). A 1:10000 to 1:5000 dilution of the primary 
antibody (6.125mg/ml) was found to give the best signal with low background (Figure 
3.20b) while a 1:40000 dilution of the secondary antibody was found to be optimal for 
detection by chemiluminescence. An overnight incubation of the filter in the primary 
antibody-containing wash buffer and an extended washing time (8 X 15 minutes) also 
ensured that the primary antibody was specific for the protein against which it was raised.
The success of protein expression in an in vitro system was determined by the 
presence of an additional band at approximately 44kD, corresponding to the size of the 
housekeeping protein (Figures 3.20a and 3.20b).
The specificity of the antibody for the human HMB-S protein was verified after all the 
conditions for Western blotting had been optimised (Figure 3.20b).
3.5.4 SEPARATION OF HUMAN AND E. coli HMB-S PROTEINS
3.5.4.1 HPLC
An attempt was made to separate the human and E. coli HMB-S proteins by HPLC. 
The gradient elution programme (Table 2.5) was devised based on the results reported by 
de Rooij et al (1987) and found to give a relatively good separation. From the 
chromatograms shown in Figures 3.21a and 3.21b, an extra peak was observed for the 
clone containing the expressed human HMB-S protein but this was not present in the
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Figure 3.20: Optimisation o f Western blotting conditions.
The effects of both antibody concentrations and washing stringencies are 
compared. The samples were run on a 12% SDS-PAGE gel.
(a) The conditions employed are those recommended by the manufacturer of the 
Western Blotting Detection Reagents (Amersham). The protein of interest is 
shown (44kD), as well as non-specific bands.
(b) The conditions have been modified such that the specificity of the primary 
antibody for the protein it has been raised against is maximum (section 3.5.3).
- = clones without the human insert 
+ = clones with the human insert 
Lane 1: R173Q
Lane 2: negative control i.e. no mutation present 
Lane 3: R26H
The additional bands below the protein band of interest (44kD) could be due to the 
presence of internal methionines within the mRNA transcript which may provide 
additional initiation codons for translation.
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Figure 3.21a: HPLC chromatogram of the clone without the human protein.
The conditions used for this HPLC run are shown in Table 2.5. Three distinct 
peaks were consistently produced with each run, hence the eluent for each of these 
peaks was collected for further analysis. The peak, as indicated by the arrow, 
shows a different profile when compared with Figure 3.21b.
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Figure 3.21b: HPLC chromatogram of the clone containing the human 
protein.
The third peak, as indicated, is significantly different from that in Figure 3.21a. 
Both peaks, in this case, were collected for further analysis.
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clone without the human protein present. Therefore, the extra peak observed is most likely 
due to the human form of the protein.
3.5.4.2 IEF
The IEF method of separation has the added advantage in that the proteins can be 
concentrated in the gel for further manipulations to be done specifically on the protein of 
interest after separation. The pis of the two forms of HMB-S protein were first determined 
and detected by (i) Coomassie Brilliant Blue staining, and (ii) silver staining which is a 
more sensitive detection method. Coomassie Brilliant Blue staining apparently showed no 
differences between the samples with and without the expressed human protein (Figure 
3.22a). The silver staining method of detection was next employed to determine if the 
resolution of the bands obtained by Coomassie Brilliant Blue staining could be further 
improved. Again, no differences were observed among the samples with the human protein 
present and those without the human protein (Figure 3.22b). The pis of the two forms of 
HMB-S protein could be too close for separation by IEF.
3.5.5 HMB-S ACTIVITIES
The total protein lysates of three different mutant clones, viz. R26H, R116W and 
R173Q, as well as a clone with the normal human sequence and a clone without any human 
insert, were used for the measurement of HMB-S activity. The latter was performed to 
establish a baseline level for the activity of the bacterial HMB-S enzyme for comparison 
with the expression levels of the human enzyme (Table 3.4). For all the clones assayed, the 
specific activities calculated were the average of two independent assays.
The clones with the three mutations gave relatively similar specific activities. If the 
specific activity of the clone without the human insert was subtracted from that of the other 
clones, then it is clear that each of the mutations causes a marked reduction in the activity 
of the enzyme, yielding an approximate 3 - 4% of residual activity. Therefore, bacterial 
activity was irrelevant due to the relative efficiency of recombinant human protein 
expression compared to endogenous bacterial protein expression.
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Figure 3.22: Isoelectric focusing of the expressed proteins.
(a) The clone without the human insert was focussed side by side with one 
containing the human form to look for the presence of an extra band due to the 
human protein. Coomassie Brilliant Blue staining did not show any differences 
between the two samples, so silver staining was undertaken to improve the 
resolution.
Lane 1: clone without the human insert 
Lane 2: clone with the human insert
(b) Silver staining of the same samples from (a) did not show any improvement.
1 2
Figure 3.22a
■
w
Figure 3.22b
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Table 3.4: Correlation of the mutations with their activities as determined by an in 
vitro expression system.
Mutation Enzyme
activity
(pmol/ml/hr)
Average 
specific activity 
(pmol/mg 
protein/hr)
Specific activity 
due to human 
HMB-S (pmol/mg 
protein/hr)
% o f
residual
activity
R26H 4.83 X I06 5.8 X 106 1.07 X 106 3.9
R116W 4.72 X I06 5.66 X 106 0.93 X 106 3.4
R173Q 4.63 X I06 5.56 X 106 0.83 X 106 3.0
Normal 
human insert
26.72 X 106 32.07 X 106 27.34 X 106 100.0
pTrc 99A (no 
human insert)
3.94 X 106 4.73 X 106
The enzyme activities of the clones with and without mutations are listed. The HMB-S 
activity of the clone which does not contain the human insert was also measured to provide 
a baseline measurement, to which the expression levels of the human enzyme can be 
normalised.
The specific activity due to the human HMB-S was obtained by subtracting the specific 
activity of the bacterial enzyme (i.e. pTrc 99A without the human insert) from the clones 
with and without mutations analysed here.
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CHAPTER 4: 
DISCUSSION
CHAPTER 4: DISCUSSION
4.1 PATHOPHYSIOLOGY OF AIP
A total of seventy-three mutations have so far been reported in the HMB-S gene 
(Table 4.1). This consolidates the fact that AIP is a heterogeneous disorder. 78.1% of the 
mutations are single base substitutions (either missense, nonsense or those leading to 
splicing defects) and the remaining 21.9% involve frameshift mutations (Daimon et al, 
1994; Gu et al, 1994; Kauppinen et al, 1995; Mgone et al, 1993; Ong et al, 1996; Schreiber 
et al, 1994; Schreiber et al, 1995) either due to insertions or deletions (Table 4.1). This is 
represented diagrammatically as Figure 4.1.
The mutations reported so far in the HMB-S housekeeping gene are spread over the 
entire length of the coding sequence. All the exons have at least one mutation reported, 
with exon 12 having the highest number of mutations, followed by exon 10 (Figure 4.2). 
Both exons are, thus, extremely important regions in the HMB-S protein molecule due to 
their frequent association with the disease (about 38.4%). Therefore, a good strategy for 
mutation detection of new samples with no previous information would be to focus initially 
on these two exons before proceeding to the other regions of the coding sequence.
4.1.1 MUTATION ANALYSIS
In this study, nine different mutations were identified and fully characterised in thirteen 
families. Two families failed to reveal any mutations in their coding sequence. This could 
be due to the presence of mutations in the promoter regions of the HMB-S gene. Six of the 
detected mutations were missense mutations (R22C, R26C, R26H, R116W, R173Q and 
L177R), one was a single base substitution affecting a 3' acceptor splice site (345-lG-»A), 
one was a single base deletion (delGioo2/ioo3/ioo4) and one was a single base insertion 
(771insT). The novel mutations identified in this study were R22C, 345-1G—>A, 
delGioo2/ioo3/ioo4 and 771insT. The mutations which have been previously described were
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Table 4.1: Summary of mutations detected in the H M B-S  gene.
No. Intron/
Exon
Base
change
Nucleotide
position
Amino acid 
change
CRIM-
status
Effect of mutation Reference
1 El G->T 33 A11A - 5' donor splice 
site mutation
Grandchamp et al (1989b)
2 11 G-»A 33+1 E12K 5' donor splice 
site mutation
Grandchamp et al (1989c)
3 E3 C->G 6 6 Skipping of E3 Llewellyn et al (1996)
4 E3 C—»T 76 R26C + Arg-»Cys Kauppinen et al (1995)
5 E3 G—>A 77 R26H + Arg-»His Llewellyn et al (1993)
6 13 G—>T 87+1 5’ donor splice 
site mutation
Lundin et al (1995)
7 E4 G->A 91 A3 IT + Ala->Thr Gu et al (1994)
8 E4 del A 97 97delA — Frameshifl=>stop 
codon lOaa away
Kauppinen et al (1995)
9 E4 C—>A 1 0 0 Q34K - Gln-»Lys Mgone et al (1992)
1 0 E4 C->T 1 0 0 Q34X - Gln-»Stop Kauppinen et al (1995)
11 E4 T->A 125 L42X Leu-»Stop Puy et al (1996)
1 2 E5 G->T 163 A55S + Ala-»Ser Gu et al (1994)
13 E5 del GT 168 168delGT Frameshift=>stop 
codon 64aa away
Schreiber et al (1995)
14 E5 del C 174 174delC — Frameshift=^>stop 
codon 40aa away
Gu et al (1994)
15 E5 ins G 182 182insG — Frameshift=>stop 
codon 5aa away
Gu et al (1994)
16 15 G-*A 2 1 0 + 1 — 5' donor splice 
site mutation
Gu et al (1994)
17 E6 del AG 218 218delAG — Frameshift=>stop 
codon 9aa away
Gu et al (1994)
18 E6 G->C 251 A84C Ala->Cys Mgone et al (1993)
19 E7 G->T 277 V93F Val->Phe Chen et al (1992)
2 0 E7 A-»G 293 K98R — Lys->Arg Kauppinen et al (1995)
2 1 E7 ins A between 
C3 1 4  and 
T315
Frameshift=>stop 
codon 1 2 1 aa 
away
Schreiber et al (1995)
2 2 E7 G-»A 331 G111R - Gly->Arg G uetal (1993a)
23 E8 C-»T 346 R116W - Arg->Trp Gu et al (1993)
24 E8 G-»A 347 R116Q Arg->Gln Mgone et al (1994)
25 E8 C—»T 356 P119L Pro—^ Leu Lundin et al (1995)
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No. Intron/
Exon
Base
change
Nucleotide
position
Amino acid 
change
CRIM-
status
Effect of mutation Reference
26 18 G—»T 422+1 5’ donor splice 
site mutation
Lundin et al (1995)
27 E9 C-»T 445 R149X — Arg-»Stop Kauppinen et al (1995)
28 E9 G-»A 446 R149Q - Arg—> Gin Delfau et al (1991)
29 E9 G-»T 446 R149L - Arg—>Leu G uetal(1994)
30 E9 C—>T 465 Q155X - Gln->Stop Scobie et al (1990)
31 E9 ins A between 
A4 7 Q and
G471
FrameshifL=>stop 
codon 52aa away
Schreiber et al (1994)
32 19 G->A 499-1 3' acceptor splice 
site m utations 
deletion of E10
Lundin et al (1994)
33 E10 C-»T 499 R167W Arg->Trp Gu et al (1993) 
Llewellyn et al (1992)
34 E10 G->A 500 R167Q Arg—> Gin Delfau et al (1990) 
Llewellyn et al (1992) 
Mgone et al (1992)
35 E10 C->T 517 R173W - Arg-»Trp Mgone et al (1994)
36 E10 G-»A 518 R173Q + Arg-»Gln Delfau et al (1990)
37 E10 T->G 530 L177R Leu-»Arg Mgone et al (1992)
38 E10 C->T 583 R195C - Arg->Cys Kauppinen et al (1995)
39 E10 G->A 593 W198X - Trp-+Stop Lee and Anvret (1991)
40 E10 C-»T 601 R201W Arg->Trp Lundin et al (1994)
41 E10 del G 604 604delG Frameshift=>stop 
codon 53aa away
Schreiber et al (1994)
42 E10 C->T 610 Q204X Gln-»Stop Mgone et al (1994)
43 E10 G-»T 612 612G-»T 5' donor splice 
site mutation, last 
9 bases of E10 
deleted
Delfau et al (1991)
44 E ll del A 629 629delA Frameshift=>stop 
codon 44aa away
Lee et al (1995)
45 11 1 C->G 652-3 3' acceptor splice 
site mutation=> 
skipping of E12
Puy et al (1996)
46 E12 G—>A 667 E223K - Glu->Lys Gu et al (1994)
47 E12 C-»G 673 R225G - A rg^G ly Kauppinen et al (1995)
48 E12 C->T 673 R225X - Arg-»Stop Kauppinen et al (1995)
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No. Intron/
Exon
Base
change
Nucleotide
position
Amino acid 
change
CRIM-
status
Effect of mutation Reference
49 E12 T-»G 713 L238R - Leu—> Arg Kauppinen et al (1995)
50 E12 del CT 730 730delCT — Frameshift=>stop 
codon 6 aa away
Mgone et al (1993) 
Gu et al (1994)
51 E12 T-»G 734 L245R - Leu->Arg Delfau et al (1991)
52 E12 T—»C 739 C247R Cys-»Arg Mgone et al (1993)
53 E12 G->T 740 C247F - Cys->Phe Chen et al(1992)
54 E12 ins
TTCGC
TGC
742 742ins8 Frameshift=>stop 
codon lOaa away
Gu et al (1994)
55 E12 G-»A 748 E250K - Glu->Lys Gu et al (1994)
56 E12 G—»C 748 E250A Glu—»AIa Lundin et al (1995)
57 E12 G-»A 754 A252T Ala-»Thr Mgone et al (1993)
58 E12 C-+T 755 A252V Ala->Val Mgone et al (1993)
59 E12 C-+A 766 H256N His-»Asn Mgone et al (1992)
60 E12 G->A 771 771G-+A + 5' donor splice 
site mutation=> 
deletion of E12
Grandchamp et al (1989a)
61 E12 G->C 771 771G-»C 5' donor splice 
site mutation=> 
deletion of E12
Daimon et al (1993)
62 E12 ins T 771 771insT Frameshift=?>stop 
codon 33aa away
Ong et al (1996)
63 E13 C->T 806 T269I Thr->Ile Mgone et al (1994)
64 E13 G->A 820 G274R Gly->Arg Mgone et al (1994)
65 E14 G->A 838 G280R ' - Gly—>Arg Kauppinen et al (1995)
6 6 E14 G->A 848 W283X Trp^Stop Mgone et al (1994)
67 E14 G—>A 849 W283X T rp ^S to p Schreiber at al (1995)
6 8 E14 C-»T 8 8 6 Q296X - Gln-+Stop Kauppinen et al (1995)
69 E14 del T 900 900delT — Frameshift=>stop 
codon 15aaaway
Delfau et al (1991)
70 114 G->A 912+1 912+1G->A 5' donor splice 
site mutation=> 
deletion of E14
Gu et al (1993a)
71 E15 ins C 913 913insC Frameshift=>stop 
codon laa away
Puy et al (1996)
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No. Intron/
Exon
Base
change
Nucleotide
position
Amino acid 
change
CRIM-
status
Effect of mutation Reference
72 E15 del A 1073 1073delA Frameshift=> 
protein contains 
449aa instead of 
361aa
Kauppinen et al (1995)
73 E15 ins C between 
-22 and -21 
from ter­
mination 
codon
Frameshift=>stop 
codon 4aa away
Daimon et al (1994)
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Figure 4.1: Percentage of occurrence of different types of mutations in the 
HMB-S gene.
The pie chart shows the frequency of the different types of mutations 
encountered in the HMB-S gene. Missense mutations form the majority of 
mutations reported so far in the HMB-S gene.
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Figure 4.2: Distribution o f mutations in the H M B-S  gene.
The chart show s the distribution o f  reported m utations in the HMB-S gene. 
A ll the exons o f  the housekeeping gene have at least one m utation. Exon 12 
has the highest num ber o f  m utations reported in  the literature, follow ed by 
exon 10.
The X -axis represents the location o f  the  m utation w ithin the gene (E = exon; 
I =  intron) and the Y-axis shows the num ber o f  m utations identified in each 
region o f  the gene.
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R26C (Kauppinen et al, 1995), R26H (Llewellyn et al, 1993), R116W (Gu et al, 1993), 
R173Q (Delfau et al, 1990) and L177R (Mgone et al, 1992). The heterogeneity of AIP is 
further emphasised in the South African group of patients where five different mutations 
were detected in seven apparently unrelated patients. All the mutations detected in this 
study are potentially pathogenic since (i) a highly conserved residue is affected; (ii) 
truncated protein products would be formed; or (iii) an exon has been skipped.
AIP has a very high incidence in Sweden with 1/1000 of the population affected 
(Waldenstrom, 1957). A number of reported mutations could be shown to originate from 
Sweden. The G-»A transition in exon 10 (W198X) (Lee and Anvret, 1991) identified in a 
family from Swedish Lapland, was also found in 15 of 33 Swedish families with AIP. 12 of 
these families with the W198X mutation were related to the index family. Another 
mutation, C—>T in exon 8 (R116W), was found to occur at a high frequency in Dutch 
patients with the CRIM-negative phenotype (15 of 49 patients or 30%) but only in 1 of 33 
French and 1 of 28 Swedish families (Lee et al, 1990; Gu et al, 1993). This mutation was 
first described in a Swedish patient (Lee, 1991) and was detected in three unrelated South 
African patients in the present study, whose ancestry revealed that they may have a mixture 
of Malay, European and Khoi blood, the latter being the original inhabitants of the Cape at 
the time of European settlement. If the European component of the mixture is Dutch, this 
might explain why this mutation is present in all three apparently unrelated patients. The 
L177R mutation has been independently reported by Mgone et al (1992) in a Scottish 
patient. This mutation was detected again in six Scottish patients (five members of a family 
and an isolated case). Their ancestry is not known but it could prove to be a common 
Scottish mutation. R173Q was first identified in French and Dutch patients (Delfau et al,
1990), and it was detected in one of the South African patients, who may have Dutch 
ancestors. Therefore, a patient’s geographical origin may lend assistance in the 
identification of the mutation responsible for AIP in that family.
The novel R22C mutation was initially identified in individuals HI:8 and 111:9 of 
Pedigree 9532 (Appendix 1). Subsequent analysis of individuals 11:2,111:3, 111:5,111:7 and 
111:11 by Hinf I digestion revealed that 11:2, 111:5 and 111:11 are carriers of the defective
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gene. This mutation in exon 3 of the HMB-S gene affects the highly conserved Arg22 
residue (Arg7 in E. coli). Because this residue is highly conserved in ten species (Louie et 
al, 1996), it is a good indication that it has an important role in the proper functioning of 
the enzyme. Arginine, a basic residue, is substituted by cysteine, a neutral, non-polar amino 
acid which, consequently, is predicted to destabilise the protein. However, the precise role 
of this residue is not known at the present time.
R26C, previously reported by Kauppinen et al (1995), was initially identified in 
individuals 111:1 and 111:3 but not in 111:2 of Pedigree 13168 (Appendix 1). By employing 
an Aci I digestion for the other members of this family, namely, 11:1 to 11:6, 11:8,111:5 to 
111:8, IV: 1 and IV:2, it was shown that 11:8, IV: 1 and IV:2 were also carrying the defective 
gene. Arg26 (Argl 1 in E. coli) is a conserved residue in twelve species. It functions to 
form a salt-bridge with the acidic side chain of the second pyrrole ring of the cofactor. Any 
substitution of this residue will result in a defective enzyme being produced. This mutation 
results in the basic arginine residue to be replaced by the polar uncharged cysteine, which is 
predicted to destabilise the protein. In this family, individual 11:6 was found to have an 
erythrocyte HMB-S activity of 20.6nmol/ml RBC/hr (normal range 22-46nmol/ml 
RBC/hr). An analysis of his entire coding sequence by direct sequencing did not reveal any 
sequence alterations. He may have a much higher proportion of alternatively spliced exons 
3 and 12 in his coding sequence, which has been found, in this study, to be a normal 
occurrence in the general population. It would be useful to express his mis-spliced 
transcripts to determine if the degree of splicing out would have an effect on his 
erythrocyte HMB-S activity.
The R26H mutation affects the same residue as the R26C mutation, and is expected 
to result in a defective protein being produced.
R116W in exon 8 was identified in three unrelated South African patients and two 
members of a family from the Republic of Ireland. This mutation was easily confirmed by 
an Aci I digestion. Argl 16 (ArglOl in E. coli) is conserved in twelve species and serves to 
interact with the interdomain hinge region by forming a salt-bridge with Glu231 and a 
hydrogen bond with the backbone carbonyl group of residue 198. Its replacement with 
tryptophan would probably result in the loss of these stabilising interactions, leading to the
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formation of a non-functional protein. Both the South African and Irish families may have 
Dutch ancestors but no information is currently available for confirmation.
The R173Q mutation in exon 10, identified in a South African patient, affects the 
highly conserved Argl73 (Argl55 in E. coli) residue. This mutation is expected to result in 
a defective protein since the substitution of the basic residue, arginine, with the polar 
neutral residue, glutamine, is anticipated to prevent the formation of salt-bridges with the 
propionate group of the first pyrrole ring of the cofactor and the carboxylate side group of 
the substrate molecule, thus leading to the inhibition of substrate elongation.
L177R in exon 10, previously reported by Mgone et al (1992) in the Scottish 
population, was identified again in two Scottish families in this study, one of which 
consisted of an isolated case. The other family, Pedigree 13543 (Appendix 1), had five 
affected members, 11:3,111:2, 111:3,111:5 and 111:6, the latter of which was initially thought 
to be an isolated case. Subsequent analysis of IV: 1, IV:3 and IV:4 revealed that the mutant 
allele was absent in these individuals. 11:1 was not analysed in this study but was diagnosed 
with AIP based on her biochemical data. Leu 177 (Leu 159 in E. coli) is conserved in eleven 
species and forms part of the hydrophobic core of the molecule. The introduction of a 
charged group in this region of the protein by arginine would be structurally deleterious. 
This mutation could prove to be a common Scottish mutation.
There are fifty-eight invariant residues in the HMB-S protein (Brownlie et al, 1994); 
twenty-eight of which have been reported to be mutated (48.3%). This comprises 38.4% of 
all reported mutations. The E. coli model has been used to explain the effects of the 
mutations on the structure and function of the enzyme because it has a high degree of 
homology with the human form (43%). The location of all seventy-three mutations listed in 
Table 4.1 is shown in Figure 4.3.
How missense mutations affect the structure, stability and function of a protein has 
been studied by Pakula and Sauer (1989) and Alber (1989). The resulting phenotypic 
effects of a mutation will depend on the nature of the amino acid substitution and its 
location within the protein. Mutations which affect the core residues of the protein 
structure and those residues involved in maintaining the stability of the protein through the
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Figure 4.3: The location of mutations within the hydroxymethylbilane
synthase (HM B-S) protein.
The location of the various mutations detected in the HMB-S protein is shown. 
The numbers refer to the number of the mutation in Table 4.1. The 
dipyrromethane cofactor is represented in red and is situated in a deep cleft 
between domains 1 and 2 (shown in yellow and green respectively). Domain 3 
is shown in blue.
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formation of hydrogen, disulphide and electrostatic bonds will most probably be 
responsible in the causation of the disease.
Conserved amino acids are usually clustered in important regions of the molecule, 
namely, the hydrophobic core, sites which are conformationally important and at the active 
site. Many of the substitutions involve residues situated close to the active site, and this 
may prove detrimental to the enzyme.
Residues Arg 149, Arg 167 and Arg 173 (Arg 131, Arg 149 and Argl55 respectively in 
the E. coli model), all of which are located in the vicinity of the active site, are involved in 
providing stabilising interactions with the acetate and propionate side groups of the 
cofactor. Arg 149 interacts with the side chains of ring Cl of the cofactor and its 
substitution, by site-directed mutagenesis (Jordan and Woodcock, 1991; Lander et al,
1991) with leucine or histidine, prevents the assembly of the cofactor and the correct 
folding of the enzyme. This results in the production of an inactive and unstable 
apoenzyme. Arg 173 serves to interact with the side chains of rings Cl and C2 of the 
cofactor, and its replacement with tryptophan or glutamine (numbers 35 and 36 
respectively, Figure 4.3) results in the prevention of substrate binding, the final stages of 
pyrrole chain extension and the final release of the tetrapyrrole product. The invariant 
Argl 16 is situated on one of the two short strands linking domains 1 and 2 (numbers 23 
and 24, Figure 4.3), with the charged side chain forming an ion pair with Glu250. Site- 
directed mutagenesis at this position does not prove to be deleterious. Arg26, like Argl73, 
forms interactions with the cofactor at the substrate-binding site, and its replacement with 
cysteine or histidine (numbers 4 and 5 respectively, Figure 4.3) inhibits the conversion of 
the enzyme to the enzyme-substrate complex, and eventually the formation of the product.
The mutations which occur at the conserved residues of the hydrophobic core are 
expected to be detrimental to the protein structure, because they either introduce a charged 
group to the apolar core of the molecule, or result in steric hindrance with the substitution 
of another amino acid e.g. L177R and A3 IT (numbers 37 and 7 respectively, Figure 4.3).
Eleven mutations (15%) have been reported in exon 10 (Table 4.1), indicating its 
important role in maintaining the proper function of the enzyme. The three highly 
conserved residues in this exon which have undergone single base substitutions are
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Arg 167, Arg 173 and Leu 177. The substitution of these residues with other amino acids is 
predicted to lead to the formation of a non-functional, unstable protein.
In this study, four of the five residues altered are conserved (Arg26, Argl 16, Argl73 
and Leu 177). The fifth residue affected, Arg22, has not been studied in detail but, from the 
table of alignment of amino acid sequences (Louie et al, 1996) of thirteen species, it is a 
highly conserved residue, being maintained in ten of the species listed. The highly 
conserved nature of these mutations indicates that they have an important role in the 
protein molecule to ensure its normal function. Any mutation affecting these conserved 
residues will consequently lead to impaired protein function.
Therefore, the missense mutations identified in the HMB-S gene have been shown to 
impair the normal function of the enzyme because they (i) destabilise the protein through 
loss of the stabilising interactions within the molecule; (ii) prevent substrate binding and 
chain elongation; (iii) introduce a charged group into the apolar core of the enzyme; or (iv) 
cause steric hindrance with the substitution of the new amino acid.
Nonsense and frameshift mutations have also been documented in the HMB-S gene 
(Table 4.1). Ten nonsense mutations (14%) were found throughout the gene and led to the 
formation of truncated proteins. Large insertions and deletions are not a common feature in 
the molecular pathology of AIP. The largest number of bases reported to be inserted was 
eight in exon 12 (Gu et al, 1994) which resulted in the formation of a premature 
termination of translation ten amino acids away. The novel insertion mutation identified in 
this study, 771insT in exon 12, was detected in a South African patient. The consequence 
of this mutation was the alteration of the thirty-two amino acids following this insertion 
prior to the formation of a termination codon. The largest number of bases reported to be 
deleted in the HMB-S gene was two, 168delGT (Schreiber et al, 1995) in exon 5, 
218delAG (Gu et al, 1994) in exon 6 and 730delCT (Mgone et al, 1993; Gu et al, 1994) in 
exon 12. Both insertions and deletions result in the formation of truncated proteins, which 
will impair the normal function of the protein.
The majority of the splice site mutations identified in the HMB-S gene occur at the 5' 
donor splice site, all of which led to the skipping of the preceding exon. The only exception 
to this rule was the identification of a 9bp deletion at the 5' splice site of exon 10 (Delfau et
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al, 1991). The relative abundance of the abnormally spliced mRNA was found to be the 
same as the normal transcript, indicating that the abnormally spliced mRNA was of equal 
stability as the normal mRNA. Only two 3' acceptor splice site mutations have been 
reported in the HMB-S gene, i.e. in intron 9 (Lundin et al, 1994) and intron 11 (Puy et 
al, 1996), leading to the skipping of exons 10 and 12 respectively. A similar pattern was 
also observed for the splice site mutation detected in this study, where the 3' splice site 
mutation detected at the last position of intron 7 resulted in the skipping of exon 8. Both 
exons 10 and 12 have recorded the highest number of mutations. Many highly conserved 
residues are present in both exons e.g. Arg 167, Arg 173 and Leu 177 in exon 10, and 
Arg225 and Glu250 in exon 12. These residues either provide stabilising interactions within 
the enzyme molecule or enable substrate binding and chain elongation. Therefore, the 
absence of either of these exons will result in a defective protein product and, 
consequently, lead to an increase in susceptibility to AIP if exposed to certain triggering 
factors. Likewise, the exclusion of exon 8 from the protein is predicted to result in its 
destabilisation since the three conserved residues, involved in maintaining its stability, 
Argl 16, Asp 121 and Leu 134, are absent. A calculation of the consensus value (CV) of the 
3' acceptor splice site of the mutant intron 7 was 77.59%, which was a reduction of 16.6% 
from that of the normal sequence (94.19%). These values provide evidence that the 
sequence alteration is most probably responsible for the splicing error.
In the two South African patients where no sequence alterations were identified in the 
coding sequence of the HMB-S gene, it would be extremely useful to obtain their DNA 
samples to enable the analysis of the promoter regions.
4.1.2 ALTERNATIVE SPLICING
The phenomenon of alternative splicing of exons 1 and 2 of the HMB-S gene in 
erythroid and non-erythroid tissues is well-documented (Chretien et al, 1988).
In this study, several patients were initially found to exhibit exon 12 skipping in their 
HMB-S gene. Several attempts were made to identify the cause of exon 12 skipping by 
sequencing the preceding and following introns of this gene but to no avail. On screening 
forty-four healthy individuals, exon 12 was found to undergo varying degrees of alternative
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splicing (Figure 3.16). The other exons were similarly screened for evidence of alternative 
splicing, and exon 3 was found to be alternatively spliced to varying degrees as well 
(Figure 3.15). Four different mRNA transcripts are likely to exist in the lymphocyte 
population (Figure 3.17): those which (i) are intact; (ii) have exon 3 missing; (iii) have exon 
12 missing; and (iv) have exons 3 and 12 missing.
Two approaches were undertaken in an attempt to identify a reason for this event. The 
first approach was to study the frequency of occurrence of each base at each position of 
the 5' and 3' splice junctions of the HMB-S gene and to compare with that of four hundred 
vertebrate genes analysed by Padgett et al (1986). The 5' and 3' splice site consensus 
sequences shown in Figure 4.4 were determined after a survey of four hundred vertebrate 
genes by Padgett et al (1986).
At some positions, the frequency of occurrence of a particular base in the HMB-S 
gene, is very close to that reported by Padgett et al (1986). However, there are significant 
differences in the frequency at other positions. For example, at position +4 of the 5' donor 
splice site, the frequency of adenine occurring was reported to be 74% but the frequency 
was only 50% in the HMB-S gene. This creates some difficulty in interpreting how 
particular sequences at the splice sites might affect the proper splicing of the HMB-S 
mRNA.
Therefore, another approach taken was to calculate the consensus values (CV) at the 
5' and 3' splice sites (Tables 4.4 and 4.5 respectively) according to the method of Shapiro 
and Senapathy (1987). These values were estimated on the basis of the conservation of 
bases at the eight positions most likely to contribute to 5' splice recognition determinants 
(positions -2 to +6) and the fourteen positions (positions -14 to +1 but excluding position 
-4) at the 3' end and were used as relative indicators of the efficacy of splice sites.
The findings that exons 3 and 12 underwent some degree of splicing out led to the 
investigation of the CVs of their flanking introns. It can be seen, however, that the values 
do not justify their splicing out from the HMB-S pre-mRNA. There are lower CVs for 
other introns which should, theoretically, make these splice sites relatively inefficient, but 
this was not observed experimentally. The nucleotides at two and three positions deviate
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5’ (DONOR) SPLICE SITE CONSENSUS SEQUENCE
-4 -3 -2 -1 +1 +2 +3 +4 +5 +6
C 29/A 34 C 38/A 35 A ^2  G 77 : G100 T100 A 60 A 74 G s 4 T50 
EXON INTRON
In the HMB-S gene, the following was observed (Table 4.2):
-4 -3 -2 -1 +1 +2 +3 +4 +5 +6
C 29/A 21 C 50/A 21 A ^4 G 64 ' G100 T100 A 79 A 50 G 64 T43
EXON INTRON
3* (ACCEPTOR) SPLICE SITE CONSENSUS SEQUENCE 
-14 -13 -12 -11 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1 +1
Y78 Ysi Y83 Yg9 Y85 Y s 2  Y s i  Ys6 Y91 Ys7 N  C78 A100 G100 : G55
INTRON EXON
Correspondingly, in the HMB-S gene (Table 4.3):
-14 -13 -12 -11 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1 +1
Y50 Y79 Y86 Ys6 Y79 Y93 Y93 Y93 Y86 Y71 N C86 A93 G93 : G29
INTRON EXON
Figure 4.4: The percentage of occurrence of the consensus sequences at the 5' and 3' 
splice junctions. Y = pyrimidine, N = any base, subscript numerals refer 
to percentage frequency of occurrence. Adapted from Krawczak et al 
(1992).
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Table 4.4: Calculation of the consensus value (CV) of the 5' donor splice site of the
HMIi-S gene.
5’ DONOR SITE CONSENSUS VALUE
Intron 1 79.58
Intron 2 79.58
..................
*• '  W W  ♦ . vX* ♦ . . ♦ * • . .  •
Intron 4 72.97
Intron 5 87.71
Intron 6 82.61
Intron 7 89.22
Intron 8 100
Intron 9 58.03
Intron 10 90.36
Intron 11 78.26
Intron 12 & > Ji ~ -
Intron 13 93.38
Intron 14 82.23
The CVs are calculated according to the method o f Shapiro and Senapathy (1987). The 
shaded boxes are the introns o f interest in this study.
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Table 4.5: Calculation of the consensus value (CV) of the 3' acceptor splice site of the
HMli-S gene.
3’ ACCEPTOR SITE CONSENSUS VALUE
Intron 1 40.24
intron 2
Intron 3 92.30
Intron 4 95.18
Intron 5 86.13
Intron 6 74.51
Intron 7 94.19
Intron 8 90.99
Intron 9 91.71
Intron 10 90.28
* . _____
Intron 11 9 t J l
Intron 12 84.83
Intron 13 95.02
Intron 14 84.12
The shaded boxes are the introns o f interest in this study.
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from the 5’ consensus sequences in introns 3 and 12 respectively (Table 4.2), and at two 
positions in the 3' consensus sequences of introns 2 and 11 (Table 4.3). However, it is 
difficult to prove that these changes contribute to the splicing out of exons 3 and 12. For 
example, the nucleotides at six positions of the 5* splice site of intron 9 deviate from the 
consensus sequence (Table 4.2), thus contributing to its low CV (58.03) (Table 4.4) but do 
not cause exon 9 to be spliced out under normal circumstances. Similarly, four variant 
nucleotides were observed at the 3' splice site of intron 9 and, although its CV is the same 
as that for intron 11 (91.71) (Table 4.5), it does not result in the removal of exon 10 in the 
mature transcript. Three possible explanations are proposed: (i) other sequence signals may 
exist in addition to the splice junction sequence signal; (ii) splice sites with infrequently 
occurring bases may be recognised by different components of the splicing machinery; (iii) 
alternative splicing is a consequence of errors made by the splicing system.
Alternative splicing may have important implications; it may have preceded or was 
concomitant with the appearance of constitutive splicing as a means of facilitating rapid 
gene evolution. This may still hold true today: genes that remain in flux would retain 
alternative splicing but those whose products have been optimised for a given cell 
environment or function would have made all their exons constitutive or eliminated their 
introns altogether. Alternative splicing would be especially advantageous for genes that are 
evolving or require flexibility.
The alternatively spliced HMB-S transcripts identified will result in new isoforms of 
the HMB-S protein. The new isoforms will be shorter by 18 and 40 amino acids due to the 
absence of exons 3 and 12 respectively but the translational reading frame of both isoforms 
is not disrupted. In Figure 3.15a, the shorter allele, missing exon 3, shows variable intensity 
among the samples analysed. A similar observation was made for that missing exon 12 
(Figure 3.16a). However, in Figure 3.15a, it is obvious that, in some individuals, the 
proportion of truncated mRNAs is equal to that of full length mRNA. In these cases, if the 
truncated enzyme has reduced or no activity, there will be a significant reduction in the 
amount of active enzyme available to the cells. Two conserved residues are located in exon 
3, Arg26 and Ser28 (Argl 1 and Seri3 respectively in the E. coli model). Arg26 has been 
shown to form a salt-bridge with the side chain of the second pyrrole ring of the cofactor
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(Llewellyn et al, 1993). Any disturbance of this residue will disrupt substrate binding and 
chain elongation. Seventeen mutations (23%) have been recorded in exon 12 (Table 4.1), 
especially in the region of the a l 3-helix, indicating its importance in the proper functioning 
of this enzyme. This exon also crosses between domains 1 and 3. The polar groups in this 
helix are in contact with the two domains, therefore, any mutation which changes the 
charge of these groups will severely disrupt the conformation of the enzyme and have 
detrimental effects on the enzyme activity. The residues Ala252, Leu254 and His256 are 
located within the ah-helix. These residues, when altered, cause steric disruption and 
destabilise the protein. It is postulated that an inverse relationship exists between total 
HMB-S activity and the number of mRNA molecules with exon skipping. If alternative 
splicing also occurs in erythrocytes, it might explain the range of HMB-S activities found in 
the general population.
No conclusions can be made at this point regarding the effects these mis-spliced 
transcripts have on the activity of the enzyme. It would be useful to express these 
transcripts in the in vitro expression system to study if a correlation exists between the 
degree of splicing out of exons 3 and 12 and the enzyme activity.
The splicing out of exons 3 and 12 from the HMB-S mRNA identified in this study 
seems to be a true occurrence in the general population. 19 cycles of amplification of the 
mRNA transcripts (Figure 3.16c), which represents the log-phase of PCR, resulted in the 
same ratio of amplified products as that generated after 35 cycles (Figure 3.16d). This 
indicates that the ratio of amplified transcripts observed is a true reflection of the 
concentration of mRNA species in the lymphocyte population.
An interesting mutation recently reported by Llewellyn et al (1996) which causes exon 
skipping was that of a C to G transversion at position -22 from the 5' splice site of intron 3, 
causing the skipping of exon 3. Such rare intraexonic mutations which affect 5' splice site 
selection have been documented in mitochondrial acetoacetyl-coenzyme A thiolase 
deficiency (Fukao et al, 1994), in an in vitro mutant of the human hypoxanthine-guanine 
phosphoribosyl transferase gene (Steingrimsdottir et al, 1992) and in bovine thyroglobulin 
deficiency (Ricketts et al, 1987). These mutations are postulated to affect splice site
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selection by altering the secondary structure of pre-mRNA and, consequently, interferes 
with the assembly of small nucleoproteins into the spliceosome.
Splicing involves the removal of the intron segments from pre-mRNA and the accurate 
end-to-end joining of exons in the proper arrangement to code for a specific polypeptide 
chain.
RNA polymerase II (Pol II) transcribes protein-encoding genes. The processing of Pol 
II transcripts depends on the sequences of three critical regions within the introns- the 5f 
and 3' ends and the branch-point sequence close to the 3’ end. Another determining factor 
is the presence of all the components of a complex particle, the spliceosome, which 
comprises a number of ribonucleoprotein subunits, each containing a small RNA molecule.
Studies of a large number of splice junctions revealed that the 5' and 3' ends of almost 
all introns begin with the sequence GT and terminate with AG respectively. The branch­
point nearly always involves a specific adenine-containing residue.
Mammalian cells, unlike those of bacteria, contain numerous small RNA species which 
are neither transfer RNA (tRNA) nor ribosomal RNA (rRNA). Six different small nuclear 
RNAs (snRNAs) called Ul, U2, U3, U4, U5 and U6, U6 being the smallest (lOObp) and 
U3 the largest (215bp), are present in the cells of all vertebrate species. The snRNAs form 
stable complexes with certain abundant nuclear proteins called small nuclear 
ribonucleoproteins (snRNPs). In splicing, the role of snRNAs is to recognise the 5' and 3' 
splice sites, and the branch-point of each intron in the intron-containing transcript (Green, 
1986; Sharp, 1987). Ul RNA is the most abundant of all the snRNAs in vertebrate cells. 
Its 5' end contains a sequence that is precisely complementary to the nine-nucleotide 
consensus for 5' splice junctions, while the U2 snRNA binds to the BPS (Watson et al, 
1987), both events being necessary for the proper splicing of pre-mRNA.
Signals important for splicing of mammalian pre-mRNAs reside at the splice junctions 
themselves. The nucleotide sequences at the 5' junction of introns almost invariably begin 
with GT and end with AG at the 3' junction. The nine-nucleotide consensus sequence for 5’ 
junctions extends three residues upstream and six residues downstream from the splice 
point (Watson et al, 1987). The average 5 'junction matches this consensus in at least seven 
positions; very rarely will there be only a five-residue match. The 3' splice junction
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consensus sequence differs from the 5' consensus in that it comprises a pyrimidine-rich 
region of variable length, usually greater than ten nucleotides, followed by a short 
consensus sequence extending only four residues upstream and one residue downstream 
from the splice point. A schematic diagram is shown below:
EXON INTRON EXON
(C/A) AG I GT (A/G) AGT----------------- (T/C)in N (C/T) AG | G
5' splice junction consensus 3' splice junction consensus
sequence sequence
Figure 4.5: Consensus sequences at the 5' and 3' splice junctions.
Splice junction sequences from genes representing the entire range of eukaryotes 
(yeast to human) involve the same 5' and 3' consensus sequences, thus reflecting the highly 
conserved nature of the splicing elements which recognise these signals. In addition, the 
conserved recognition element known as the branch-point sequence (BPS) is located 18 - 
40 base pairs upstream of the 3' splice site. It is important in the formation of a branch with 
the 5' terminus of the intron in the splicing process but seems to have a weak consensus 
sequence.
The conserved sequences at the splice junctions are utilised in such a way that introns 
are precisely recognised by the splicing elements and accurately spliced out by two 
transesterification reactions. The first step, which involves cleavage at the 5' splice site, 
requires prior Ul snRNA binding and ATP hydrolysis. This is accompanied by the 
subsequent formation of an unusual 2' - 5' phosphodiester bond between the 5' terminal G 
residue of the intron and the 2'-hydroxyl of the adenylate residue at the branch-point, about 
thirty nucleotides upstream from the 3' end of the intron. This results in a loop structure 
known as a lariat intermediate. The second step involves cleavage at the 3' splice site and 
subsequent joining of the two exons by another phosphodiester bond, resulting in the 
removal of the intron in a lariat conformation. The RNA fragments that are removed during 
splicing remain in the nucleus to be degraded into ribonucleotides by enzymes. These
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ribonucleotides can be used again in the synthesis of more RNA after being converted back 
into the triphosphate form (Figure 4.6).
Thus, it can be seen that the efficiency of mammalian pre-mRNA splicing is governed 
by four sequence elements within the introns, viz. the invariant GT dinucleotide at the 5' 
splice junction, the highly conserved AG dinucleotide at the 3' end, the weakly conserved 
BPS and a pyrimidine-rich region known as the polypyrimidine [poly(Y)] tract (Padgett et 
al, 1986; Sharp, 1987). However, no sequence variations at these four sequence elements 
which could be responsible for the splicing out of exons 3 and 12 in the HMB-S gene were 
observed.
In the processing of RNA in higher eukaryotes, the amount of discarded RNA ranges 
from 50 to nearly 90% of the primary transcripts (Freifelder, 1987). Introns are excised one 
by one and the two exons are spliced together before the next intron is excised. Thus, it is 
expected that a large number of different nuclear RNA molecules would be present at any 
one instant.
If the excision of introns were to take place in a specific order, then only particular 
RNA intermediates should result. However, if intron excision occurs randomly, then all 
intermediates would be expected. For example, in the chick ovomucoid gene, which has 
seven introns (A to G), intron excision was found to take place in a preferred order. 
Random excision would result in more than 300 intermediates but only a few are observed. 
Intron E or F is usually lost in intermediates lacking one intron, and both E and F are lost in 
intermediates lacking two introns. Introns G and D are preferentially removed next, 
followed by B, and then A and C. Such preferential excision could be due to intramolecular 
base pairing which determines the order of removal. Once excision occurs, the 
conformation of the RNA would be altered, making it suitable for another intron to be 
excised as new pairs of splicing sites become available. It is expected that conformational 
changes would take place after each splicing event until all the introns are removed.
Eukaryotic differentiation is characterised by the regulated expression of structurally 
distinct, developmentally regulated and cell type-specific protein isoforms (Breitbart et al, 
1987). This protein diversity could arise either due to (a) preferential selection of one of 
the members of a multigene family for expression in a particular cell, developmental stage
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Exon 1 -piG U- •A  AG pa- Exon 2
Step 1
Exon 1 -  OH
Pa- Exon 2
Step 2
Exon 1 - Pa Exon 2
-OH
Figure 4.6: The pre-mRNA splicing pathway.
Step 1 involves the 5' splice site cleavage and lariat formation and step 2 
involves the 3' splice site cleavage and exon joining, p indicates a 
phosphodiester bond.
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or physiological condition; or (b) the generation of several different proteins from a single 
gene, where the molecular mechanism involved is alternative splicing. This leads to the 
differential expression of genomic sequences, thereby producing numerous protein 
isoforms from a single gene, varying only in their specific domains. This could allow the 
fine modulation of protein function (Smith et al, 1989). Through such changes, most 
aspects of protein function, ranging from the determination of cellular and subcellular 
localisation to the modulation of enzyme activity, can be altered. The number of different 
mRNAs, and hence protein isoforms encoded by a given gene, increases exponentially as a 
function of the number of exons that participate in alternative splicing. This, in turn, leads 
to phenotypic variability derived from a single gene. Alternative splicing can also 
quantitatively regulate gene expression by giving rise to prematurely truncated open 
reading frames, or by regulating mRNA stability or translational efficiency via variability in 
the untranslated regions.
A single base substitution within an intron can alter the splicing from a normal donor 
or acceptor site to a cryptic one that competes successfully for the splicing factors. Most 
cases of alternative splicing, involving internal donor or acceptor sites, as well as retained 
introns, are variant forms of this concept. If the resulting proteins produced by these 
alternative splice sites are advantageous, they will be retained. If a further mutation results 
in a new splice site behaving more strongly than the original one, it could be used 
constitutively where the coding capacity of the exons can be either increased by 
incorporating intronic sequences, or lost when part of the exon is excised.
The regulation of alternative splicing must reside in information encoded in the gene 
transcript (cis) but may require additional control by diffusible factors (trcms) that may be 
cell-specific (Andreadis et al, 1987). Certain genes generate heterogeneous primary 
transcripts with either different promoters or polyadenylation sites. The information in cis 
may be sufficient to control the different splicing routes these different transcripts follow, 
hence specific tram  factors may not be necessary. Other genes may, however, produce 
variant mRNAs from a single unique primary transcript that is initiated at the single 
promoter site and terminated at a single polyadenylation site. The execution of tissue- 
specific or developmentally regulated splicing in these identical transcripts cannot be
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encoded in the cis elements only and requires additional control by cell-specific trans 
factors.
At this stage, neither the biological significance of alternative splicing nor the 
contribution of the missing exons 3 and 12 to the condition of patients with other HMB-S 
mutations is known. However, the presence of this phenomenon must be taken into 
account when providing clinical molecular genetic analysis of AIP i.e. the absence of exons 
3 and 12 from RT-PCR products does not necessarily lead to the conclusion that the 
molecular pathology of the disorder has been defined.
4.1.3 IN  VITRO GENE EXPRESSION
Of the six missense mutations detected in this study, three (R22C, R26C and L177R) 
consistently failed to express the desired protein in the in vitro system. A possible reason 
for the failure of these mutant clones to express the mutant proteins could be that the 
mutation results in an unstable protein product. Therefore, only three missense mutations, 
R26H, R116W and R173Q, were suitable for studying their effects on the HMB-S enzyme 
activity by using the expression system develop in this study.
The functional importance of three missense mutations identified in this study has been 
determined by using an in vitro expression system. From Table 3.4, the specific activities of 
the three missense mutations analysed, due to the human HMB-S protein, are 1.07 X 106 
pmol/mg protein/hr (R26H), 0.93 X 106 pmol/mg protein/hr (R116W) and 0.83 X 106 
pmol/mg protein/hr (R173Q), corresponding to 3.9%, 3.4% and 3% residual activity 
respectively. All these mutations have a very destructive effect on the mature protein, 
therefore, it was expected that a very much reduced activity would be observed. The 
HMB-S activities of all three mutated proteins are very similar to one another, probably 
indicating that the severity of these mutations down-regulates the enzyme activity to a 
similar extent. In vitro expression studies have been done by other groups and have found 
that the R116W mutation did not produce any enzyme activity in an in vitro system (Lee et 
al, 1990) and R173Q yielded a specific activity of 0.6% of the normal enzyme (Delfau et al, 
1990). Therefore, the damaging nature of these mutations has been confirmed by in vitro 
expression studies.
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Both the in vivo and in vitro systems have a similar pattern of expression, thus 
indicating that the in vitro system could be used as a representative of the in vivo system. 
However, these findings should be supported with further mutation analyses to provide 
convincing data that what is observed in the in vitro system can be correlated with the in 
vivo system.
The in vitro expression system can be further applied to the analysis of the other six 
mutations identified in this study to assess their effects on protein stability and activity. In 
addition to that, the transcripts missing exons 3 and 12 could also be expressed in the 
expression system to ascertain their effects on protein stability and enzyme activity.
4.2 FUTURE PERSPECTIVES
The mutations which have been identified during this project and by others will 
continue to throw light on the necessary structure of HMB-S, required for full enzyme 
activity. In vitro expression of these naturally occurring mutations will be particularly 
useful in this respect. For example, expression of the missense mutations (R22C, R26C and 
L177R) described above will help in this process. Also, our ability to target precise regions 
of the enzyme by site-directed mutagenesis should increase more rapidly, our 
understanding of the mechanisms involved in both the assembly of the dipyrromethane 
cofactor and the tetrapyrrolic product, hydroxymethylbilane. There is also the question of 
substrate binding and release of the tetrapyrrole from HMB-S.
The discovery, in this project, that exons 3 and 12 of HMB-S can be differentially 
spliced out in non-erythroid cells generates some interesting questions. For example, 
erythrocyte HMB-S activities should be measured in the general population and the 
proportion of alternatively spliced HMB-S mRNAs in these cells, determined. This would 
show whether or not there is a relationship between the range of enzyme activities known 
to occur and the level of alternative mRNA splicing present. It would also be intriguing to 
know if individuals with a higher proportion of exons 3 and 12 skipping and who also have 
a pathological mutation in HMB-S, have a higher risk of AIP crisis.
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The detection of carriers of mutations in the HMB-S gene will continue to be a 
problem for diagnostic laboratories, given that there are no common mutations or marker 
haplotypes associated with the disorder. A reverse transcriptase/PCR analysis of the 
mRNA should be the first approach and will quickly reveal exon skipping in the cDNA. 
However, as discussed earlier, it is important to identify the splice signal mutations 
responsible for this. The small size of the cDNA (1083bp) means that its PCR product can 
be sequenced directly, paying particular attention to exons 10 and 12 which are known 
hotspots for mutation. Sequencing is, of course, the labour-intensive part of any diagnosis 
and therefore, until the technology has been simplified, it will not be used routinely in many 
molecular genetics diagnostic laboratories.
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APPENDIX 2
Complete coding sequence of the hydroxymethylbilane synthase (HMB-S) gene.
10 20 30 _  |  _ _  40 50 60  7061 I e
CGGCAATGC GUCTGCAACG GCGjGJATGTCTGGTA A G ’I’ GpAAGAAA ACAGCCCAAA GATGAGAGTG. ATTCGCGTGG
00 ,  90 100  110  120  130  14063 I E *
GTACCCGCAA GAGCCAGj3TT GCTCUCATAC AGACGGACAG TGTGGTGGCA ACATTGAAAG CCTCGTACGC
150 I P O * ,  170  180  190  200  £1064  I  6S  £5 1 Bi
TGGCCTGCAG TTTGAAATCAj TTGCTATGTC CACCACAGGQ GACAAGATTC TTGATACTGC ACTCTCTAAC|
220 230 240 250  260  E 6 1 °
ATTGGAGAGA AAAGCCTGTT TACCAAGGAG CTTQAACATG CCCTGGAGAA GAATGAjAGTG GACCTGGTTG
290 300  *310 320  330  "  340  j  &  350
TTCACTCCTT GAAGGACCTG CCCACTGTGC TTOCTCCTGG CTTGACCATC GGAGCCATCT GCAAJs CGGGA
360 370  380  390  400  410  420
AAACCCTCAT GATGCTGTTG TCTTTCACCC AAAATTTGTT GGGAAGACCC TAGAAACCCT GCCAGAGAAG
430  440  450  460  470  480  490
E8 J E S
ACfTGTGGTGG GAACCAGCTC CCTGl’GAAGA GCAGCCCAGC TGGAGAGAAA GTTCCCGCAT CTGGAGTTOA 
5.00 510  520  530  540  550  560
GGAGTAT'I|CG GGGAAACCTC AACAfGCGGC TTGGGAAGCTJGGACGT^GCAG CAGGAGTTCA GTGCCATCAT 
570  “  580  590  600  k ‘ 610  . .  - -  , 620  630
£10 j CM
CCTGGCAACA GCTGGCCTGC AGCGCATGGG UTGGCACAAC CGGGTGGGGC ACjATCCTGCA CCCJGAGGAA
640 650  ,  660  670  680  ‘  690   ^ 700
E l l  J e i %
TGCATGTATG CTGTGGGCCA GpGGGCCTTG GGCGTGGAAG TGCGAGCCAA GGACCAGGAC ATCTTGGATC
710  720  730  740  750  760  770
TGGTGGGTGT GCTGCACGAT CCCGAGACTC TGCTTCGCTG CATCGCTGAA AGGGCCTTCC TGAGGCACCT
-  700  790  000  810  820  * ^  ^  83(1 840  :
E U  I  *£13 E I3 r l  E l *  .
GPAAGGAGGC TGCAGTGTGC CAGTAGCCGT CiCATACAGCT ATGAAGGATG GGCAJjGTGTA CCTGACTGG A 
850 860  ^  '  870  a g o  :■ ' . .  910 . . . ;
GGAGTCTGGA GTCTAGACGG CTCAGATAGC ATACAAGAGA CCATGCAGGC TACCATCCAT GTCCCTGCCC 
^20  930  940  950  '  T  "  960  970  980
AGPATGAAGA TGGCCCTGAG GATGACCCAC AGTTGGTAGG CATCACTGCT CGTAACATTC CACGAGGGrjC 
990 1000  1010  1020  1030  - :  1040  1050
CCAGTTGGCT GCCCAGAACT TGGGCATCAG Ci.'TGGCCAAC TTGTTGCTGA GCAAAGGAGC CAAAAACATC 
1060  1070  1080
E <5
CTGGATGTTG CACGGCAGCT TAAGGATGCC U A ljtB B ..
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NUCLEOTIDE
POSITIONS
CODON AMINO
ACID
AMINO ACID 
SYMBOL
AMINO ACID 
NO.
EXON
1-3 ATG MET M 1 1
4-6 TCT SER S 2 1
7-9 GGT GLY G 3 1
10-12 AAC ASN N 4 1
13-15 GGC GLY G 5 1
16-18 AAT ASN N 6 1
19-21 GCG ALA A 7 1
22-24 GCT ALA A 8 1
25-27 GCA ALA A 9 1
28-30 ACG THR T 10 1
31-33 GCG ALA A 11 1
34-36 GAA GLU E 12 3
37-39 GAA GLU E 13 3
40-42 AAC ASN N 14 3
43-45 AGC SER S 15 3
46-48 CCA PRO P 16 3
49-51 AAG LYS K 17 3
52-54 ATG MET M 18 3
55-57 AGA ARG R 19 3
58-60 GTG VAL V 20 3
61-63 ATT ILE I 21 3
64-66 CGC ARG R 22 3
67-69 GTG VAL V 23 3
70-72 GGT GLY G 24 3
73-75 ACC THR T 25 3
76-78 CGC ARG R 26 3
79-81 AAG LYS K 27 3
82-84 AGC SER S 28 3
85-87 CAG GLN Q 29 3
88-90 CTT LEU L 30 4
91-93 GCT ALA A 31 4
94-96 CGC ARG R 32 4
97-99 ATA ILE I 33 4
100-102 CAG GLN Q 34 4
103-105 ACG THR T 35 4
106-108 GAC ASP D 36 4
109-111 AGT SER S 37 4
112-114 GTG VAL V 38 4
115-117 GTG VAL V 39 4
118-120 GCA ALA A 40 4
121-123 ACA THR T 41 4
124-126 TTG LEU L 42 4
127-129 AAA LYS K 43 4
130-132 GCC ALA A 44 4
133-135 TCG SER S 45 4
136-138 TAC TYR Y 46 4
139-141 CCT PRO P 47 4
142-144 GGC GLY G 48 4
145-147 CTG LEU L 49 4
184
148-150 CAG GLN Q 50 4
151-153 TTT PHE F 51 4
154-156 GAA GLU E 52 4
157-159 ATC ILE I 53 4
160-162 ATT ILE I 54 4-5
163-165 GCT ALA A 55 5
166-168 ATG MET M 56 5
169-171 TCC SER S 57 5
172-174 ACC THR T 58 5
175-177 ACA THR T 59 5
178-180 GGG GLY G 60 5
181-183 GAC ASP D 61 . 5
184-186 AAG LYS K 62 5
187-189 ATT ILE I 63 5
190-192 CTT LEU L 64 5
193-195 GAT ASP D 65 5
196-198 ACT THR T 66 5
199-201 GCA ALA A 67 5
202-204 CTC LEU L 68 5
205-207 TCT SER S 69 5
208-210 AAG LYS K 70 5
211-213 ATT ILE I 71 6
214-216 GGA GLY G 72 6
217-219 GAG GLU E 73 6
220-222 AAA LYS K 74 6
223-225 AGC SER S 75 6
226-228 CTG LEU L 76 6
229-231 TTT PHE F 77 6
232-234 ACC THR T 78 6
235-237 AAG LYS K 79 6
238-240 GAG GLU E 80 6
241-243 CTT LEU L 81 6
244-246 GAA GLU E 82 6
247-249 CAT HIS H 83 6
250-252 GCC ALA A 84 6
253-255 CTG LEU L 85 6
256-258 GAG GLU E 86 6
259-261 AAG LYS K 87 6
262-264 AAT ASN N 88 6
265-267 GAA GLU E 89 6-7
268-270 GTG VAL V 90 7
271-273 GAC ASP D 91 7
274-276 CTG LEU L 92 7
277-279 GTT VAL V 93 7
280-282 GTT VAL V 94 7
283-285 CAC HIS H 95 7
286-288 TCC SER S 96 7
289-291 TTG LEU L 97 7
292-294 AAG LYS K 98 7
295-297 GAC ASP D 99 7
298-300 CTG LEU L 100 7
185
301-303 CCC PRO P 101 7
304-306 ACT THR T 102 7
307-309 GTG VAL V 103 7
310-312 CTT LEU L 104 7
313-315 CCT PRO P 105 7
316-318 CCT PRO P 106 7
319-321 GGC GLY G 107 7
322-324 TTC PHE F 108 7
325-327 ACC THR T 109 7
328-330 ATC ILE I 110 7
331-333 GGA GLY G 111 7
334-336 GCC ALA A 112 7
337-339 ATC ILE I 113 7
340-342 TGC CYS C 114 7
343-345 AAG LYS K 115 7-8
346-348 CGG ARG R 116 8
349-351 GAA GLU E 117 8
352-354 AAC ASN N 118 8
355-357 CCT PRO P 119 8
358-360 CAT HIS H 120 8
361-363 GAT ASP D 121 8
364-366 GCT ALA A 122 8
367-369 GTT VAL V 123 8
370-372 GTC VAL V 124 8
373-375 TTT PHE F 125 8
376-378 CAC HIS H 126 8
379-381 CCA PRO P 127 8
382-384 AAA LYS K 128 8
385-387 TTT PHE F 129 8
388-390 GTT VAL V 130 8
391-393 GGG GLY G 131 8
394-396 AAG LYS K 132 8
397-399 ACC THR T 133 8
400-402 CTA LEU L 134 8
403-405 GAA GLU E 135 8
406-408 ACC THR T 136 8
409-411 CTG LEU L 137 8
412-414 CCA PRO P 138 8
415-417 GAG GLU E 139 8
418-420 AAG LYS K 140 8
421-423 AGT SER S 141 8-9
424-426 GTG VAL V 142 9
427-429 GTG VAL V 143 9
430-432 GGA GLY G 144 9
433-435 ACC THR T 145 9
436-438 AGC SER S 146 9
439-441 TCC SER S 147 9
442-444 CTG LEU L 148 9
445-447 CGA ARG R 149 9
448-450 AGA ARG R 150 9
451-453 GCA ALA A 151 9
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454-456 GCC ALA A 152 9
457-459 CAG GLN Q 153 9
460-462 CTG LEU L 154 9
463-465 CAG GLN Q 155 9
466-468 AGA ARG R 156 9
469-471 AAG LYS K 157 9
472-474 TTC PHE F 158 9
475-477 CCG PRO P 159 9
478-480 CAT HIS H 160 9
481-483 CTG LEU L 161 9
484-486 GAG GLU E 162 9
487-489 TTC PHE F 163 9
490-492 AGG ARG R 164 9
493-495 AGT SER S 165 9
496-498 ATT ILE I 166 9
499-501 CGG ARG R 167 10
502-504 GGA GLY G 168 10
505-507 AAC ASN N 169 10
508-510 CTC LEU L 170 10
511-513 AAC ASN N 171 10
514-516 ACC THR T 172 10
517-519 CGG ARG R 173 10
520-522 CTT LEU L 174 10
523-525 CGG ARG R 175 10
526-528 AAG LYS K 176 10
529-531 CTG LEU L 177 10
532-534 GAC ASP D 178 10
535-537 GAG GLU E 179 10
538-540 CAG GLN Q 180 10
541-543 CAG GLN Q 181 10
544-546 GAG GLU . E 182 10
547-549 TTC PHE F 183 10
550-552 AGT SER S 184 10
553-555 GCC ALA A . 185 10
556-558 ATC ILE I 186 10
559-561 ATC ILE I 187 10
562-564 CTG LEU L 188 10
565-567 GCA ALA A 189 10
568-570 ACA THR T 190 10
571-573 GCT ALA A 191 10
574-576 GGC GLY G 192 10
577-579 CTG LEU L 193 10
580-582 CAG GLN Q 194 10
583-585 CGC ARG R 195 10
586-588 ATG MET M 196 10
589-591 GGC GLY G 197 10
592-594 TGG TRP W 198 10
595-597 CAC HIS H 199 10
598-600 AAC ASN N 200 10
601-603 CGG ARG R 201 10
604-606 GTG VAL V 202 10
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607-609 GGG GLY G 203 10
610-612 CAG GLN Q 204 10
613-615 ATC ILE I 205 11
616-618 CTG LEU L 206 11
619-621 CAC HIS H 207 11
622-624 CCT PRO P 208 11
625-627 GAG GLU E 209 11
628-630 GAA GLU E 210 11
631-633 TGC CYS C 211 11
634-636 ATG MET M 212 11
637-639 TAT TYR Y 213 11
640-642 GCT ALA A 214 11
643-645 GTG VAL V 215 11
646-648 GGC GLY G 216 11
649-651 CAG GLN Q 217 11
652-654 GGG GLY G 218 12
655-657 GCC ALA A 219 12
658-660 TTG LEU L 220 12
661-663 GGC GLY G 221 12
664-666 GTG VAL V 222 12
667-669 GAA GLU E 223 12
670-672 GTG VAL V 224 12
673-675 CGA ARG R 225 12
676-678 GCC ALA A 226 12
679-681 AAG LYS K 227 12
682-684 GAC ASP D 228 12
685-687 CAG GLN Q 229 12
688-690 GAC ASP D 230 12
691-693 ATC ILE I 231 12
694-696 TTG LEU L 232 12
697-699 GAT ASP D 233 12
700-702 CTG LEU L 234 12
703-705 GTG VAL V 235 12
706-708 GGT GLY G 236 12
709-711 GTG VAL V 237 12
712-714 CTG LEU L 238 12
715-717 CAC HIS H 239 12
718-720 GAT ASP D 240 12
721-723 CCC PRO P 241 12
724-726 GAG GLU E 242 12
727-729 ACT THR T 243 12
730-732 CTG LEU L 244 12
733-735 CTT LEU L 245 12
736-738 CGC ARG R 246 12
739-741 TGC CYS C 247 12
742-744 ATC ILE I 248 12
745-747 GCT ALA A 249 12
748-750 GAA GLU E 250 12
751-753 AGG ARG R 251 12
754-756 GCC ALA A 252 12
757-759 TTC PHE F 253 12
188
760-762 CTG LEU L 254 12
763-765 AGG ARG R 255 12
766-768 CAC HIS H 256 12
7 69-7'7l CTG LEU L 257 12
772-7"4 GAA GLU E 258 13
775-7’77 GGA GLY G 259 13
778-780 GGC GLY G 260 13
781-783 TGC CYS C 261 13
784-786 AGT SER S 262 13
787-789 GTG VAL V 263 13
790-792 CCA PRO p 264 13
793-795 GTA VAL V 265 13
796-798 GCC ALA A 266 13
799-801 GTG VAL V 267 13
802-804 CAT HIS H 268 13
805-807 ACA THR T 269 13
808-810 GCT ALA A 270 13
811-813 ATG MET M 271 13
814-816 AAG LYS K 272 13
817-819 GAT ASP D 273 13
820-822 GGG GLY G 274 13
823-825 CAA GLN Q 275 13
826-828 CTG LEU L 276 14
829-831 TAC TYR Y 277 14
832-834 CTG LEU L 278 14
835-837 ACT THR T 279 14
838-840 GGA GLY G 280 14
841-843 GGA GLY G 281 14
844-846 GTC VAL V 282 14
847-849 TGG TRP W 283 14
850-852 AGT SER S 284 14
853-855 CTA LEU L 285 14
856-858 GAC ASP D 286 14
859-861 GGC GLY G 287 14
862-864 TCA SER S 288 14
865-867 GAT ASP D 289 14
868-870 AGC SER S 290 14
871-873 ATA ILE I 291 14
874-876 CAA GLN Q 292 14
877-879 GAG GLU E 293 14
880-882 ACC THR T 294 14
883-885 ATG MET M 295 14
886-888 CAG GLN Q 296 14
889-891 GCT ALA A 297 14
892-894 ACC THR T 298 14
895-897 ATC ILE I 299 14
898-900 CAT HIS H 300 14
901-903 GTC VAL V 301 14
904-906 CCT PRO P 302 14
907-909 GCC ALA A 303 14
910-912 CAG GLN Q 304 14
189
913-915
916-918
919-921
922-924
925-927
928-930
931-933
934-936
937-939
940-942
943-945
946-948
949-951
952-954
955-957
958-960
961-963
964-966
967-969
970-972
973-975
976-978
979-981
982-984
985-987
988-990
991-993
994-996
997-999
1 0 0 0 - 1 0 0 2
1003-1005
1006-1008
1009-1011
1012-1014
1015-1017
1018-1020
1021-1023
1024-1026
1027-1029
1030-1032
1033-1035
1036-1038
1039-1041
1042-1044
1045-1047
1048-1050
1051-1053
1054-1056
1057-1059
1060-1062
1063-1065
190
140969849
1066-1068 CAG GLN Q 356 15
1069-1071 CTT LEU L 357 15
1072-1074 AAC ASN N 358 15
1075-1077 GAT ASP D 359 15
1078-1080 GCC ALA A 360 15
1081-1083 CAT HIS H 361 15
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